WO2003104427A2 - Methods and compositions for detecting cancers - Google Patents

Abstract

In certain aspects, the invention provides isolated SLC5A8 (also referred to as Huil) nucleic acid molecules, which encode novel sodium solute symporter members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing SLC5A8 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a SLC5A8 gene has been introduced or disrupted. The invention still further provides isolated SLC5A8 proteins, fusion proteins, antigenic peptides, and anti-SLC5A8 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. In other aspects, the invention provides methods and compositions for detecting and treating SLC5A8-associated cancer. Differential methylation of the SLC5A8 nucleotide sequences has been observed in SLC5A8-associated cancer, such as colon cancer, breast cancer, thyroid cancer, or stomach cancer.

Description

METHODS AND COMPOSITIONS FOR DETECTING CANCERS

Cross-Reference to Related Applications

This application claims the benefit of priority of U.S. Provisional Application No. 60/386,653 filed June 5, 2002, the specification of which is incorporated by reference herein in its entirety.

Funding

Work described herein was supported by National Institutes of Health Grant R01CA 67409. The United States Government has certain rights in the invention.

Background

In 2001, over 1.2 million new cases of human c ancer will be diagnosed and over 0.5 million people will die from cancer (American C ancer Society e stimate). Despite this, more people than ever are living with and surviving cancer. In 1997, for example, approximately 8.9 million living Americans had a history of cancer (National Cancer Institute estimate). People are more likely to survive cancer if the disease is diagnosed at an early stage of development, since treatment at that time is more likely to be successful. Early detection depends upon availability of high-quality methods. Such methods are also useful for determining patient prognosis, selecting therapy, monitoring response to therapy and selecting patients for additional therapy. Consequently, there is a need for cancer diagnostic methods that are specific, accurate, minimally invasive, technically simple and inexpensive.

Colorectal cancer (cancer of the colon or rectum) is one particularly important type of human cancer. Colorectal cancer is the second most common cause of cancer mortality in adult Americans (Landis, et al., 1999, CA Cancer J Clin, 49:8-31). Approximately 40% of individuals with colorectal cancer die. In 2001, it is estimated that there will be 135,400 new cases of colorectal cancer (98,200 cases of colon and 37,200 cases of rectal cancer) and 56,700 deaths (48,000 colon cancer and 8,800 rectal cancer deaths) from the disease (American Cancer Society). As with other cancers, these rates can be decreased by improved methods for diagnosis. Although methods for detecting colon cancer exist, the methods are not ideal. Digital rectal exams (i.e., manual probing of rectum by a physician), for example, although relatively inexpensive, are unpleasant and can be inaccurate. Fecal occult blood testing (i.e., detection of blood in stool) is nonspecific because blood in the stool has multiple causes. Colonoscopy and sigmoidoscopy (i.e., direct examination of the colon with a flexible viewing instrument) are both uncomfortable for the patient and expensive. Double-contrast barium enema (i.e., taking X-rays of barium-filled colon) is also an expensive procedure, usually performed by a radiologist.

Other cancers such as breast cancer, thyroid cancer and stomach cancer, cause significant public health problem as well. For example, thyroid cancer is the most common endocrine malignancy. In the United States, there are approximately 14,000 new patients and 1,100 deaths per year (Shah et al., 1995, CA Cancer J Clin 45:352-68). Because of the disadvantages of existing methods for detecting and treating cancer, new methods and tools in cancer diagnosis and cancer therapy are needed.

Summary of the Invention

In accordance with the present invention, new diagnostic tools and methods for detecting cancer (e.g., colon cancer, breast cancer, thyroid cancer, or stomach cancer) are provided. In certain aspects, the mvention is based in part on the discovery of a novel polynucleotide sequence encoding a novel sodium/solute symporter-like protein (SLC5A8). Applicants previously referred to the SLC5A8 gene as the "Huil" gene.

In one embodiment, the invention provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of: a) an amino acid sequence at least 95% identical to SEQ ID NO: 1; and b) an amino acid sequence encoded by a nucleic acid that hybridizes under high stringency conditions to a nucleic acid of any one of SEQ ID NOs: 3 or 4, wherein said polypeptide is a cell surface protein. The subject polypeptide comprises a transmembrane domain as set forth in any one of SEQ ID NOs: 19-31. The present invention contemplates the subject polypeptide as a sodium symporter.

In another embodiment, the invention provides an isolated antibody or fragment thereof, which is specifically immunoreactive with an epitope of a SCL5A8 protein sequence as set forth in SEQ ID NO: 1. The antibody of the invention can be selected from the group consisting of: a polyclonal antibody, a monoclonal antibody, an Fab fragment and a single chain antibody. Optionally, the antibody is labeled with a detectable label. In another embodiment, the invention provides an isolated SCL5A8 nucleic acid selected from the group consisting of: a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 2, or a complement thereof; b) a nucleic acid molecule that encodes a polypeptide comprising the amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 7; and c) a nucleic acid molecule that hybridizes under stringent conditions to SEQ ID NO: 2. O ptionally, the nucleic acid o f the invention further comprises a v ector nucleic acid sequence. In certain embodiments, the mvention provides a kit comprising the SLC5A8 nucleic acid probes or primers and instructions for use.

hi another embodiment, the invention provides a host cell which contains the subject SCL5A8 nucleic acid of the invention. In another embodiment, the invention provides a method for producing the subject polypeptide, comprising culturing the host cell under conditions in which the subject nucleic acid molecule is expressed.

hi another embodiment, the invention provides a method for detecting the presence of the subject SCL5A8 polypeptide in a sample, comprising: a) contacting the sample with an antibody which selectively binds to the polypeptide of claim 1; and b) determining whether the antibody binds to the polypeptide in the sample.

hi another embodiment, the invention provides a kit for detecting a human SCL5A8 polypeptide comprising: (i) an antibody of claim 2; and (ii) a detectable label for detecting said antibody.

In another embodiment, the invention provides a method for detecting the presence of the SCL5A8 nucleic acid in a sample, comprising: a) contacting the sample with an SCL5A8 probe or primer; and b) determining whether the probe or primer binds to a SCL5A8 nucleic acid in the sample.

In another embodiment, the invention provides a method for identifying a compound which binds to the SCL5A8 polypeptide, comprising: a) contacting the p olypeptide, or a cell expressing the SCL5A8 polypeptide, with a test compound; andb) determining whether the polypeptide binds to the test compound.

In another embodiment, the invention provides a method for modulating the activity of the SCL5A8 polypeptide, comprising contacting the polypeptide or a cell expressing the polypeptide with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.

In another embodiment, the invention provides a method of inhibiting aberrant activity of a SLC5A8-expressing cell, comprising contacting the cell with a compound that modulates the activity or expression of the polypeptide, in an amount which is effective to reduce or inhibit the aberrant activity of the cell.

In certain embodiments, compounds used in the methods of the invention are selected from the group consisting of a peptide, a phosphopeptide. a small organic molecule, an antibody, and a peptidomimetic. Cells in the methods of the invention can be found in the colon, kidney, lung, esophagus, small bowel, stomach, thyroid, uterus, and breast.

In another embodiment, the invention provides a method of treating or preventing a disorder characterized by aberrant activity of a SLC5A8-expressing cell, in a subject, comprising administering to the subject an effective amount of a compound that modulates the activity or expression of the SLC5A8 polypeptide, such that the aberrant activity of the SLC5A8- expressing cell is reduced or inhibited.

hi another embodiment, the invention provides a transgenic mouse having germline and somatic cells comprising a chromosomally incorporated transgene that disrupts the genomic SLC5A8 gene and inhibits expression of said gene, wherein said disruption comprises insertion of a selectable marker sequence resulting in said transgenic mouse exhibiting increased susceptibility to the formation o f tumors as c ompared to the wildtype mouse. The transgenic mouse can be homozygous r heterozygous for the disruption.

In another embodiment, the invention provides a transgenic mouse having germline and somatic cells in which at least one allele of a genomic SLC5A8 gene is disrupted by a chromosomally incorporated transgene, which transgene inhibits the expression of the genomic SLC5A8 gene, wherein (i) the genomic SLC5A8 gene encodes a SLC5A8 protein; and (ii) the disruption comprises insertion of a selectable marker sequence, which replaces all or a portion of the genomic SLC5A8 gene or is inserted into the coding sequence of the genomic SLC5A8 gene; and (iii) the transgenic mouse has increased susceptibility to the development of neoplasms. hi another embodiment, the invention provides isolated mammalian cells comprising a diploid genome including a chromosomally incorporated transgene, which transgene disrupts the genomic SLC5A8 gene and inhibits expression of said gene. Optionally, the cells are mouse cells.

In another embodiment, the invention provides a method for generating a mouse and mouse embryonic stem cells having a functionally disrupted endogenous SLC5A8 gene, comprising the steps of: (i) constructing a transgene construct including (a) a recombination region having all or a portion of the endogenous SLC5A8 gene, which recombination region directs recombination of the transgene with the endogenous SLC5A8 gene; and (b) a marker sequence which provides a detectable signal for identifying the presence of the transgene in a cell; (ii) transferring the transgene into embryonic stem cells of a mouse; (iii) selecting embryonic stem cells having a correctly targeted homologous recombination between the transgene and the SLC5A8 gene; (iv) transferring said cells identified in step (iii) into a mouse blastocyst and implanting the resulting chimeric blastocyst into a female mouse; and (v) selecting offspring harboring an endogenous SLC5A8 gene allele comprising the correctly targeted recombination.

In another embodiment, the invention provides a method of evaluating the carcinogenic potential of an agent comprising: (i) contacting the transgenic mouse of claim 16A with a test agent; and (ii) comparing the number of transformed cells in a sample from the treated mouse with the number of transformed cells in a sample from an untreated transgenic mouse or transgenic mouse treated with a control agent, wherein the difference in the number of transformed cells in the treated mouse, relative to the number of transformed cells in the absence of treatment or treatment with a control agent, indicates the carcinogenic potential of the test compound.

In another embodiment, the invention provides a method of evaluating an anti- proliferative activity of a test compound, comprising: (i) providing a transgenic mouse of claim 16A having germline and somatic cells in which the expression of the SLC5A8 gene is inhibited by said chromosomally incorporated transgene, or a sample of cells derived therefrom; (ii) contacting the transgenic mouse or the sample of cells with a test agent; and (iii) determining the number of transformed cells in a specimen from the transgenic mouse or in the sample of cells, wherein a s tatistically s ignificant d ecrease i n t he n umber oft ransformed c ells, r elative t o t he number of transformed cells in the absence of the test agent, indicates the test compound is a potential anti-proliferative agent.

In certain aspects, the present invention is based, at least in part, on Applicants' discovery of a particular human genomic DNA region in which the cytosines within CpG dinucleotides are methylated in tissues from human cancers and unmethylated in normal human tissues. The region is referred to hereinafter as the "SLC5A8-methylation target region" is encompassed by base pairs 82200 to 83267 of GenBank entry AC063951, and is located in the promoter and/or exon 1 of the SLC5A8 gene. The present methods are also based, at least in part, on Applicants' discovery that the levels of SLC5A8 transcript in tissues from human cancers are lower than the levels of SLC5A8 transcript in normal tissues.

In one embodiment, the method comprises assaying for the presence of differentially methylated SLC5A8 nucleotide sequences (e.g., in the SLC5A8 methylation target region) in a tissue sample or a bodily fluid sample from a subject. Preferred bodily fluids include blood, serum, plasma, a blood-derived fraction, stool, colonic effluent or urine. In one embodiment, the method involves restriction enzyme/methylation-sensitive PCR. In another embodiment, the method comprises reacting DNA from the sample with a chemical compound that converts non- methylated cytosine bases (also called "conversion-sensitive" cytosines), but not methylated cytosine bases, to a different nucleotide base. In a preferred embodiment, the chemical compound is sodium bisulfite, which converts unmethylated cytosine bases to uracil. The compound-converted DNA is then amplified using a methylation-sensitive polymerase chain reaction (MSP) employing primers that amplify the compound-converted DNA template if cytosine bases within CpG dinucleotides of the DNA from the sample are methylated. Production of a PCR product indicates that the subject has cancer or precancerous adenomas. Other methods for assaying for the presence of methylated DNA are known in the art.

In another embodiment, the method comprises assaying for decreased levels of an SLC5A8 transcript in the sample. A sequence of the SLC5A8 transcript (SEQ ID NO: 3) is shown in Figure 2. The SLC5A8 transcript is encoded by 15 exons within the present genomic contig. In another aspect the method comprises assaying for decreased levels of a protein encoded by the SLC5A8 transcript in the sample.

In another embodiment, the present invention provides a detection method for prognosis of a cancer (e.g., colon cancer, breast cancer, thyroid cancer, or stomach cancer) in a subject known to have or suspected of having cancer. Such method comprises assaying for the presence of methylated SLC5A8 DNA (e.g., in the SLC5A8 methylation target region) in a tissue sample or bodily fluid from the subject. In certain cases, it is expected that detection of methylated SLC5A8 DNA in a blood fraction is indicative of an advanced state of cancer (e.g., colon cancer). In other cased, detection of methylated SLC5A8 DNA in a tissue or stool derived sample or sample from other bodily fluids may be indicative of a cancer that will respond to therapeutic agents that demethylate DNA or reactivate expression of the SLC5A8 gene.

hi another embodiment, the present invention provides a method for monitoring over time the status of cancer (e.g., colon cancer, breast cancer, thyroid cancer, or stomach cancer) in a subject. The method comprises assaying for the presence of methylated SLC5A8 DNA (e.g., in the SLC5A8 methylation target region) in a tissue sample or bodily fluid taken from the subject at a first time and in a corresponding tissue sample or bodily fluid taken from the subject at a second time. Absence of methylated SLC5A8 DNA from the tissue sample or bodily fluid taken at the first time and presence of methylated SLC5A8 DNA in the tissue sample or bodily fluid taken at the second time indicates that the cancer is progressing. Presence of methylated SLC5A8 DNA in the tissue sample or bodily fluid taken at the first time and absence of methylated SLC5A8 DNA from the tissue sample or bodily fluid taken at the second time indicates that the cancer is regressing.

In another embodiment, the present invention provides a method for evaluating therapy in a subject having cancer or suspected of having cancer (e.g., colon cancer, breast cancer, thyroid cancer, or stomach cancer). The method comprises assaying for the presence of methylated SLC5A8 DNA (e.g., in the SLC5A8 methylation target region) in a tissue sample or bodily fluid taken from the subject prior to therapy and a corresponding bodily fluid taken from the subject during or following therapy. Loss of or a decrease in the levels of methylated SLC5A8 DNA in the sample taken after or during therapy as compared to the levels of methylated SLC5A8 DNA in the sample taken before therapy is indicative of a positive effect of the therapy on cancer regression in the treated subject.

The present invention also relates to oligonucleotide primer sequences for use in assays (e.g., methylation-sensitive PCR assays or Hpall assays) designed to detect the methylation status of the SLC5A8 gene. The present invention also relates to antibodies and to oligonucleotides or oligomers for detecting the presence the SLC5A8 protein or the SLC5A8 ^•„+ -_eSpectively, in samples obtained from a subject. The present invention also provides a method of inhibiting or reducing growth of cancer cells (e.g., colon cancer, breast cancer, thyroid cancer, or stomach cancer). The method comprises increasing the levels of the protein encoded by SLC5A8 in cancer cells. In one embodiment, the cells are contacted with the SLC5A8 protein or a biologically active equivalent or fragment thereof under conditions permitting uptake of the protein or fragment. In another embodiment, the cells are contacted with a nucleic acid encoding the SLC5A8 protein and comprising a promoter active in the cancer cell, wherein the promoter is operably linked to the region encoding the SLC5A8 protein, under conditions permitting the uptake of the nucleic acid by the cancer cell. In another embodiment, the method comprises demethylating the methylated SLC5A8 DNA, or otherwise reactivating the silenced SLC5A8 promoter.

In one embodiment, the application provides isolated or recombinant SLC5A8 nucleotide sequences that are at least 80%, 85%, 90%, 95%, 98%, 99% or identical to the nucleotide sequence of any one of SEQ ID NOs: 2-4 and 21, fragments of said sequences that are 10, 15, 20, 25, 50, 100, or 150 base pairs in length wherein the SLC5A8 nucleotide sequences are differentially methylated in an SLC5A8-associated disease cell.

In another embodiment, the application provides a method for detecting colon cancer, comprising: a) obtaining a sample from a patient; and b) assaying said sample for the presence of methylation of nucleotide sequences within at least two genes selected from the group consisting of: SLC5A8, HLTF, pl6, and hMLHl; wherein methylation of nucleotide sequences within the two genes is indicative of colon cancer. In such methods, the sample is a bodily fluid selected from the group consisting of blood, serum, plasma, a blood-derived fraction, stool, urine, and a colonic effluent. For example, the bodily fluid is obtained from a subject suspected of having or is known to have colon cancer.

hi another embodiment, the application provides a kit for detecting colon cancer in a subject, comprising primers for detecting methylation of nucleotide sequence within at least two genes selected from the group consisting of: SLC5A8, HLTF, ρl6, and hMLHl, wherein the primers for detecting methylation of SLC5A8 nucleotide sequence are selected from SEQ ID NOs: 5-11; wherein the primers for detecting methylation of HLTF nucleotide sequence are selected from 5'-TGGGGTTTCGTGGTTTTTTCGCGC-3', 5'-

CCGCGAATCCAATCAAACGTCGACG-3', 5'-

ATTTTTGGGGTTTTGTGGTTTTTTTGTGT-3', 5'-

^Λ ^ ^{Λ .}^ ^.^AAATCCAATCAAACATCAACA-3', 5'- GCACGACTAAAAAATAAATCGCCGCG-3', 5'-

AAACACACAACTAAAAAATAAATCACCACA-3', 5'-

TAAAACCTCGTAACTTTCCCGCGCG-3', 5'-GTCGCGAGTTTAGTTAGACGTCGAC-3', 5'-TCCTAAAACCTCATAACTTTCCCACACA-3\ and 5'-

AGTTGTTGTGAGTTTAGTTAGATGTTGAT-3', wherein the primers for detecting methylation of hMLHl nucleotide sequence are selected from 5AACGAATTAATAGGAAGAGCGGATAGCG-3', 5'-

CGTCCCTCCCTAAAACGACTACTACCC-3*, 5'-

CGTTTTTTTTTGAAGCGGTTATTGTTTGT-3', and 5'-

AACGAACCAATAAAAAAAACAAACAACG-3'. Tthe kit may further comprise a compound to convert a template DNA. Optioanally the compound is bisulfite.

Brief Description of The Drawings

Figure 1 shows the complete sequence of the Genomic clone AC063951 (SEQ ID NO: 2), with nucleotides 82200-83267 underlined on pages 35 of Figure 1. This region (nucleotides 82200-83267 of AC063951, SEQ ID NO: 12, see Figure 4) encompasses the promoter and/or exon 1 of the SLC5A8 gene, and is herein referred to as the "SLC5A8 methylation target region."

Figure 2 shows the nucleotide sequence of the SLC5A8 mRNA transcript (SEQ ID NO: 3). The SLC5A8 transcript is encoded by 15 exons within the present genomic contig.

Figure 3 shows a diagram of the SLC5A8 methylation target region. CpG sites are shown with circles and stems. The numerical coordinates are those of genomic clone AC063951. Lollipops designate CpG sites that are potential acceptors of aberrant methylation. Asterisks designate sites recognized by the Hpall restriction enzyme. Shown are the positions of PCR primers that amplify regions crossing 6 Hpall sites, or regions crossing 4 Hpall sites. Also shown is the position of PCR primers designed for a methyl-specific PCR (MS-PCR) assays. Also shown in the gray bar is the 5' end of exon 1 of the SLC5A8 transcript which overlaps with the methylation sites detected in both MS-PCR and Hpall based assays. Lastly indicated is a Notl site corresponding to methylation site 2D41 detected in Restriction Landmark Genome Scanning assay as methylated in colon cancer cell lines, though not in primary tumors. Figure 4 provides the sequence of AC063951 between nucleotides 82200-83267 (SEQ ID NO: 12), and designates every CpG site with a gray lollipop, and shows the Hpall sites in the assay as dark lollipops, and also shows the location of the PCR primers used in the assay. In this figure, the base pairs have been renumbered sequentially from 1-1068, with nucleotide 82200 being renumbered as nucleotide 1.

Figure 5 shows the correlation between Hpall assays (over 4 Hpall sites and 6 Hpall sites) and silencing of expression of the SLC5A8 transcript.

Figure 6 shows the results of the Hpall assays (over 4 Hpall sites and 6 Hpall sites) in actual colon cancer tumors and normal control colon tissues.

Figure 7 shows the results of assay for methylation at 61 CpG sites enumerated in Figure 4 with site 1 corresponding to basepair 466 in Figure 4 and site 61 corresponding to basepair 1010. The bold arrows correspond to 4 of the Hpall sites at respectively basepairs 466, 691, 709, and 716 in Figure 4. Methylation was assayed by sequencing DNA from samples following sodium bisulfite treatment of DNA that converts cytosine to uracil but leaves methyl- cytosine unchanged. Bases that are methylated are coded black, unmethylated bases are coded dark gray, and samples with both methylated and unmethylated bases are coded light gray.

Figure 8 shows the wild-type sequence of the anti-sense strand of AC063951 between bases 82200-83267 (SEQ ID NO: 13). Note that the sequence is the reverse complement of that shown in Figure 4, and therefore base number 1 on this diagram corresponds to basepair 83267 in AC063951, and to basepair 1068 in Figure 4. Indicated on this diagram is the position of the MS-PCRl primers (AS-meth) and the UMS-PCR1 primers (AS-unmethy). The methyl specific MS-PCRl primers amplify a CpG sites numbered 6, 1, 8 and 15, 16, 17, 18 respectively in Figure 7. The UMS-PCRl primers interrogate CpG sites 7, 8 and 15, 16, 17, 18 respectively.

Figure 9 shows a region within SEQ ID NO: 13 shown in Figure 8 (nucleotides 300-600, SEQ ID NO: 14), and the sequences of the antisense strand that are amplified by the methyl- specific and unmethyl-specific PCR primers.

Figure 10 shows the bisulfite converted sequence of a uniformly methylated SLC5A8 antisense s trand ( SEQ ED N O: 15), b ut n ot t he w ild-type s equence o f t he S LC5 A8 a ntisense strand (corresponding to Figure 8). Indicated again are the position of the methylation specific PCR primers for the MS-PCRl assay. Figure 11 shows the bisulfite converted sequence of a uniformly unmethylated SLC5 A8 antisense strand (SEQ ID NO: 16), butnot the wild-type sequence of the SLC5A8 antisense strand shown in Figure 8. Indicated are the position ofthe unmethylation specific PCR primers for the UMS-PCRl assay.

Figure 12 provides the bisulfite converted sequence of the unmethylated SLC5A8 sense strand of nucleotides 82200-83267 of AC063951, renumbered such that basepair 82200 is designated as nucleotide 1 (SEQ ID NO: 17).

Figure 13 provides the bisulfite converted sequence of a uniformly methylated SLC5A8 sense strand of nucleotides 82200-83267 (SEQ ID NO: 18).

Figure 14 shows the tabular results of MS-PCRl assay performed on 31 colon cancer cell lines that do or do not express the SLC5 A8 transcript.

Figure 15 shows the tabular results of MS-PCRl assay performed on 63 matched sets of primary colon cancer tumor tissue and accompanying normal colon tissue.

Figure 16 shows the results of testing 12 normal colon tissues from individuals without colon cancer.

Figure 17 shows the tabular results of the MS-PCRl assay of 28 premalignant colon adenomas, 68% of which are detected.

Figure 18 shows the amino acid sequence (SEQ ID NO: 1) ofthe SLC5A8 protein.

Figure 19 shows RT-PCR detection of the SLC5 A8 transcript in normal colon and in a minority subset of colon cancer cell lines.

Figure 20 shows RT-PCR detection of SLC5A8 transcript in colon cancer cell lines that have been treated with the DNA-demethylating agent 5-azacytidine. 5-azacytidine reactivates expression ofthe SLC5A8 gene in 6 of 8 colon cancer cell lines.

Figure 21 demonstrates detection of methylation of the SLC5A8 locus by showing resistance ofthe locus to Hpall digestion. T he 4 Hpall assay (as described in the invention disclosure) is based on PCR amplification of a portion of the SLC5A8 locus. Lanes labeled U show control amplification of undigested SLC5A8 DNA. Lanes labeled M show amplification --^■~-.τ . ^,. _ϊt ^_as g_rgt tø_{een cut w}- ^ _regtrjcti_on enzyme Mspl . Figure 22 demonstrates detection of SLC5A8 DNA methylation in primary colon cancer tumors but not in matched normal tissue from the same patients. Samples labeled T represent colon cancer tumor tissue; whereas samples labeled N represent the matched normal tissue.

Figures 23A-23B show the identification of SLC5A8. (A) Shown is the genomic structure ofthe SLC5A8 gene. Black boxes represent exons, and arrows the start codon and stop codons respectively. (B) The nucleotide sequence ofthe SLC5A8 coding region (SEQ ID NO: 4).

Figures 24A-24F show SLC5 A8 expression. (A) Shown is RT-PCR analysis demonstrating SLC5A8 transcript expression in three normal colon mucosa samples (NI, N2, N3), but absence of SLC5A8 transcript in most colon cancer cell lines (remaining samples). (B) Shown is RT-PCR analysis demonstrating reactivation of SLC5A8 expression in cell lines treated with 5-azacytidine (+) compared to untreated (-) controls. (C) Methylation specific PCR (MS-PCR) assay for methylated (M) or unmethylated (U) SLC5A8 exon 1 sequences detects exclusively methylated templates in SLC5A8 silenced cell lines. (D) MS-PCR detects only unmethylated SLC5A8 templates in SLC5A8 expressing cell lines. (E) MS-PCR detection of methylated SLC5A8 templates in colon cancer tumors (T) antecedent to SLC5A8 methylated cell lines (V425, N670). Matched normal colon tissue (Ν) shows only unmethylated templates. Unmethylated templates in tumor tissue presumptively arise from contaminating non-malignant cells. (F) MS-PCR analysis of colon cancer tumors (T) and matched normal (Ν) colon tissues. Methyl specific bands are seen in each ofthe tumor samples, but none ofthe normal controls.

Figures 25A-25B show real time MS-PCR analysis of SLC5A8 methylation. Plotted are 1000 times the ratio of measured SLC5A8 methylated product to the control MYOD1 derived product. (A) Detection of SLC5A8 methylation in primary colon cancer tissues. Column 1 displays values for normal colon tissues harvested from non-cancer resections (dark diamonds). Column 2 displays values for normal colon tissues harvested from colon cancer resections (dark diamonds). Column 3 displays values for colon cancer tissues divided into unmethylated samples falling within the normal tissue range (dark diamonds at the bottom), versus methylated samples showing values greater than the normal tissue range (light diamonds at the top). Adjacent bars indicate population means. (B) Real time MS-PCR analysis of SLC5A8 methylation in aberrant crypt foci. Column 1 displays values for 24 normal colon tissues harvested from colon resections from 11 individuals (dark diamonds). Column 2 displays values ^c~~ ^{1 c} " ™τant crypt foci harvested from the same 11 individuals' resections. Dark diamonds (at the bottom) indicate unmethylated samples within the normal range, and light diamonds (at the top) indicate methylated samples falling within the range previously demonstrated by methylated cancers. Adjacent bars indicate the mean value for each group.

Figure 26 shows real time MS-PCR analysis of SLC5A8 methylation in DNA precipitated from the serum of colon cancer patients. Plotted are 1000 times the ratio of measured SLC5A8 methylated product to the control MYOD1 derived product. Column 1 displays absence of detectable SLC5A8 methylation in serum of 13 individuals whose colon cancer tumors assayed as unmethylated by MS-PCR (dark diamonds at the bottom). Column 2 displays values of SLC5A8 methylation in the serum of 10 individuals whose colon cancer tumors assayed as methylated by MS-PCR. Dark diamonds (at the bottom) indicate 6 sera without detectable methylation, and light diamonds (at the top) indicate 4 sera in which SLC5A8 methylation was detectable.

Figures 27A-27B show SLC5A8 suppression of colon cancer colony formation. Shown are the number of G418 resistant colonies arising from transfection with a SLC5A8 expression vector (SLC5A8) or a control empty expression vector (pcDNA) in SLC5A8 unmethylated and expressing N364, V457, and V9M cells (panel A) as compared to SLC5A8 methylated and deficient FET, V400, and RKO cells (panel B).

Figure 27 shows the cloning of SLC5A8 transcript. Black bars indicate representative ESTs. The lighter gray bar indicates sequence generated from an image clone. The dark gray bar indicates open reading frame encoding SLC5A8 protein.

Figure 28 shows the protein alignments of SLC5 A8, the closest murine homologue of SLC5A8, the human sodium iodide symporter SLC5A5, and the human sodium dependent multivitamin transporter SLC5A6.

Figures 30A-30B show methylation in SLC5A8 exon 1. (A) Diagrammatic representation ofthe CpG island in SLC5A8 exon 1. Balloons represent CpG dinucleotides. Coordinates represent nucleotide positions numbered as per GenBank entry AC063951. Positions ofthe ATG and ΝotI site are indicated. Arrows cover the regions interrogated by primers for MS-PCR. (B) Diagrammatic summary of methylation status ofthe 62 CpG sites in SLC5A8 exon 1 as determined by sequencing of bisulfite converted genomic DΝA. Each site is sequentially represented by one shaded block. Black represents sites that are fully methylated. ^{~ '} _/ represents sites that are fully unmethylated. And lighter gray represents sites that are partially methylated. Samples include 9 SLC5A8 silenced cell lines (Off samples), 6 SLC5 A8 expressing normal colonic mucosa (On samples designated N), and 3 SLC5 A8 expressing cell lines (On samples designated V). Arrows indicate sites that are interrogated by MS-PCR primers and bracket a differentially methylated region that is unmethylated in SLC5A8 expressing samples and is methylated in SLC5A8 silenced samples.

Figure 30 shows methylation events in primary colon cancers. Shown is analysis of 64 primary colon cancers for aberrant methylation at 4 genomic loci, SLC5A8, HLTF, hMLHl, and pi 6. Black bars represent positive assays for methylation in tumor tissue, and gray bars represent detection only of unmethylated alleles.

Figure 31 shows suppression of xenograft growth in 4 of 5 SLC5A8 expressing V400 transfected clones (square symbols, gray lines) as compared with control pools of V400 cells transfected with an empty expression vector (triangular symbols, black lines).

Detailed Description ofthe Invention

I. Definitions

For convenience, certain terms employed in the specification, examples, and appended claims are collected here. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) ofthe grammatical object ofthe article, unless the context clearly indicates otherwise. By way of example, "an element" means one element or more than one element.

The terms "adenoma", "colon adenoma," and "polyp" are used herein to describe any precancerous neoplasia ofthe colon.

The term "blood-derived fraction" herein refers to a component or components of whole blood. Whole blood comprises a liquid portion (i.e., plasma) and a solid portion (i.e., blood cells). The liquid and solid portions of blood are each comprised of multiple components; e.g., different proteins in plasma or different cell types in the solid portion. One of these components or a mixture of any of these components is a blood-derived fraction as long as such fraction is m . o o.n rme or more components found in whole blood. "Cells," "host cells" or "recombinant host cells" are terms used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope ofthe term as used herein.

A "chimeric polypeptide" or "fusion polypeptide" is a fusion of a first amino acid sequence with a second amino acid sequence where the first and second amino acid sequences are not naturally present in a single polypeptide chain.

The term "colon" as used herein is intended to encompass the right colon (including the cecum), the transverse colon, the left colon, and the rectum.

The terms "colorectal cancer" and "colon cancer" are used interchangeably herein to refer to any cancerous neoplasia ofthe colon (including the rectum, as defined above).

The terms "compound", "test compound," and "agent" are used herein interchangeably and are meant to include, but are not limited to, peptides, nucleic acids, carbohydrates, small organic molecules, natural product extract libraries, and any other molecules (including, but not limited to, chemicals, metals, and organometallic compounds).

The term "compound-converted DNA" herein refers to DNA that has been treated or reacted with a chemical compound that converts unmethylated C bases in DNA to a different nucleotide base. For example, one such compound is sodium bisulfite, which converts unmethylated C to U. If DNA that contains conversion-sensitive cytosine is treated with sodium bisulfite, t he c ompound-converted D NA w ill c ontain U i n p lace ofC . I ftheD NA w hich i s treated with sodium bisulfite contains only methylc tosine, the compound-converted DNA will not contain uracil in place ofthe methylcytosine.

The term "de-methylating agent" as used herein refers agents that restore activity and/or gene expression of target genes silenced by methylation upon treatment with the agent. Examples of such agents include without limitation 5-azacytidine and 5-aza-2'-deoxycytidine.

The term "detection" is used herein to refer to any process of observing a marker, in a biological sample, whether or not the marker is actually detected. In other words, the act of probing a sample for a marker is a "detection" even if the marker is determined to be not present or b elow t he 1 evel o f s ensitivity. D etection m ay be a q uantitative, s emi-quantitative o r n on- quantitative observation.

The term "differentially methylated SLC5A8 nucleotide sequence" refers to a region of the SLC5A8 nucleotide sequence that is found to be methylated in a SLC5 A8-associated cancer such as a region of the SLC5A8 nucleotide sequence that is found to be methylated in cancer tissues or cell lines, but not methylated in the normal tissues or cell lines. For example, Figure 3 delineates certain SLC5A8 regions that are differentially methylated, such as SEQ ID NOs: 11- 13.

"Expression vector" refers to a replicable DNA construct used to express DNA which encodes the desired protein and which includes a transcriptional unit comprising an assembly of (1) genetic element(s) having a regulatory role in gene expression, for example, promoters, operators, or enhancers, operatively linked to (2) a DNA sequence encoding a desired protein (in this case, a SLC5A8 protein) which is transcribed into mRNA and translated into protein, and (3) appropriate transcription and translation initiation and termination sequences. The choice of promoter and other regulatory elements generally varies according to the intended host cell. In general, expression vectors of utility in recombinant DNA techniques are often in the form of "plasmids" which refer to circular double stranded DNA loops which, in their vector form are not bound to the chromosome. In the present specification, "plasmid" and "vector" are used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which become known in the art subsequently hereto.

hi the expression vectors, regulatory elements controlling transcription or translation can be generally derived from mammalian, microbial, viral or insect genes. The ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants may additionally be incorporated. Vectors derived from viruses, such as retroviruses, adenoviruses, and the like, may be employed.

As used herein, the phrase "gene expression" or "protein expression" includes any information pertaining to the amount of gene transcript or protein present in a sample, as well as information about the rate at which genes or proteins are produced or are accumulating or being degraded (e.g., reporter gene data, data from nuclear runoff experiments, pulse-chase data etc.). Certain kinds of data might be viewed as relating to both gene and protein expression. For example, protein levels in a cell are reflective of the level of protein as well as the level of transcription, and such data is intended to be included by the phrase "gene or protein expression information." Such information may be given in the form of amounts per cell, amounts relative to a control gene or protein, in unitless measures, etc.; the term "information" is not to be limited to any particular means of representation and is intended to mean any representation that provides relevant information. The term "expression levels" refers to a quantity reflected in or derivable from the gene or protein expression data, whether the data is directed to gene transcript accumulation or protein accumulation or protein synthesis rates, etc.

The terms "healthy", "normal," and "non-neoplastic" are used interchangeably herein to refer to a subject or particular cell or tissue that is devoid (at least to the limit of detection) of a disease condition, such as a neoplasia (e.g., cancer), that is associated with SLC5A8 such as for example n eoplasia a ssociated w ith s ilencing o f S LC5 A8 g ene e xpression d ue t o m ethylation. These terms are often used herein in reference to tissues and cells of the colon. Thus, for the purposes of this application, a patient with severe heart disease but lacking a SLC5A8 silencing- associated disease would be termed "healthy."

"Homology" or "identity" or "similarity" refers to sequence similarity between two peptides or between two nucleic acid molecules. Homology and identity can each be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When an equivalent position in the compared sequences is occupied by the same base or amino acid, then the molecules are identical at that position; when the equivalent site occupied by the same or a similar amino acid residue (e.g., similar in steric and/or electronic nature), then the molecules can be referred to as homologous (similar) at that position. Expression as a percentage of homology/similarity or identity refers to a function of the number of identical or similar amino acids at positions shared by the compared sequences. A sequence which is "unrelated" or "non-homologous" shares less than 40% identity, preferably less than 25% identity with a sequence of the present invention. In comparing two sequences, the absence of residues (amino acids or nucleic acids) or presence of extra residues also decreases the identity and homology/similarity.

The term "homology" describes a mathematically based comparison of sequence similarities which is used to identify genes or proteins with similar functions or motifs. The nucleic acid and protein sequences of the present invention may be used as a "query sequence" a s earch a gainst p ublic d atabases t o, for e xample, i dentify o ther family m embers, related sequences or homologs. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. ( 1990) J Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to nucleic acid molecules of the invention. BLAST protem searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to protein molecules of the invention. To obtain gapped alignments for c omparison p urposes, G apped BLAST c an b e u tilized a s d escribed i n Altschul et al, (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and BLAST) can be used. See http://www.ncbi.nlm.mh.gov.

As used herein, "identity" means the percentage of identical nucleotide or amino acid residues at corresponding positions in two or more sequences when the sequences are aligned to maximize sequence matching, i.e., taking into account gaps and insertions. Identity can be readily calculated by known methods, including but not limited to those described in (Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part i, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48: 1073, 1988). Methods to determine identity are designed to give the largest match between the sequences tested. Moreover, methods to determine identity are codified in publicly available computer programs. Computer program methods to determine identity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al, Nucleic Acids Research 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Altschul, S. F. et al, J. Molec. Biol. 215: 403-410 (1990) and Altschul et al. Nuc. Acids Res. 25: 3389-3402 (1997)). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al, NCBI NLM NIH Bethesda, Md. 20894; Altschul, S., et al, J. Mol. Biol. 215: 403-410 (1990)). The well known Smith Waterman algorithm may also be used to deteπnine identity.

"SLC5A8-associated cancer" refers to cancer associated with reduced expression or no expression ofthe SLC5A8 gene (previously referred to as the Huil gene), and cancer associated

^•ential methylation of SLC5A8 DNA. Examples of SLC5A8-associated cancer include, but are not limited to, colon cancer, breast cancer, thyroid cancer, and stomach cancer. As used herein, the SLC5A8-associated cancers includes both cancers and pre-cancer adenomas.

"SLC5A8-associated proliferative disorder" refers to a disease that is associated with either reduced expression or over-expression ofthe SLC5A8 gene.

A "SLC5A8-associated protein" refers to a protein capable of interacting with and/or binding to a SLC5A8 polypeptide. Generally, the SLC5A8-associated protein may interact directly or indirectly with the SLC5A8 polypeptide.

"SLC5A8-methylation target regions" as used herein refer to those regions of SLC5A8 that are found to be methylated. These regions include nucleotide regions that may be either constitutively or differentially methylated regions. For example, Figure 3 discloses a SLC5A8 region wherein certain sequences of this region are differentially methylated regions.

"SLC5A8-nucleotide sequence" or "SLC5A8-nucleic acid sequence" as used herein refers to the SLC5A8 nucleotide sequences as set forth in SEQ ED NOs: 2-7 and fragments thereof.

"SLC5A8-silencing associated diseases" as used herein includes SLC5A8-associated cancer.

The term "including" is used herein to mean, and is used interchangeably with, the phrase "including but not limited to."

The term "isolated" as used in reference to nucleic acids or polypeptides indicates a nucleic acid or polypeptide, such as a SLC5 A8 nucleic acid or polypeptide, that is isolated from, or otherwise substantially free of other proteins that are normally associated with the nucleic acid or polypeptide.

The term "methylation-sensitive PCR" (i.e., MSP) herein refers to a polymerase chain reaction in which amplification of the compound-converted template sequence is perforaied. Two sets of primers are designed for use in MSP. Each set of primers c omprises a forward primer and a reverse primer. One set of primers, called methylation-specific primers, will amplify the compound-converted template sequence if C bases in CpG dinucleotides within the template DNA (e.g., a SLC5A8 nucleic acid) are methylated. Another set of primers, called nnτnethv1ation-specific primers, will amplify the compound-converted template sequences if C bases in CpG dinucleotides within the template DNA (e.g., a SLC5A8 nucleic acid) are not methylated.

The term "nucleic acid" refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The term should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single (sense or antisense) and double-stranded polynucleotides.

"Operably linked" when describing the relationship between two DNA regions simply means that they are functionally related to each other. For example, a promoter or other transcriptional regulatory sequence is operably linked to a coding sequence if it controls the transcription ofthe coding sequence.

The term "or" is used herein to mean, and is used interchangeably with, the term "and/or", unless context clearly indicates otherwise.

The terms "polypeptide" and "protein" are used interchangeably herein.

The term "recombinant" as used in reference to a nucleic acid indicates any nucleic acid that is positioned adjacent to one or more nucleic acid sequences that it is not found adjacent to in nature. A recombinant nucleic acid may be generated in vitro, for example by using the methods of molecular biology, or in vivo, for example by insertion of a nucleic acid at a novel chromosomal location by homologous or non-homologous recombination. The term "recombinant" as used in reference to a polypeptide indicates any polypeptide that is produced by expression and translation of a recombinant nucleic acid.

A "sample" includes any material that is obtained or prepared for detection of a molecular marker or a change in a molecular marker such as the methylation state, or any material that is contacted with a detection reagent or detection device for the purpose of detecting a molecular marker or a change in the molecular marker.

A "subject" is any organism of interest, generally a mammalian subject, such as a mouse, and preferably a human subject.

The term "transgene" is used herein to describe genetic material which has been or is about to be artificially inserted into the genome of a mammal, particularly a mammalian cell of a al. By "transgenic animal" is meant a non-human animal, usually a mammal (e.g., mouse, rat, rabbit, hamster, etc.), having a non-endogenous nucleic acid sequence present as an extrachromosomal element in a portion of its cells or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells). Heterologous nucleic acid is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells ofthe host animal.

II. Overview

In certain aspects, the invention relates, in part, to methods for determining whether a patient is likely or unlikely to have a cancer, for example, colon neoplasia. A colon neoplasia is any cancerous or precancerous growth located in, or derived from, the colon. The colon is a portion of the intestinal tract that is roughly three feet in length, stretching from the end of the small intestine to the rectum. Viewed in cross section, the colon consists of four distinguishable layers arranged in concentric rings surrounding an interior space, termed the lumen, through which digested materials pass, hi order, moving outward from the lumen, the layers are termed the mucosa, the submucosa, the muscularis propria and the subserosa. The mucosa includes the epithelial layer (cells adjacent to the lumen), the basement membrane, the lamina propria and the muscularis mucosae. In general, the "wall" of the colon is intended to refer to the submucosa and the layers outside ofthe submucosa. The "lining" is the mucosa.

Precancerous colon neoplasias are referred to as adenomas or adenomatous polyps. Adenomas are typically small mushroom-like or wart-like growths on the lining ofthe colon and do not invade into the wall ofthe colon. Adenomas may be visualized through a device such as a colonoscope or flexible sigmoidoscope. Several studies have shown that patients who undergo screening for and removal of adenomas have a decreased rate of mortality from colon cancer. For this and other reasons, it is generally accepted that adenomas are an obligate precursor for the vast majority of colon cancers. When a colon neoplasia invades into the basement membrane of the colon, it is considered a colon cancer, as the term "colon cancer" is used herein. In describing colon cancers, this specification will generally follow the so-called "Dukes" colon cancer staging system. The characteristics that the describe a cancer are generally of greater significance than the particular tenn used to describe a recognizable stage. The most widely used staging systems generally use at least one ofthe following characteristics for staging: the extent of tumor penetration into the colon wall, with greater penetration generally correlating with a more dangerous tumor; the extent of invasion of the tumor through ti.--. r.πlnτ- Λyall and into other neighboring tissues, with greater invasion generally correlating with a more dangerous tumor; the extent of invasion ofthe tumor into the regional lymph nodes, with greater invasion generally correlating with a more dangerous tumor; and the extent of metastatic invasion into more distant tissues, such as the liver, with greater metastatic invasion generally correlating with a more dangerous disease state.

"Dukes A" and "Dukes B" colon cancers are neoplasias that have invaded into the wall ofthe colon but have not spread into other tissues. Dukes A colon cancers are cancers that have not invaded beyond the s ubmucosa. Dukes B colon cancers are subdivided into two groups: Dukes Bl and Dukes B2. "Dukes Bl" colon cancers are neoplasias that have invaded up to but not through the muscularis propria. D ukes B2 colon cancers are c ancers that have breached completely through the muscularis propria. Over a five year period, patients with Dukes A cancer who receive surgical treatment (i.e., removal of the affected tissue) have a greater than 90%) survival rate. Over the same period, patients with Dukes Bl and Dukes B2 cancer receiving surgical treatment have a survival rate of about 85% and 75%, respectively. Dukes A, Bl and B2 cancers are also referred to as Tl, T2 and T3-T4 cancers, respectively. "Dukes C" colon cancers are cancers that have spread to the regional lymph nodes, such as the lymph nodes of the gut. Patients with Dukes C cancer who receive surgical treatment alone have a 35% survival rate over a five year period, but this survival rate is increased to 60% in patients that receive chemotherapy. " Dukes D" colon c ancers are cancers that have metastasized to other organs. The liver is the most common organ in which metastatic colon cancer is found. Patients with Dukes D colon cancer have a survival rate of less than 5% over a five year period, regardless ofthe treatment regimen. In general, colon neoplasia develops through one of at least three different pathways, teraied chromosomal instability, microsatellite instability, and the CpG island methylator phenotype (CIMP). Although there is some overlap, these pathways tend to present somewhat different biological behavior. By understanding the pathway of tumor development, the target genes involved, and the mechanisms underlying the genetic instability, it is possible to implement strategies to detect and treat the different types of colon neoplasias.

In one aspect, this application is based at least in part, on the recognition that certain target genes may be silenced or inactivated by the differential methylation of CpG islands in the 5' flanking or promoter regions of the target gene. CpG islands are clusters of cytosine- guanosine residues in a DNA sequence, that are prominently represented in the 5-flanking region or promoter region of about half the genes in our genome. In particular, this application is based at least in part on the recognition that differential methylation of the SLC5A8 nucleotide sequence may be indicative of a cancer (e.g., colon cancer, breast cancer, thyroid cancer, or stomach cancer).

As noted above, early detection of colon neoplasia, coupled with appropriate intervention, is important for increasing patient survival rates. Present systems for screening for colon neoplasia are deficient for a variety of reasons, including a lack of specificity and/or sensitivity (e.g., Fecal Occult Blood Test, flexible sigmoidoscopy) or a high cost and intensive use of medical resources (e.g., colonoscopy). Alternative systems for detection of colon neoplasia would be useful in a wide range of other clinical circumstances as well. For example, patients who receive surgical and/or pharmaceutical therapy for colon cancer may experience a relapse. It would be advantageous to have an alternative system for determining whether such patients have a recurrent or relapsed colon neoplasia. As a further example, an alternative diagnostic system would facilitate monitoring an increase, decrease or persistence of colon neoplasia in a patient known to have a colon neoplasia. A patient undergoing chemotherapy maybe monitored to assess the effectiveness ofthe therapy.

In another aspect, the invention is also based, in part, on the discovery of a novel polynucleotide sequence encoding a novel sodium/solute symporter-like protein (SLC5A8). In particular, SLC5A8 is closely related to the human sodium iodide symporter (SLC5A5) and the human sodium-dependent multivitamin transporter (SLC5A6).

Cell surface receptors and transmembrane transporter systems facilitate communication between cells and their environment by direct exchange of chemicals between the intracellular and extracellular milieu. Distinct transporter systems (also called permeases, porters, transporters, carriers, and channel proteins) are specific for ions, small and medium size solutes and macromolecules. A major class of transporter proteins couple solute transport to the movement of other species (often cations, such as protons and sodium ions) either in the same direction (cotransporter or symporter) or in the opposite direction (counter transporter or antiporter). Sodium/solute symport is a widespread mechanism of solute transport across cytoplasmic membranes of prokaryotic and eukaryotic cells. Proteins that catalyze sodium/solute symport have been grouped into eleven families based on their degree of sequence similarities, their solute and cation specificities, size, topographical features, and evolutionary relationships (see, e.g., Reizer et al, (1994) Bichemica et Biphysica Acta, 1197:133-166). There are mixed families of transporters whose members differ in the choice of -^.1 ----.g j_{on or} catalyze symport or antiport processes. Human sodium iodide transporter (NIS, or SLC5A5) is a best characterized member among the sodium/solute symporter superfamily. NIS localizes at the basolateral membrane and catalyses the active transport of iodide from blood into the cells using the inwardly directed sodium gradient with a 2 sodium 1 iodide stoichiometry. The tissue distribution of NIS includes the thyroid, salivary glands, stomach, thymus, and breast. Lower levels of expression of NIS are detected in the prostate, ovary, adrenal gland, lung, and heart. By contrast, the NIS gene has not been detected in the colon, orbital fibroblasts, or nasopharyngeal mucosa (see, e.g., Filetti et al, 1999, Eur J Endocrinol. 141:443-457). Abnormal NIS expression and/or iodide transport activity have been linked to many thyroid diseases including autoimmune thyroid diseases, thyroid nodular hyperplasia, thyroid adenoma, thyroid carcinoma, and congenital hypothyroidism, as well as non-thyroid diseases such as breast cancer and stomach cancer (Chung, 2002, J Nucl Med 43:1188-200).

Besides sequence homology to the human sodium iodide transporter, SLC5A8 transcript was found by Applicants to be expressed in the normal colon mucosa, kidney, lung, esophagus, small bowel, stomach, thyroid, and uterus. In addition, Applicants found that SLC5A8 may function as a sodium iodide transporter, and that differential methylation of SLC5A8 and/or reduced expression of SLC5A8 are linked to diseases such as colon cancer, breast cancer, and stomach c ancer. A ccordingly, t he p resent i nvention r elates to rn ethods a nd c ompositions for detecting and treating such SLC5A8 associated cancers.

III. SLC5A8 polypeptides

In certain aspects, the invention provides a full-length SLC5A8 polypeptide (SEQ ID NO: 1) and functional variants thereof. Preferred functional variants of SLC5A8 polypeptides are those that have tumor suppressor activity or sodium transporter activity. In certain aspects, the present invention includes biologically-active fragments of the SLC5 A8 protein and fusion proteins including at least a portion of the SLC5A8 protein. These include proteins with SLC5A8 activity that have amino acid substitutions or have sugars or other molecules attached to amino acid functional groups.

In certain embodiments, the present disclosure makes available isolated and/or purified forms of the SLC5 A8 polypeptides, which are isolated from, or otherwise substantially free of, other proteins which might normally be associated with the protein or a particular complex including the protein. In certain embodiments, variant polypeptides have an amino acid sequence that is at least 75 % identical to an amino acid sequence as set forth in SEQ ID NO: 1. In other embodiments, the variant polypeptide has an amino acid sequence at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to an amino acid sequence as set forth in SEQ ED NO: l.

In certain aspects, variant SLC5A8 polypeptides are agonists or antagonists of the SLC5A8 polypeptide as set forth in SEQ ID NO: 1. Variants of these polypeptides may have a hyperactive or constitutive activity, or, act to prevent the tumor suppressor activity or sodium transporter activity of SLC5A8. For example, a truncated form lacking one or more domain may have a dominant negative effect.

In certain aspects, isolated peptidyl portions ofthe SLC5A8 polypeptide can be obtained by screening polypeptides recombinantly produced from the corresponding fragment of the nucleic acid encoding the polypeptide as set forth in SEQ ID NO: 1. In addition, fragments can be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chemistry. The fragments can be produced (recombinantly or by chemical synthesis) and tested to identify those peptidyl fragments which can function as either agonists or antagonists of the SLC5A8 activity (e.g., tumor suppressor or sodium solute symporter).

The SLC5A8 protein is a transmembrane protein, with portions of the protein that are positioned outside the cell (the extracellular portions) and portions of the protein that are positioned inside the cell (the intracellular portions). Sequences and positions ofthe predicated thirteen transmembrane domains (TM1- TM13) are listed below.

TM1 (residues 10-32): FVVWDYVVFAGMLVISAAIGIYY (SEQ ED NO: 19)

TM2 (residues 52-74): MTAVPVALSLTASFMSAVTVLGT (SEQ ID NO: 20)

TM3 (residues 84-106): IFSIFAFTYFFVWISAEVFLPV (SEQ ID NO: 21)

TM4 (residues 127-149): VRLCGTVLFIVQTILYTGIVIYA (SEQ ID NO: 22)

TM5 (residues 164-186): GAVVATGVVCTFYCTLGGLKAVI (SEQ ID NO: 23)

TM6 (residues 193-215): IGIMVAGFASVIIQAVVMQGGIS (SEQ ID NO: 24)

^m "1 (residues 240-259): HTFWTIIIGGTFTWTSIYGV (SEQ ID NO: 25) TM8 (residues 280-302): LYINLVGLWAILTCSVFCGLALY (SEQ ID NO: 26)

TM9 (residues 337-359): LPGLFVACAYSGTLSTVSSSINA (SEQ ID NO: 27)

TM10 (residues 380-402): SLSWISQGMSVVYGALCIGMAAL (SEQ ID NO: 28)

TM11 (residues 412-434): AALSVFGMVGGPLMGLFALGILV (SEQ ID NO: 29)

TM12 (residues 441-463): GALVGLMAGFAISLWVGIGAQIY (SEQ ED NO: 30)

TM13 (residues 519-541): LSYLYFSTVGTLVTLLVGILVSL (SEQ ID NO: 31)

Thus, certain embodiments of the invention include SLC5A8 fragments comprising a transmembrane domain as set forth in any of SEQ ID NOs: 19-21. In other embodiments, the present invention includes SLC5A8 fragments comprising an intracellular domain or an extracellular portion ofthe SLC5A8 protein.

In certain aspects, variant SLC5A8 polypeptides containing one or more fusion domains. Well known examples of such fusion domains include, for example, polyhistidine, Glu-Glu, glutathione S transferase (GST), thioredoxin, protein A, protein G, and an immunoglobulin heavy chain constant region (Fc), maltose binding protein (MBP), which are particularly useful for isolation of the fusion polypeptide by affinity chromatography. For the purpose of affinity purification, relevant matrices for affinity chromatography, such as glutathione-, amylase-, and nickel- or cobalt- conjugated resins are used. Many of such matrices are available in "kit" form, such as the Pharmacia GST purification system and the QIAexpress™ system (Qiagen) useful with (HIS₆) fusion partners. Another fusion domain well known in the art is green fluorescent protein (GFP). This fusion partner serves as a fluorescent "tag" which allows the fusion polypeptide of the invention to be identified by fluorescence microscopy or by flow cytometry. The GFP tag is useful when assessing subcellular localization of the fusion SLC5A8 polypeptide. The GFP tag is also useful for isolating cells which express the fusion SLC5A8 polypeptide by flow cytometric methods such as a fluorescence activated cell sorting (FACS). Fusion domains also include "epitope tags," which are usually short peptide sequences for which a specific antibody is available. Well known epitope tags for which specific monoclonal antibodies are readily available include FLAG, influenza virus haemagglutinin (HA), and c-myc tags. In some cases, the fusion domains have a protease cleavage site, such as for Factor Xa or Thrombin, which allow the relevant protease to partially digest the fusion SLC5A8 polypeptide and thereby liberate the recombinant polypeptide therefrom. The liberated polypeptide can then be isolated from the fusion partner by subsequent chromatographic separation.

Different elements of fusion proteins may be arranged in any manner that is consistent with the desired functionality. For example, a SLC5A8 polypeptide may be placed C-terminal to a heterologous domain, or, alternatively, a heterologous domain may be placed C-terminal to a SLC5A8 polypeptide. The SLC5A8 and the heterologous domain need not be adjacent in a fusion protein, and additional domains or amino acid sequences may be included C- or N- terminal to either domain or between the domains.

It is also possible to modify the structure of the subject SLC5A8 polypeptides for such purposes as enhancing therapeutic or prophylactic efficacy, or stability (e.g., ex vivo shelf life and resistance to proteolytic degradation in vivo). Such modified polypeptides, when designed to retain at least one activity of the naturally occurring form of the protein, are considered functional equivalents of the SLC5A8 polypeptides described in more detail herein. Such modified polypeptides can be produced, for instance, by amino acid substitution, deletion or addition.

For instance, it is reasonable to expect, for example, that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid (i.e., conservative mutations) will not have a major effect on the biological activity of the resulting molecule. Conservative replacements are those that take place within a family of amino acids that are related in their side chains (see, for example, Biochemistry, 2nd ed., Ed. by L. Stryer, W.H. Freeman and Co., 1981). Whether a change in the amino acid sequence of a polypeptide results in a functional homolog can be readily determined by assessing the ability of the variant polypeptide to produce a response in c ells in a fashion similar to the wild-type protein. F or instance, such variant forms of a SLC5A8 polypeptide can be assessed, e.g., for their ability to transport sodium solute or their ability to suppress tumor formation. Polypeptides in which more than one replacement has taken place can readily be tested in the same manner.

This mvention further contemplates a method of generating sets of combinatorial mutants ofthe SLC5A8 polypeptides, as well as truncation mutants, and is especially useful for identifying potential variant sequences (e.g., homologs) that are functional in binding to a SLC5A8 polypeptide. The purpose of screening such combinatorial libraries may be to generate, for example, SLC5A8 homologs which can act as either agonists or antagonist, or alternatively, which possess novel activities all together. Combinatorially-derived homologs can be generated which have a selective potency relative to a naturally occurring SLC5A8 polypeptide. Such proteins, when expressed from recombinant DNA constructs, can be used in gene therapy protocols. Likewise, mutagenesis can give rise to variants which have intracellular half-lives dramatically different than the corresponding wild-type protein. For example, the altered protein c an be rendered either more stable or less stable to proteolytic degradation or other cellular process which result in destruction of, or otherwise inactivation of the SLC5A8 polypeptide of interest. Such variants, and the genes which encode them, can be utilized to alter SLC5A8 levels by modulating the half-life ofthe protein. For instance, a short half-life can give rise to more transient biological effects and, when part of an inducible expression system, can allow tighter control of recombinant SLC5A8 levels within the cell. As above, such proteins, and particularly their recombinant nucleic acid constructs, can be used in gene therapy protocols, hi similar fashion, SLC5A8 homologs can be generated by the present combinatorial approach to act as antagonists, in that they are able to interfere with the ability ofthe corresponding wild- type protein to function.

In a representative embodiment of this method, the amino acid sequences for a population of SLC5A8 homologs are aligned, preferably to promote the highest homology possible. Such a population of variants can include, for example, homologs from one or more species, or homologs from the s ame species but which differ due to mutation. A mino acids which appear at each position of the aligned sequences may be selected to create a degenerate set of combinatorial sequences, hi a preferred embodiment, the combinatorial library is produced by way of a degenerate library of genes encoding a library of polypeptides which each include at least a portion of potential SLC5A8 sequences. For instance, a mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degenerate set of potential SLC5A8 nucleotide sequences are expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display).

There are many ways by which the library of potential homologs can be generated from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be carried out in an automatic DNA synthesizer, and the synthetic genes then be ligated into an appropriate gene for expression. The purpose of a degenerate set of genes is to provide, in one mixture, all of the sequences encoding the desired set of potential SLC5A8 sequences. The if degenerate oligonucleotides is well known in the art (see for example, Narang, SA (1983) Tetrahedron 39:3; Itakura et al, (1981) Recombinant DNA, Proc. 3rd Cleveland Sympos. Macromolecules, ed. AG Walton, Amsterdam: Elsevier pp273-289; Itakura et al, (1984) Annu. Rev. Biochem. 53:323; Itakura et al, (1984) Science 198:1056; Ike et al, (1983) Nucleic Acid Res. 11 :477). Such techniques have been employed in the directed evolution of other proteins (see, for example, Scott et al, (1990) Science 249:386-390; Roberts et al, (1992) PNAS USA 89:2429-2433; Devlin et al, (1990) Science 249: 404-406; Cwirla et al, (1990) PNAS USA 87: 6378-6382; as well as U.S. Patent Nos: 5,223,409, 5,198,346, and 5,096,815).

Alternatively, other forms of mutagenesis can be utilized to generate a combinatorial library. For example, SLC5A8 variants (both agonist and antagonist forms) can be generated and isolated from a library by screening using, for example, alanine scanning mutagenesis and the like (Ruf et al, (1994) Biochemistry 33:1565-1572; Wang et al, (1994) J. Biol. Chem. 269:3095-3099; Balint et al, (1993) Gene 137:109-118; Grodberg et al, (1993) Eur. J. Biochem. 218:597-601; Nagashima et al, (1993) J. Biol. Chem. 268:2888-2892; Lowman et al,

(1991) Biochemistry 30:10832-10838; and Cunningham et al, (1989) Science 244:1081-1085), by linker scanning mutagenesis (Gustin et al, (1993) Virology 193:653-660; Brown et al,

(1992) Mol. Cell Biol. 12:2644-2652; McKnight et al, (1982) Science 232:316); by saturation mutagenesis (Meyers et al, (1986) Science 232:613); by PCR mutagenesis (Leung et al, (1989) Method Cell Mol Biol 1:11-19); or by random mutagenesis, including chemical mutagenesis, etc. (Miller et al, (1992) A Short Course in Bacterial Genetics, CSHL Press, Cold Spring Harbor, NY; and Greener et al, (1994) Strategies in Mol Biol 7:32-34). Linker scanning mutagenesis, particularly in a combinatorial setting, is an attractive method for identifying truncated (bioactive) forms of SLC5A8 polypeptides.

A wide range of techniques are known in the art for screening gene products of combinatorial libraries made by point mutations and truncations, and, for that matter, for screening cDNA libraries for gene products having a certain property. Such techniques will be generally adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of SLC5A8 variants. The most widely used techniques for screening large gene libraries typically comprises cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates relatively easy isolation of the vector encoding the gene whose product was detected. Each of the illustrative assays described below are amenable to high through-put analysis as necessary to e numbers of degenerate sequences created by combinatorial mutagenesis techniques. In an illustrative embodiment of a screening assay, candidate combinatorial gene products of one of the subject proteins are displayed on the surface of a cell or virus, and the ability of particular cells or viral particles to bind a SLC5A8 polypeptide is detected in a "panning assay." For instance, a library of SLC5A8 variants can be cloned into the gene for a surface membrane protein of a bacterial cell (Ladner et al„ WO 88/06630; Fuchs et al, (1991) Bio/Technology 9:1370-1371; and Goward et al, (1992) TIBS 18:136-140), and the resulting fusion protein detected by panning, e.g., using a fluorescently labeled molecule which binds the SLC5A8 polypeptide, to score for potentially functional homologs. Cells can be visually inspected and separated under a fluorescence microscope, or, where the morphology of the cell permits, separated by a fluorescence-activated cell sorter.

In similar fashion, the gene library can be expressed as a fusion protein on the surface of a viral particle. For instance, in the filamentous phage system, foreign peptide sequences can be expressed on the surface of infectious phage, thereby conferring two significant benefits. First, since these phage can be applied to affinity matrices at very high concentrations, a large number of phage can be screened at one time. Second, since each infectious phage displays the combinatorial g ene p roduct o n i ts s urface, i f a p articular p hage i s r ecovered from an a ffinity matrix in low yield, the phage can be amplified by another round of infection. The group of almost identical E. coli filamentous phages Ml 3, fd, and fl are most often used in phage display libraries, as either ofthe phage gill or gVIII coat proteins can be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle (Ladner et al, PCT publication WO 90/02909; Garrard et al, PCT publication WO 92/09690; Marks et al, (1992) J. Biol. Chem. 267:16007-16010; Griffiths et al, (1993) EMBO J. 12:725-734; Clackson et al, (1991) Nature 352:624-628; and Barbas et al, (1992) PNAS USA 89:4457-4461).

In certain embodiments, the mvention also provides for reduction ofthe subject SLC5A8 polypeptides to generate mimetics, e.g., peptide or non-peptide agents, which are able to mimic binding of the authentic protein to another cellular partner. Such mutagenic techniques as described above, as well as the thioredoxin system, are also particularly useful for mapping the determinants of a SLC5A8 polypeptide which participate in protein-protein interactions involved in, for example, binding of proteins involved in angiogenesis to each other. To illustrate, the critical residues of a SLC5A8 polypeptide which are involved in molecular recognition of a substrate protein can be determined and used to generate SLC5A8 polypeptide- derived peptidomimetics which bind to the substrate protem, and by inhibiting SLC5A8 binding, >it its biological activity. By employing, for example, scanning mutagenesis to map the amino acid residues of a SLC5A8 polypeptide which are involved in binding to another polypeptide, peptidomimetic compounds can be generated which mimic those residues involved in binding. For instance, non-hydrolyzable peptide analogs of such residues can be generated using benzodiazepine (e.g., see Freidinger et al, in Peptides: Chemistry and Biology, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), azepine (e.g., see Huffman et al, in Peptides: Chemistry and Biology, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted gamma lactam rings (Garvey et al, in Peptides: Chemistry and Biology, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), keto-methylene pseudopeptides (Ewenson et al, (1986) J. Med. Chem. 29:295; and Ewenson et al, in Peptides: Structure and Function (Proceedings ofthe 9th American Peptide Symposium) Pierce Chemical Co. Rockland, IL, 1985), b-turn dipeptide cores (Nagai et al, (1985) Tetrahedron Lett 26:647; and Sato et al, (1986) J Chem Soc Perkin Trans 1:1231), and b-aminoalcohols (Gordon et al, (1985) Biochem Biophys Res Commun 126:419; and Dann et al., (1986) Biochem Biophys Res Commun 134:71).

In certain embodiments, the SLC5A8 polypeptides may further comprise post- translational or non-amino acid elements, such as hydrophobic modifications (e.g., polyethylene glycols or lipids), poly- or mono-saccharide modifications, phosphates, acetylations, etc. Effects of such elements on the functionality of a SLC5A8 polypeptide may be tested as described herein for other SLC5A8 variants.

In certain aspects, the present invention contemplates directly delivery of SLC5A8 polypeptides into a cell. Methods of directly introducing a polypeptide into a cell include, but are not limited to, protein transduction and protein therapy. For example, a protein transduction domain (PTD) can be fused to a nucleic acid encoding a SLC5A8 protein, and the fusion protein is expressed and purified. Fusion proteins containing the PTD are permeable to the cell membrane, and thus cells can be directly contacted with a fusion protein (Derossi et al. (1994) Journal of Biological Chemistry 269: 10444-10450; Han et al. (2000) Molecules and Cells 6: 728-732; Hall et al. (1996) Current Biology 6: 580-587; Theodore et al. (1995) Journal of Neuroscience 15: 7158-7167).

Although some protein transduction based methods rely on fusion of a polypeptide of interest to a sequence which mediates introduction of the protein into a cell, other protein transduction methods do not require covalent linkage of a protein of interest to a transduction ^ ^{r.α .τ.} M least two commercially available reagents exist that mediate protein transduction without covalent modification of the protein (Chariot™, produced by Active Motif, www.activemotif.com and Bioporter® Protein Delivery Reagent, produced by Gene Therapy Systems, www.genetherapysystems.com). Briefly, these p rotein transduction reagents c an b e used t o d eliver p roteins, p eptides a nd antibodies d irectly to e ells i ncluding m ammalian c ells. Delivery of proteins directly to cells has a number of advantages. Firstly, many current techniques o f g ene d elivery are b ased o n d elivery of a n ucleic a cid s equence w hich m ust b e transcribed and or translated by a cell before expression of the protein is achieved. This results in a time lag between delivery ofthe nucleic acid and expression ofthe protein. Direct delivery of a protein decreases this delay. Secondly, delivery of a protein often results in transient expression ofthe protein in a cell.

As outlined herein, protein transduction mediated by covalent attachment of a PTD to a protein can be used to deliver a protein to a cell. These methods require that individual proteins be covalently appended with PTD moieties, hi contrast, methods such as Chariot™ and Bioporter® facilitate transduction by forming a noncovalent interaction between the reagent and the protein. Without being bound by theory, these reagents are thought to facilitate transit ofthe cell membrane, and following interaalization into a cell the reagent and protein complex disassociates so that the protein is free to function in the cell.

IV. SLC5A8 nucleic acids

In certain aspects, the invention provides isolated and/or recombinant SLC5A8 nucleic acids encoding SLC5A8 polypeptides, for example, SEQ ID NOs: 3 and 4. The SLC5A8 polynucleotides may be single-stranded or double stranded. Such nucleic acids may be DNA or RNA molecules. The SLC5A8 nucleic acids are useful as diagnostic or therapeutic agents, such as for example, these nucleic acid molecules encode the SLC5A8 protein, and are useful in assaying for the presence of SLC5A8 transcripts in cancer cells (e.g., colon cancer cells, breast cancer cells, thyroid cancer cells, or stomach cancer cells).

SLC5A8 nucleic acids of the invention are further understood to include nucleic acids that comprise variants of SEQ ID NOs: 3 and 4. Variant nucleotide sequences include sequences t hat d iffer b y o ne o r m ore nucleotide s ubstitutions, a dditions or d eletions, s uch a s allelic variants; and will, therefore, include coding sequences that differ from the nucleotide sequence of the coding sequence designated in SEQ ID NOs: 3 and 4. Optionally, a SLC5A8 nucleic acid of the invention will genetically complement a partial or complete SLC5A8 loss of function phenotype. For example, a SLC5A8 nucleic acid ofthe invention may be expressed in a cell in which the endogenous SLC5A8 gene has been deleted, and the introduced SLC5A8 nucleic acid will mitigate a phenotype resulting from the gene deletion.

The present invention is based, at least in part, on the observation that SLC5A8 nucleotide sequences can be differentially methylated in certain SLC5A8-associated cancer, such as colon cancer, breast cancer, thyroid cancer or stomach cancer. Accordingly, certain aspects of the present invention provide SLC5A8 nucleic acids having certain regions that are differentially methylated in SLC5A8-associated cancer, for example, SEQ ID NOs: 12, 13, and 14, and fragments thereof. Detection of methylation in any one of such differentially methylated nucleic acid sequences would be indicative of a SLC5 A8-associated cancer.

hi certain embodiments, the application provides isolated or recombinant SLC5A8 nucleic acid sequences that are at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100%. identical to the SLC5A8 nucleic acid sequences (e.g., SEQ ID NOs: 3-4 and 12-14). One of ordinary skill in the art will appreciate that SLC5A8 nucleic acid sequences complementary to SEQ ID NOs: 3-4 and 12-14, and variants of SEQ ID NOs: 3-4 and 12-14 are also within the scope of this invention, hi further embodiments, the SLC5A8 nucleic acid sequences of the invention can be isolated, recombinant, and/or fused with a heterologous nucleotide sequence, or in a DNA library.

In other embodiments, SLC5A8 nucleic acid sequences also include nucleotide sequences that hybridize under highly stringent conditions to the nucleotide sequences designated in SEQ ID NOs: 3-4 and 12-14, or fragments thereof. As discussed above, one of ordinary skill in the art will understand readily that appropriate stringency conditions which promote DNA hybridization can be varied. One of ordinary skill in the art will understand readily that appropriate stringency conditions which promote DNA hybridization can be varied. For example, one could perform the hybridization at 6.0 x sodium chloride/sodium citrate (SSC) at about 45 °C, followed by a wash of 2.0 x SSC at 50 °C. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0 x SSC at 50 °C to a high stringency of about 0.2 x SSC at 50 °C. In addition, the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22 °C, to high stringency conditions at about 65 °C. Both temperature and salt may be varied, or temperature or salt concentration may be held constant while the other variable is changed. In one embodiment, the invention provides nucleic acids which hybridize under low stringency conditions of 6 x SSC at room temperature followed by a wash at 2 x SSC at room temperature.

Isolated SLC5A8 nucleic acids which differ from the nucleic acids (e.g., SEQ DD NOs: 3-4 and 12-14) due to degeneracy in the genetic code are also within the scope ofthe mvention. For example, a number of amino acids are designated by more than one triplet. Codons that specify the same amino acid, or synonyms (for example, CAU and CAC are synonyms for histidine) may result in "silent" mutations which do not affect the amino acid sequence of the protein. However, it is expected that DNA sequence polymorphisms that do lead to changes in the amino acid sequences ofthe subject proteins will exist among mammalian cells. One skilled in the art will appreciate that these variations in one or more nucleotides (up to about 3-5% of the nucleotides) of the nucleic acids encoding a particular protein may exist among individuals of a given species due to natural allelic variation. Any and all such nucleotide variations and resulting amino acid polymorphisms are within the scope of this invention.

hi certain embodiments, the recombinant SLC5A8 nucleic acid may be operably linked to one or more regulatory nucleotide sequences in an expression construct. Regulatory nucleotide sequences will generally be appropriate for a host cell used for expression. Numerous types of appropriate expression vectors and suitable regulatory sequences are known in the art for a variety of host cells. Typically, said one or more regulatory nucleotide sequences may include, but are not limited to, promoter sequences, leader or signal sequences, ribosomal binding sites, transcriptional start and termination sequences, translational start and termination sequences, and enhancer or activator sequences. Constitutive or inducible promoters as known in the art are contemplated by the invention. The promoters may be either naturally occurring promoters, or hybrid promoters that combine elements of more than one promoter. An expression construct may be present in a cell on an episome, such as a plasmid, or the expression construct may be inserted in a chromosome. In a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selectable marker genes are well known in the art and will vary with the host cell used.

hi c ertain aspects, the application provides methylated forms of SLC5A8 nucleic acid sequences of SEQ ID NOs: 12-14 or fragments thereof, wherein the cytosine bases of the CpG islands present in said sequences are methylated. In other words, the SLC5A8 nucleic acid sequences of the present invention may be either in the methylated status (e.g., as seen in SLC5A8-associated cancer tissues) or in the unmethylated status (e.g., as seen in normal tissues).

In certain embodiments, the present invention provides bisulfite-converted SLC5A8 template DNA sequences, for example, SEQ ID NOs: 15-18, and fragments thereof. Such bisulfite-converted SLC5A8 template DNA can be used for detecting the methylation status, for example, by an MSP reaction or by direct sequencing. These bisulfite-converted SLC5A8 sequences are also of use for designing primers for MS-PCR reactions that specifically detect methylated or unmethylated SLC5A8 templates following bisulfite conversion, hi yet other embodiments, the bisulfite-converted SLC5A8 nucleotide sequences of the invention also include nucleotide sequences that will hybridize under highly stringent conditions to any nucleotide sequence selected from SEQ ID NOs: 15-18. In further aspects, the application provides methods for producing such bisulfite- converted nucleic acid sequences, for example, the application provides methods for treating a nucleotide sequence with a bisulfite agent such that the unmethylated cytosine bases are converted to a different nucleotide base such as a uracil.

The present invention also provides primers which can be used in PCR to obtain the SLC5A8 nucleic acids from cDNA The present invention also encompasses oligonucleotides that are useful as hybridization probes for detecting transcripts of the genes which encode the SLC5A8 protein Preferably, such oligonucleotides comprise at least 200 nucleotides. Such hybridization probes have a sequence which is at least 90% complementary with a contiguous sequence contained within the sense strand or antisense strand of a double stranded DNA molecule which encodes the SLC5A8 protein. Such hybridization probes bind to the sense strand or antisense under stringent conditions, preferably under highly stringent conditions. The probes are used in Northern assays to detect transcripts of SLC5A8 homologous genes and in Southern assays to detect SLC5A8 homologous genes. The identity of probes which are 200 nucleotides in length and have full complementarity with a portion of the sense or antisense strand of a double-stranded DNA molecule which encodes the SLC5A8 protein as set forth in SEQ ID NO: 1.

The various Sequence Identification Numbers that have been used in this application are summarized below in Table 1.

Table 1. Sequence Identification Numbers that have been used in this application.

V. SLC5A8 Expression Vectors

In certain aspects, nucleic acids encoding SLC5A8 polypeptides and variants thereof may be used to mcrease SLC5A8 expression in an organism or cell by direct delivery of the nucleic acid. A nucleic acid therapy c onstruct o f the present invention can be delivered, for example, as an expression plasmid which, when transcribed in the cell, produces RNA which encodes a SLC5A8 polypeptide.

In another aspect of the invention, the subject nucleic acid is provided in an expression vector comprising a nucleotide sequence encoding a subject SLC5A8 polypeptide and operably linked to at least one regulatory sequence. Regulatory sequences are art-recognized and are selected to direct expression of the SLC5A8 polypeptide. Accordingly, the term regulatory sequence includes promoters, enhancers, and other expression control elements. Exemplary regulatory sequences are described in Goeddel; Gene Expression Technology: Methods in Enzymology, Academic Press, San Diego, CA (1990). For instance, any of a wide variety of expression control sequences that control the expression of a DNA sequence when operatively linked to it may be used in these vectors to express DNA sequences encoding a SLC5A8 polypeptide. Such useful expression control sequences, include, for example, the early and late promoters of SV40, tet promoter, adenovirus or cytomegalovirus immediate early promoter, the , lac system, the trp system, the TAC or TRC system, T7 promoter whose expression is directed by T7 RNA polymerase, the major operator and promoter regions of phage lambda , the control regions for fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, thepromoters of acidphosphatase, e.g., Pho5, the promoters of the yeast -mating factors, the polyhedron promoter of the baculovirus system and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof. It should be understood that the design of the expression vector may depend on such factors as the choice ofthe host cell to be transformed and/or the type of protein desired to be expressed. Moreover, the vector's copy number, the ability to control that copy number and the expression of any other protein encoded by the vector, such as antibiotic markers, should also be considered.

As will be apparent, the subject gene constructs can be used to cause expression of the subject SLC5A8 polypeptides in cells propagated in culture, e.g., to produce proteins or polypeptides, including fusion proteins or polypeptides, for purification. This invention also pertains to a host cell transfected with a recombinant gene including a coding sequence for one or more of the subject SLC5A8 polypeptides. The host cell may be any prokaryotic or eukaryotic cell. For example, a polypeptide of the present invention may be expressed in bacterial cells such as E. coli, insect cells (e.g., using a baculovirus expression system), yeast, or mammalian cells. Other suitable host cells are known to those skilled in the art.

Accordingly, the present invention further pertains to methods of producing the subject SLC5A8 polypeptides. For example, a host cell transfected with an expression vector encoding a SLC5A8 polypeptide can be cultured under appropriate conditions to allow expression of the polypeptide to occur. The polypeptide may be secreted and isolated from a mixture of cells and medium containing the polypeptide. Alternatively, the polypeptide may be retained cytoplasmically or in a membrane fraction and the cells harvested, lysed and the protein isolated. A cell culture includes host cells, media and other byproducts. Suitable media for cell culture are well known in the art. The polypeptide can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins, including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for particular epitopes of the polypeptide. In a preferred embodiment, the SLC5A8 polypeptide is a fusion protein containing a domain which facilitates its purification, such as a SLC5A8-GST fusion protein, SLC5A8-intein fusion protein, SLC5A8-cellulose binding domain usion protein, SLC5A8-polyhistidine fusion protein, etc.

A recombinant SLC5A8 nucleic acid can be produced by ligating the cloned gene, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells (yeast, avian, insect or mammalian), or both. Expression vehicles for production of a recombinant SLC5A8 polypeptides include plasmids and other vectors. For instance, suitable vectors for the expression of a SLC5A8 polypeptide include plasmids of the types: pBR322- derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids and pUC-derived plasmids for expression in prokaryotic cells, such as E. coli.

The preferred mammalian expression vectors contain both prokaryotic sequences to facilitate the propagation ofthe vector in bacteria, and one or more eukaryotic transcription units that are expressed in eukaryotic cells. The pcDNAI/amp, pcDNAI/neo, pRc/CMV, pSV2gpt, τ.^ςv τ,^pn r,SV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo and pHyg derived vectors are examples of mammalian expression vectors suitable for transfection of eukaryotic cells. Some of these vectors are modified with sequences from bacterial plasmids, such as pBR322, to facilitate replication and drug resistance selection in both prokaryotic and eukaryotic cells. Alternatively, d erivatives o f v iruses s uch a s t he b ovine p apilloma v irus ( BPV-1), o r E pstein- Barr virus (pHEBo, pREP-derived and p205) can be used for transient expression of proteins in eukaryotic cells. Examples of other viral (including retroviral) expression systems can be found below in the description of gene therapy delivery systems. The various methods employed in the preparation ofthe plasmids and transformation of host organisms are well known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells, as well as general recombinant procedures, see Molecular Cloning A Laboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press, 1989) Chapters 16 and 17. In some instances, it may be desirable to express the recombinant SLC5A8 polypeptide by the use of a baculovirus expression system. Examples of such baculovirus expression systems include pVL-derived vectors (such as pVL1392, pVL1393 and pVL941), pAcUW-derived vectors (such as pAcUWl), and pBlueBac-derived vectors (such as the β-gal containing pBlueBac III).

In another embodiment, a fusion gene coding for a purification leader sequence, such as a poly-(His)/enterokinase cleavage site sequence at the N-terminus of the desired portion of the recombinant SLC5A8 protein, can allow purification ofthe expressed fusion protein by affinity chromatography using a Ni²⁺ metal resin. The purification leader sequence can then be subsequently removed by treatment with enterokinase to provide the purified SLC5A8 polypeptide (e.g., see Hochuli et al, (1987) J. Chromatography 411:177; and Janknecht et al, PNAS USA 88:8972).

Techniques for making fusion genes are well known. Essentially, the joining of various DNA fragments coding for different polypeptide sequences is performed in accordance with conventional techniques, employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al, John Wiley & Sons: 1992).

VI. Antibodies

Another aspect of the invention pertains to an antibody reactive with a SLC5A8 polypeptide, preferably antibodies that are specifically reactive with SLC5A8 polypeptide. For example, by using immunogens derived from a SLC5A8 polypeptide, anti-protein/anti-peptide antisera or monoclonal antibodies can be made by standard protocols (see, for example, Antibodies: A Laboratory Manual ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)). A mammal, such as a mouse, a hamster or rabbit can be immunized with an immunogenic form of the peptide (e.g., a SLC5A8 polypeptide or an antigenic fragment which is capable of eliciting an antibody response, or a fusion protein). Techniques for conferring immunogenicity on a protein or peptide include conjugation to carriers or other techniques well known in the art. An immunogenic portion of a SLC5A8 polypeptide can be administered in the presence of adjuvant. T he p rogress of i mmunization c an b e m onitored b y d etection o f antibody t iters i n plasma or serum. Standard ELISA or other immunoassays can be used with the immunogen as antigen to assess the levels of antibodies. In a preferred embodiment, the subject antibodies are immunospecific for antigenic d eterminants o f a SLC5A8 p olypeptide a s s et forth in S EQ ID NO: l.

In one embodiment, antibodies are specific for the SLC5A8 protein as encoded by nucleic acid sequences as set forth in SEQ ID NOs: 3 and 4. In other embodiments, an antibody is immunoreactive with one or more proteins having an amino acid sequence that is at least 85%, 90%, 95%, 98%, 99%, 99.3%, 99.5%, 99.7% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 1.

In another embodiment, antibodies of the invention are specific for the extracellular portion of the SLC5A8 protein. In a set of exemplary embodiments, an antibody binds to an extracellular portion of SEQ ID NO: 1. In another embodiment, antibodies ofthe invention are specific for the intracellular portion or the transmembrane portion of the SLC5A8 protein. In a further embodiment, antibodies ofthe invention are specific for the soluble SLC5A8 protein and variants thereof.

Following immunization of an animal with an antigenic preparation of a SLC5A8 oolvDeotide, anti-SLC5A8 antisera can be obtained and, if desired, polyclonal anti-SLC5A8 antibodies can be isolated from the serum. To produce monoclonal antibodies, antibody- producing cells (lymphocytes) can be harvested from an immunized animal and fused by standard somatic cell fusion procedures with immortalizing cells such as myeloma cells to yield hybridoma cells. Such techniques are well known in the art, and include, for example, the hybridoma technique (originally developed by Kohler and Milstein, (1975) Nature, 256: 495- 497), the human B cell hybridoma technique (Kozbar et al, (1983) Immunology Today, 4: 72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al, (1985) Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. pp. 77-96). Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with a SLC5A8 polypeptide ofthe present invention and monoclonal antibodies isolated from a culture comprising such hybridoma cells. In one embodiment, anti-SLC5A8 antibodies specifically react with the protein encoded by a nucleic acid having the sequence of SEQ ID NO: 3 or 4.

The term "antibody" as used herein is intended to include fragments thereof which are also specifically reactive with a subject SLC5A8 polypeptide. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab)2 fragments can be generated by treating antibody with pepsin. The resulting F(ab)2 fragment can be treated to reduce disulfide bridges to produce Fab fragments. The antibody of the present invention is further intended to include bispecific, single-chain, and chimeric and humanized molecules having affinity for a SLC5A8 polypeptide conferred by at least one CDR region of the antibody. In preferred embodiments, the antibody further comprises a label attached thereto and able to be detected (e.g., the label can be a radioisotope, fluorescent compound, enzyme or enzyme co-factor).

In certain preferred embodiments, an antibody ofthe invention is a monoclonal antibody, and in certain embodiments, the invention makes available methods for generating novel antibodies. For example, a method for generating a monoclonal antibody that binds specifically to a SLC5A8 polypeptide may comprise administering to a mouse an amount of an immunogenic composition comprising the SLC5A8 polypeptide effective to stimulate a detectable immune response, obtaining antibody-producing cells (e.g., cells from the spleen) from the mouse and fusing the antibody-producing cells with myeloma cells to obtain antibody- producing hybridomas, and testing the antibody-producing hybridomas to identify a hybridoma that produces a monocolonal antibody that binds specifically to the SLC5A8 polypeptide. Once obtained, a hybridoma can be propagated in a cell culture, optionally in culture conditions where the hybridoma-derived cells produce the monoclonal antibody that binds specifically to the SLC5A8 polypeptide. The monoclonal antibody may be purified from the cell culture.

Anti-SLC5A8 antibodies can be used, e.g., to detect SLC5A8 polypeptides in biological samples and/or to monitor SLC5A8 polypeptide levels in an individual The level of SLC5A8 polypeptide maybe measured in a variety of sample types such as, for example, in cells , stools, and/or in bodily fluid, such as in whole blood samples, blood serum, blood plasma and urine. The adjective "specifically reactive with" as used in reference to an antibody is intended to mean, as is generally understood in the art, that the antibody is sufficiently selective between the antigen of interest (e.g., a SLC5 A8 polypeptide) and other antigens that are not of interest that the antibody i s useful for, at minimum, detecting the presence o f the antigen o f interest in a particular type of biological sample. In certain methods employing the antibody, a higher degree of specificity in binding may be desirable. For example, an antibody for use in detecting a low abundance protein of interest in the presence of one or more very high abundance protein that are not of interest may perform better if it has a higher degree of selectivity between the antigen of interest and other cross-reactants. Monoclonal antibodies generally have a greater tendency (as compared to polyclonal antibodies) to discriminate effectively between the desired antigens and cross-reacting polypeptides. In addition, an antibody that is effective at selectively identifying an antigen of interest in one type of biological sample (e.g., a stool sample) may not be as effective for selectively identifying the same antigen in a different type of biological sample (e.g., a blood sample). Likewise, an antibody that is effective at identifying an antigen of interest in a purified protein preparation that is devoid of other biological contaminants may not be as effective at identifying an antigen of interest in a crude biological sample, such as a blood or urine sample. Accordingly, in preferred embodiments, the application provides antibodies that have demonstrated specificity for a SLC5A8 protein in a sample type that is likely to be the sample type of choice for use of the antibody. In a particularly preferred embodiment, the application provides antibodies that bind specifically to a SLC5A8 polypeptide in a protein preparation from blood (optionally serum or plasma) from a patient that has a SLC5A8 associated cancer or that bind specifically in a crude blood sample (optionally a crude serum or plasma sample).

One characteristic that influences the specificity of an antibody:antigen interaction is the affinity ofthe antibody for the antigen. Although the desired specificity may be reached with a range of different affinities, generally preferred antibodies will have an affinity (a dissociation f about IO^"6, IO^"7, 10^"s, IO^"9 or less. In addition, the techniques used to screen antibodies in order to identify a desirable antibody may influence the properties ofthe antibody obtained. For example, an antibody to be used for certain therapeutic purposes will preferably be able to target a particular cell type. Accordingly, to obtain antibodies of this type, it may be desirable to screen for antibodies that bind to cells that express the antigen of interest (e.g., by fluorescence a ctivated cell sorting). Likewise, if an antibody is to be used for binding an antigen in solution, it may be desirable to test solution binding. A variety of different techniques are available for testing interaction between antibodies and antigens to identify particularly desirable antibodies. Such techniques include ELISAs, surface plasmon resonance binding assays (e.g., the Biacore binding assay, Bia-core AB, Uppsala, Sweden), sandwich assays (e.g., the paramagnetic bead system of IGEN International, Inc., Gaithersburg, Maryland), western blots, immunoprecipitation assays, and immunohistochemistry.

In certain embodiment, antibodies of the invention may be useful as diagnostic or therapeutic agents for detecting or treating SLC5A8-associated diseases (e.g., cancers). The diagnostic method comprises the steps of contacting a sample of test cells or a protein extract thereof with immunospecific anti-SLC5A8 antibodies and assaying for the formation of a complex between the antibodies and a protein in the sample. Formation of low levels of complex in the test cell as compared to the normal cells indicates that the test cell is cancerous.

VII. Transgenic Animals

Another aspect of the invention features transgenic non-human animals which express a heterologous SLC5A8 gene, e.g., having a sequence of SEQ ID NO: 3 or 4, or fragments thereof. In another aspect, the invention features transgenic non-human animals which have had one or both copies of the endogenous SLC5A8 genes disrupted in at least one of the tissue or cell-types of the animal. In one embodiment, the transgenic non-human animals is a mammal such as a mouse, rat, rabbit, goat, sheep, dog, cat, cow or non-human primate. Without being bound to theory, it is proposed that such an animal may display a phenomenon associated with reduced or increased chance of cancer development (e.g., colon cancer, breast cancer, thyroid cancer, or stomach cancer). Accordingly, such a transgenic animal may serve as a useful animal model to study the progression of cancer diseases.

The term "transgene" is used herein to describe genetic material that has been or is about to be artificially inserted into the genome of a mammalian cell, particularly a mammalian cell of a living animal. The transgene is used to transform a cell, meaning that a permanent or transient genetic change, preferably a permanent genetic change, is induced in a cell following incoφoration of exogenous DNA. A permanent genetic change is generally achieved by introduction of the DNA into the genome of the cell. Vectors for stable integration include plasmids, retroviruses and other animal viruses, YACs, and the like. Of interest are transgenic mammals, e.g., cows, pigs, goats, horses, etc., and particularly rodents, e.g., rats, mice, etc. Preferably, the transgenic-animals are mice.

Transgenic animals comprise an exogenous nucleic acid sequence present as an extrachromosomal element or stably integrated in all or a portion of its cells, especially in germ cells. Unless otherwise indicated, it will be assumed that a transgenic animal comprises stable changes to the germline sequence. During the initial construction of the animal, "chimeras" or "chimeric animals" are generated, in which only a subset of cells have the altered genome. Chimeras are primarily used for breeding puφoses in order to generate the desired transgenic animal. Animals having a heterozygous alteration are generated by breeding of chimeras. Male and female heterozygotes are typically bred to generate homozygous animals.

The exogenous gene is usually either from a different species than the animal host, or is otherwise altered in its coding or non-coding sequence. The introduced gene may be a wild-type gene, naturally occurring polymoφhism, or a genetically manipulated sequence, for example having deletions, substitutions or insertions in the coding or non-coding regions. Where the introduced gene is a coding sequence, it is usually operably linked to a promoter, which may be constitutive or inducible, and other regulatory sequences required for expression in the host animal.

In one aspect ofthe invention, a SLC5A8 transgene can encode the wild-type form ofthe protein, homologs thereof, as well as antisense constructs. A SLC5A8 transgene can also encode a soluble form of SLC5A8 that has tumor suppressor activity or sodium solute transporter activity.

It may be desirable to express the heterologous S LC5A8 transgene conditionally such that either the timing or the level of SLC5A8 gene expression can be regulated. Such conditional expression can be provided using prokaryotic promoter sequences which require prokaryotic proteins to be simultaneous expressed in order to facilitate expression of the SLC5A8 transgene. Exemplary promoters and the corresponding trans-activating prokaryotic proteins are given in U.S. Patent No. 4,833,080.

Moreover, transgenic animals exhibiting tissue specific expression can be generated, for example, by inserting a tissue specific regulatory element, such as an enhancer, into the transgene. For example, the endogenous SLC5A8 gene promoter or a portion thereof can be replaced with another promoter and/or enhancer, e.g., a CMV or a Moloney murine leukemia virus (MLV) promoter and/or enhancer.

Transgenic animals containing an inducible SLC5A8 transgene can be generated using inducible regulatory elements (e.g., metallothionein promoter), which are well-known in the art. SLC5A8 transgene expression can then be initiated in these animals by administering to the animal a compound which induces gene expression (e.g., heavy metals). Another preferred inducible system comprises a tetracycline-inducible transcriptional activator (U.S. Patent Nos. 5,654,168 and 5,650,298).

The present invention provides transgenic animals that carry the transgene in all their cells, as well as animals that carry the transgene in some, but not all cells, i.e., mosaic animals. The transgene can be integrated as a single transgene or in tandem, e.g., head to head tandems, or head to tail or tail to tail or as multiple copies.

The successful expression ofthe transgene can be detected by any of several means well known to those skilled in the art. Non-limiting examples include Northern blot, in situ hybridization of mRNA analysis, Western blot analysis, immunohistochemistry, and FACS analysis of protein expression.

In a further aspect, the invention features non-human animal cells containing a SLC5A8 transgene, preferentially a human SLC5A8 transgene. For example, the animal cell (e.g., somatic cell or germ cell (i.e., egg or sperm)) can be obtained from the transgenic animal. Transgenic somatic cells or cell lines can be used, for example, in drug screening assays. Transgenic germ cells, on the other hand, can be used in generating transgenic progeny.

Although not necessary to the operability of the invention, the transgenic animals described herein may comprise alterations to endogenous genes in addition to, or alternatively, to the genetic alterations described above. For example, the host animals may be either "knockouts" or "knockins" for the SLC5A8 gene. Knockouts have a partial or complete loss of function in one or both alleles of an endogenous gene of interest. Knockins have an introduced transgene with altered genetic sequence and/or function from the endogenous gene. The two may be combined, for example, such that the naturally occurring gene is disabled, and an altered form introduced. For example, it may be desirable to knockout the host animal's endogenous SLC5A8 gene, while introducing an exogenous SLC5A8 gene (e.g., a human SLC5A8 gene).

In a knockout, preferably the target gene expression is undetectable or insignificant. For example, a knock-out of a SLC5A8 gene means that function of the SLC5A8 has been substantially decreased so that expression is not detectable or only present at insignificant levels. This may be achieved by a variety of mechanisms, including introduction of a disruption ofthe coding sequence, e.g., insertion of one or more stop codons, insertion of a DNA fragment, deletion of coding sequence, substitution of stop codons for coding sequence, etc. In some cases, the exogenous transgene sequences are ultimately deleted from the genome, leaving a net change to the native sequence. Different approaches may be used to achieve the "knock-out." A chromosomal deletion of all or part ofthe native gene may be induced, including deletions ofthe non-coding regions, particularly the promoter region, 3' regulatory sequences, enhancers, or deletions of gene that activate expression of APP genes. A functional knock-out may also be achieved by the introduction of an anti-sense construct that blocks expression ofthe native genes (for example, see Li and Cohen (1996) Cell 85:319-329). "Knock-outs" also include conditional knock-outs, for example, where alteration ofthe target gene occurs upon exposure ofthe animal to a substance that promotes target gene alteration, introduction of an enzyme that promotes recombination at the target gene site (e.g., Cre in the Cre-lox system), or other method for directing the target gene alteration postnatally.

A "knockin" of a target gene means an alteration in a host cell genome that results in altered expression or function of a native target gene. Increased (including ectopic) or decreased expression may be achieved by introduction of an additional copy of the target gene, or by operatively inserting a regulatory sequence that provides for enhanced expression of an endogenous c opy of t he t arget gene. T hese c hanges m ay b e c onstitutive o r conditional, i .e., dependent on the presence of an activator or repressor. The use of knockin technology may be combined with production of exogenous sequences to produce the transgenic animals of the invention.

DNA constructs for random integration need not include regions of homology to mediate -^¹-.-^; — ^. j_on ^'Wh_ere homologous recombination is desired, the DNA constructs will comprise at least a portion of the target gene with the desired genetic modification, and will include regions of homology to the target locus. Conveniently, markers for positive and negative selection are included. Methods for generating cells having targeted gene modifications through homologous recombination are known in the art. For various techniques for transfecting mammalian cells, see Keown et al. (1990) Methods in Enzymology 185:527-537.

For embryonic stem (ES) cells, an ES cell line may be employed, or embryonic cells may be obtained freshly from a host, e.g., mouse, rat, or guinea pig. Such cells are grown on an appropriate fibroblast-feeder layer or grown in the presence of appropriate growth factors, such as leukemia inhibiting factor (LIF). When ES cells have been transformed, they may be used to produce transgenic animals. After transformation, the cells are plated onto a feeder layer in an appropriate medium. Cells containing the construct may be detected by employing a selective medium. After sufficient time for colonies to grow, they are picked and analyzed for the occurrence of homologous recombination or integration ofthe construct. Those colonies that are positive may then be used for embryo manipulation and blastocyst injection. Blastocysts are obtained from 4 to 6 week old superovulated females. The ES cells are trypsinized, and the modified cells are injected into the blastocoel of the blastocyst. After injection, the blastocysts are returned to each uterine horn of pseudopregnant females. Females are then allowed to go to term and the resulting litters screened for mutant cells having the construct. By providing for a different phenotype ofthe blastocyst and the ES cells, chimeric progeny can be readily detected.

The chimeric animals are screened for the presence of the modified gene and males and females having the modification are mated to produce homozygous progeny. If the gene alterations cause lethality at some point in development, tissues or organs can be maintained as allogeneic or congenic grafts or transplants, or in in vitro culture.

The transgenic animals ofthe present invention may be an animal model for a SLC5A8- associated disease (e.g., cancer), and display cancer-related phenotypes (e.g., colon cancer, breast cancer, thyroid cancer, or stomach cancer), depending on different alleles generated. Accordingly, such transgenic animals can be used in in vivo assays to identify cancer therapeutics. In an exemplary embodiment, the assay comprises administering a test compound to a transgenic animal of the invention, and comparing a phenotypic change in cancer development in the animal relative to a transgenic animal which has not received the test compound. To illustrate, the transgenic animals and cell lines are particularly useful in screening compounds that have potential as prophylactic or therapeutic treatments of diseases such as may involve aberrant expression, or loss, of the SLC5A8 gene. Screening for a useful drug would involve administering the candidate drug over a range of doses to the transgenic animal, and assaying a t v arious t ime p oints for t he effect(s) of t he d rug o n t he d isease o r d isorder b eing evaluated. Alternatively, or additionally, the drug could be administered prior to or simultaneously with exposure to induction ofthe disease, if applicable.

In one embodiment, candidate compounds are screened by being administered to the transgenic animal, over a range of doses, and evaluating the animal's physiological response to the compound(s) over time. Administration may be oral, or by suitable injection, depending on the chemical nature of the compound being evaluated. In some cases, it may be appropriate to administer the compound in conjunction with co-factors that would enhance the efficacy of the compound.

In screening cell lines derived from the subject transgenic animals for compounds useful in treating various disorders, the test compound is added to the cell culture medium at the appropriate time, and the cellular response to the compound is evaluated over time using the appropriate biochemical and/or histological assays. In some cases, it may be appropriate to apply the compound of interest to the culture medium in conjunction with co-factors that would enhance the efficacy ofthe compound.

In another aspect, the animals of this invention can be used as a source of cells, differentiated or precursor, which can be immortalized in cell culture. Cells in which the normal function of the SLC5A8 protein is altered by a transgene may be isolated from potentially any tissue of the animal, as well as form animals at any developmental stage, e.g. embryonic to adult. The subject transgenic animals can, accordingly, be used as a source of material for the growth, identification, purification and detailed analysis of, inter aha, precursor cells, including stem cells and pluripotent progenitor cells for a variety of tissues.

Vectors used for transforming animal embryos are constructed using methods well known in the art, including, without limitation, the standard techniques of restriction endonuclease digestion, ligation, plasmid and DNA and RNA purification, DNA sequencing, and the like as described, for example in Sambrook, Fritsch, and Maniatis, eds., Molecular Cloning: A Laboratory Manual, (Cold Spring H arbor L aboratory Press, Cold Spring Harbor, N.Y. >1989!). Most practitioners are familiar with the standard resource materials as well as specific conditions and procedures.

VIII. Screening Assays

The mvention provides methods (also referred to herein as "screening assays") for identifying modulators, i.e., candidate or test compounds or agents (e.g., proteins, peptides, peptidomimetics, peptoids, small molecules or other drugs) which bind to SLC5A8 proteins, have a stimulatory or inhibitory effect on, for example, SLC5 A8 expression or SLC5A8 activity, or have a stimulatory or inhibitory effect on, for example, the expression or activity of a SLC5A8 substrate. Compounds thus identified can be used to modulate the activity of target gene products (e.g., the SLC5A8 gene) in a therapeutic protocol, to elaborate the biological function of the target gene product, or to identify compounds that disrupt normal target gene interactions. Given that the SLC5A8 polypeptide is a transmembrane protein, agents that bind to a SLC5A8 polypeptide may include its natural ligands, downstream signaling molecules, and other endogenous polypeptides as well as artificial compounds. In one embodiment, an assay detects agents which inhibit interaction of the subject SLC5A8 polypeptides with a SLC5A8- associated protein. A wide variety of assays may be used for this ptnpose, including labeled in vitro protein-protein binding assays, interaction trap assay, immunoassays for protein binding, and the like.

Given the role of SLC5 A8 in transporting sodium solute and in cancer development, the agents that bind to SLC5A8 as well as the agents that interfere with SLC5A8 binding to SLC5A8-associated proteins may be able to modulate transporting sodium solute or cancer development. Accordingly, one aspect of the invention provides a method for assessing the ability of an agent to modulate transporting sodium solute or cancer development, comprising: 1) combining: a first polypeptide including at least a portion of a SLC5A8 polypeptide, a second polypeptide including at least a portion of a SLC5A8-associated protein that interacts with the first polypeptide, and an agent, under conditions wherein the first polypeptide interacts with the second polypeptide in the absence of said agent, 2) determining if said agent interferes with the interaction, and 3) for an agent that interferes with the interaction, further assessing its ability to interfere with SLC5A8's ability to transport sodium solute or suppress tumor development.

hi one embodiment, an activity (e.g., the sodium solute transporting activity) of a SLC5A8 protein can be assayed as follows. Xenopus laevis oocytes are injected with mRNA encoding the SLC5A8 protein or a eukaryotic expression vector able to express such an mRNA, using a Drummond Nanoject (Drummond Scientific, Broomall, Pa. into the animal pole of defolliculated oocytes as described by Swick et al. ((1992) Proc. Natl. Acad. Sci. USA. 89:1812- 1816). The injected oocytes are then transferred to microtiter wells about 12 to 24 hours prior to being assayed. The transporter function of oocyte-expressed SLC5A8 polypeptide is assessed by sodium uptakes as described (see e.g., Romera et al. (2000) J. Biol. Chem. 275:24552-24559; Sciortino et al. (1999) Am. J. Physiol. 277-F611-623).

A variety of assay formats will suffice and, in light of the present disclosure, those not expressly described herein will nevertheless be comprehended by one of ordinary skill in the art. Assay formats which approximate such conditions as formation of protein complexes, enzymatic activity, may be generated in many different forms, and include assays based on cell-free systems, e.g., purified proteins or cell lysates, as well as cell-based assays which utilize intact cells. Simple binding assays can also be used to detect agents which bind to SLC5A8. Such binding assays may also identify agents that act by disrupting the interaction between a SLC5A8 polypeptide and a SLC5A8 interacting protein. Agents to be tested can be produced, for example, by bacteria, yeast or other organisms (e.g., natural products), produced chemically (e.g., small molecules, including peptidomimetics), or produced recombinantly. hi a preferred embodiment, the test agent is a small organic molecule, e.g., other than a peptide or oligonucleotide, having a molecular weight of less than about 2,000 daltons.

In many drug screening programs which test libraries of compounds and natural extracts, high throughput assays are desirable in order to maximize the number of compounds surveyed in a given period of time. Assays of the present invention which are performed in cell-free systems, such as may be developed with purified or semi-purified proteins or with lysates, are often preferred as "primary" screens in that they can be generated to permit rapid development and relatively easy detection of an alteration in a molecular target which is mediated by a test compound. Moreover, the effects of cellular toxicity and/or bioavailability ofthe test compound can be generally ignored in the in vitro system, the assay instead being focused primarily on the effect ofthe drug on the molecular target as maybe manifest in an alteration of binding affinity with other proteins or changes in enzymatic properties ofthe molecular target.

In preferred in vitro embodiments ofthe present assay, a reconstituted SLC5A8 complex comprises a reconstituted mixture of at least semi-purified proteins. By semi-purified, it is m^pϋnt t T..-.. the proteins utilized in the reconstituted mixture have been previously separated from other cellular or viral proteins. For instance, in contrast to cell lysates, the proteins involved in SLC5A8 complex formation are present in the mixture to at least 50% purity relative to all other proteins in the mixture, and more preferably are present at 90-95 %> purity. In certain embodiments of the subject method, the reconstituted protein mixture is derived by mixing highly purified proteins such that the reconstituted mixture substantially lacks other proteins (such as of cellular or viral origin) which might interfere with or otherwise alter the ability to measure SLC5 A8 complex assembly and/or disassembly.

Assaying SLC5A8 complexes, in the presence and absence of a candidate agent, can be accomplished in any vessel suitable for containing the reactants. Examples include microtitre plates, test tubes, and micro-centrifuge tubes. In a screening assay, the effect of a test agent may be assessed by, for example, assessing the effect ofthe test agent on kinetics, steady-state and/or endpoint ofthe reaction.

In one embodiment of the present invention, drug screening assays can be generated which detect inhibitory agents on the basis of their ability to interfere with assembly or stability ofthe SLC5A8 complex, hi an exemplary binding assay, the compound of interest is contacted with a mixture comprising a SLC5A8 polypeptide and at least one interacting polypeptide. Detection and quantification of SLC5A8 complexes provides a means for determining the compound's efficacy at inhibiting (or potentiating) interaction between the two polypeptides. The efficacy of the compound can be assessed by generating dose response curves from data obtained using various concentrations ofthe test compound. Moreover, a control assay can also be performed to provide a baseline for comparison. In the control assay, the formation of complexes is quantitated in the absence ofthe test compound.

Complex formation between the SLC5A8 polypeptides and a substrate polypeptide may be detected by a variety of techniques. For instance, modulation in the formation of complexes can be quantitated using, for example, detectably labeled proteins (e.g., radiolabeled, fluorescently labeled, or enzymatically labeled), by immunoassay, or by chromatographic detection. Surface plasmon resonance systems, such as those available from Biacore International AB (Uppsala, Sweden), may also be used to detect protein-protein interaction.

Often, it will be desirable to immobilize one of the polypeptides to facilitate separation of complexes from uncomplexed forms of one of the proteins, as well as to accommodate automation of the assay, hi an illustrative embodiment, a fusion protein can be provided which adds a domain that permits the protein to be bound to an insoluble matrix. For example, GST- SLC5A8 fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with a potential interacting protein, e.g., an ³⁵S-labeled polypeptide, and the test compound and incubated under conditions conducive to complex formation . Following incubation, the beads are washed to remove any unbound interacting protein, and the matrix bead-bound radiolabel determined directly (e.g., beads placed in scintillant), or in the supernatant after the complexes are dissociated, e.g., when microtitre plate is used. Alternatively, after washing away unbound protein, the complexes can be dissociated from the matrix, separated by SDS-PAGE gel, and the level of interacting polypeptide found in the matrix-bound fraction quantitated from the gel using standard electrophoretic techniques.

In a further embodiment, agents that bind to a SLC5A8 may be identified by using an immobilized SLC5A8. In an illustrative embodiment, a fusion protein can be provided which adds a domain that permits the protein to be bound to an insoluble matrix. For example, GST- SLC5A8 fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with a potential labeled binding agent and incubated under conditions conducive to binding. Following incubation, the beads are washed to remove any unbound agent, and the matrix bead-bound label determined directly, or in the supernatant after the bound agent is dissociated.

h yet another embodiment, the SLC5A8 polypeptide and potential interacting polypeptide can be used to generate an interaction trap assay (see also, U.S. Patent No. 5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J Biol Chem 268:12046- 12054; Bartel et al. (1993) Biotechniques 14:920-924; andlwabuchi et al. (1993) Oncogene 8:1693-1696), for subsequently detecting agents which disrupt binding ofthe proteins to one and other.

One aspect ofthe present invention provides reconstituted protein preparations including a SLC5A8 polypeptide and one or more interacting polypeptides.

In still further embodiments of the present assay, the SLC5 A8 complex is generated in whole cells, taking advantage of cell culture techniques to support the subject assay. For example, as described below, the SLC5A8 complex can be constituted in a eukaryotic cell culture system, including mammalian and yeast cells. Advantages to generating the subject assay in an intact cell include the ability to detect inhibitors which are nmctional in an environment more closely approximating that which therapeutic use of the inhibitor would require, including the ability of the agent to gain entry into the cell. Furthermore, certain ofthe in vivo embodiments ofthe assay, such as examples given below, are amenable to high throughput analysis of candidate agents.

The components of the SLC5A8 complex can be endogenous to the cell selected to support the assay. Alternatively, some or all of the components can be derived from exogenous sources. For instance, fusion proteins can be introduced into the cell by recombinant techniques (such as through the use of an expression vector), as well as by microinj ecting the fusion protein itself or m-RNA encoding the fusion protein.

In many embodiments, a cell is manipulated after incubation with a candidate agent and assayed for a SLC5A8 activity. In certain embodiments a SLC5A8 activity is represented by sodium transporting activity or tumor suppressing activity. In certain embodiments, SLC5A8 activities may also include, without limitation, complex formation between SLC5A8 and its associated proteins. SLC5A8 complex formation may be assessed by immunoprecipitation and analysis of co-immunoprecipiated proteins or affinity purification and analysis of co-purified proteins. Fluorescence Resonance Energy Transfer (FRET)-based assays may also be used to determine complex formation. Fluorescent molecules having the proper emission and excitation spectra that are brought into close proximity with one another can exhibit FRET. The fluorescent molecules are chosen such that the emission spectrum of one of the molecules (the donor molecule) overlaps with the excitation spectrum of the other molecule (the acceptor molecule). The donor molecule is excited by light of appropriate intensity within the donor's excitation spectrum. The donor then emits the absorbed energy as fluorescent light. The fluorescent energy it produces is quenched by the acceptor molecule. FRET can be manifested as a reduction in the intensity ofthe fluorescent signal from the donor, reduction in the lifetime of its excited state, and/or re-emission of fluorescent light at the longer wavelengths (lower energies) characteristic of the acceptor. When the fluorescent proteins physically separate, FRET effects are diminished or eliminated. (U.S. Patent No. 5,981,200).

In general, where the screening assay is a binding assay (whether protein-protein binding, agent-protein binding, etc.), one or more of the molecules may b e joined to a label, where the label c an directly or indirectly provide a detectable signal. V arious labels include ~~^J-^'~^'" ^<--"es, fluorescers, chemiluminescers, enzymes, specific binding molecules, particles, e.g., magnetic particles, and the like. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc. For the specific binding members, the complementary member would normally be labeled with a molecule that provides for detection, in accordance with known procedures.

A variety of other reagents may be included in the screening assay. These include reagents like salts and neutral proteins (e.g., albumin, detergents, etc) that are used to facilitate optimal protein-protein binding and or reduce nonspecific or background interactions. Reagents that improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, antimicrobial agents, etc. may be used. The mixture of components are added in any order that provides for the requisite binding. Incubations are performed at any suitable temperature, typically between 4 °C and 40 °C. Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high-throughput screening.

It is to be understood that the screening assays discussed above are applicable to identify therapeutic agents related to soluble SLC5A8 polypeptides and derivatives thereof. An exemplary derivative of soluble SLC5A8 polypeptides is a fusion protein containing soluble SLC5A8 polypeptide. Given the role of soluble SLC5A8 polypeptides in sodium transporting and/or tumor suppression, c ompositions that p erturb the formation or stability o f the p rotein- protein interactions between soluble SLC5A8 polypeptides and the proteins that they interact with, are c andidate pharmaceuticals for the treatment of SLC5A8-associated diseases such as cancer.

IX. Predictive Medicine

The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring clinical trials are used for prognostic (predictive) puφoses to thereby treat an individual. Generally, the invention provides a method of determining if a subject is at risk for a disorder related to a lesion in or the misexpression of a gene which encodes SLC5A8, for example cancers (e.g., colon cancer, breast cancer, thyroid cancer, or stomach cancer).

The method includes one or more of the following: 1) detecting, in a tissue of the subject, the presence or absence of a mutation which affects the expression ofthe SLC5A8 gene, or detecting the presence or absence of a mutation in a region which controls the expression of -^.1 ^ g_{^ a m}utation i_n the 5' control region; 2) detecting, in a tissue of the subject, the presence or absence of a mutation which alters the structure of the SLC5 A8 gene; 3) detecting, in a tissue of the subject, the misexpression of the SLC5A8 gene, at the mRNA level, e.g., detecting a non-wild type level of a mRNA; 4) detecting, in a tissue of the subject, the misexpression ofthe gene, at the protein level, e.g., detecting a non- wild type level of a SLC5A8 polypeptide; and 5) detecting, in a tissue ofthe subject, methylation ofthe SLC5A8 gene in the 5' SLC5A8 genomic nucleotide sequences (see detailed descriptions in the following section).

In preferred embodiments, the method may also include ascertaining the existence of at least one of: 1) a deletion of one or more nucleotides from the SLC5A8 gene; 2) an insertion of one or more nucleotides into the gene; 3) a point mutation, e.g., a substitution of one or more nucleotides of the gene; and 4) a gross chromosomal rearrangement of the gene, e.g., a translocation, inversion, or deletion.

For example, detecting the genetic lesion can include: (i) providing a probe/primer including an oligonucleotide containing a region of nucleotide sequence which hybridizes to a sense or antisense sequence from SEQ ID NO: 3 or 4, or naturally occurring mutants thereof, or 5' or 3' flanking sequences naturally associated with the SLC5A8 gene; (ii) exposing the probe/primer to nucleic acid of the tissue; and detecting, by hybridization, e.g., in situ hybridization, of the probe/primer to the nucleic acid, the presence or absence of the genetic lesion.

hi preferred embodiments, detecting the misexpression includes ascertaining the existence of at least one of: an alteration in the level of a messenger RNA transcript of the SLC5 A8 gene; the presence of a non-wild type splicing pattern of a messenger RNA transcript ofthe gene; or a non-wild type level of SLC5A8.

Methods of the invention can be used prenatally or to determine if a subject's offspring will be at risk for a disorder. In prefeπed embodiments, the method includes determining the structure of a SLC5A8 gene, an abnormal structure being indicative of risk for the disorder.

In preferred embodiments, the method includes contacting a sample from the subject with an antibody to the SLC5A8 protein or a nucleic acid which hybridizes specifically with the gene. These and other embodiments are discussed below.

X. Diagnostic and Prognostic Assays Diagnostic and prognostic assays of the invention include method for assessing the expression level of SLC5A8 molecules and for identifying variations and mutations in the sequence of SLC5A8 molecules. In certain embodiments, the invention provides methods by assaying the SLC5A8 expression leyel so as to determine whether a patient has or does not have a disease condition. Further, such a disease condition may be characterized by decreased expression of SLC5A8 nucleic acid or protein described herein. In certain embodiments, the invention provides methods for determining whether a patient is or is not likely to have a SLC5A8-associated disease by detecting the expression of the SLC5A8 nucleotide sequences. In further embodiments, the invention provides methods for determining whether the patient is having a relapse or determining whether a patient's cancer is responding to treatment.

The presence, level, or absence of SLC5A8 protein or nucleic acid in a biological sample can be evaluated by obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting SLC5A8 protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes SLC5A8 protem such that the presence of SLC5 A8 protein or nucleic acid is detected in the biological sample. The level of expression of the SLC5A8 gene can be measured in a number of ways, including, but not limited to: measuring the mRNA encoded by the SLC5A8 genes; measuring the amount of protein encoded by the SLC5A8 gene; or measuring the activity of the protein encoded by the SLC5A8 gene. The level of mRNA corresponding to the SLC5A8 gene in a cell can be determined both by in situ and by in vitro formats.

The isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, polymerase chain reaction (PCR) analyses and probe arrays. One preferred diagnostic method for the detection of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to the mRNA encoded by the SLC5A8 gene. The nucleic acid probe can be, for example, a full-length SLC5A8 nucleic acid, such as the nucleic acid of SEQ ID NO: 3 or 4, or a portion thereof, such as an oligonucleotide of at least 7, 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient t o specifically hybridize under s tringent c onditions t o S LC5A8 mRNA or genomic DNA. The probe can be disposed on an address of an array, e.g., an array described below. Other suitable probes for use in the diagnostic assays are described herein.

In one format, mRNA (or cDNA) is immobilized on a surface and contacted with the — ~" -^f— example, by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose, hi an alternative format, the probes are immobilized on a surface and the mRNA (or cDNA) is contacted with the probes, for example, in a two-dimensional gene chip array d escribed below. A skilled artisan can adapt known mRNA detection methods for use in detecting the level of mRNA encoded by the SLC5A8 gene.

The level of SLC5A8 mRNA in a sample can be evaluated with nucleic acid amplification, e.g., by RT-PCR (Mullis (1987) U.S. Pat. No. 4,683,202), ligase chain reaction (Barany (1991) Proc. Natl. Acad. Sci. USA 88:189-193), self sustained sequence replication (Guatelli et al, (1990) Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh et al, (1989), Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-Beta Replicase (Lizardi et al, (1988) Bio/Technology 6:1197), rolling circle replication (Lizardi et al, U.S. Patent. No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques known in the art. As used herein, amplification primers are defined as being a pair of nucleic acid molecules that can anneal to 5' or 3' regions of a gene (plus and minus strands, respectively, or vice-versa) and contain a short region in between. In general, amplification primers are from about 10 to 30 nucleotides in length and flank a region from about 50 to 200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a nucleic acid molecule comprising the nucleotide sequence flanked by the primers.

For in situ methods, a cell or tissue sample can be prepared/processed and immobilized on a support, typically a glass slide, and then contacted with a probe that can hybridize to mRNA that encodes the SLC5 A8 gene being analyzed.

In another embodiment, the methods further contacting a control sample with a compound or agent capable of detecting SLC5A8 mRNA, or genomic DNA, and comparing the presence of SLC5A8 mRNA or genomic DNA in the control sample with the presence of SLC5 A8 mRNA or genomic DNA in the test sample.

A variety of methods can be used to determine the level of protein encoded by SLC5A8. In general, these methods include contacting an agent that selectively binds to the protein, such as an antibody with a sample, to evaluate the level of protein in the sample. In a preferred embodiment, the antibody bears a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')₂) can be used. The term "labeled," with regard to the probe or antibody, is intended to encompass direct labeling ofthe probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with a detectable substance. Examples of detectable substances are provided herein.

The detection methods can be used to detect SLC5A8 protein in a biological sample in vitro as well as in vivo. In vitro techniques for detection of SLC5A8 protein include enzyme linked immunosorbent assays (ELISAs), immunoprecipitations, immunofluorescence, enzyme immunoassay (EIA), radioimmunoassay (RIA), and Western blot analysis. In vivo techniques for detection of SLC5A8 protein include introducing into a subject a labeled anti-SLC5A8 antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques, hi another embodiment, the sample is labeled, e.g., biotinylated and then contacted to the antibody, e.g., an anti-SLC5A8 antibody positioned on an antibody array (as described below). The sample can be detected, e.g., with avidin coupled to a fluorescent label.

In another embodiment, the methods further include contacting the control sample with a compound or agent capable of detecting SLC5A8 protein, and comparing the presence of SLC5A8 protein in the control sample with the presence of SLC5A8 protein in the test sample.

The invention also includes kits for detecting the presence of SLC5A8 in a biological sample. For example, the kit can include a compound or agent capable of detecting SLC5A8 protein or mRNA in a biological sample; and a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect SLC5A8 protein-or nucleic acid.

For antibody-based kits, the kit can include: (1) a first antibody (e.g., attached to a solid support) which binds to a polypeptide corresponding to a marker of the invention; and, optionally, ( 2) a s econd, d ifferent antibody which b inds to e ither t he p olypeptide o r t he first antibody and is conjugated to a detectable agent.

For oligonucleotide-based kits, the kit can include: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a polypeptide corresponding to a marker of the invention or (2) a pair of primers useful for amplifying a nucleic acid molecule corresponding to a marker ofthe invention. The kit can also buffering agent, a preservative, or a protein stabilizing agent. The kit can also includes components necessary for detecting the detectable agent (e.g., an enzyme or a substrate). The kit can also contain a control sample or a series of control samples which can be assayed and compared to the test sample contained. Each component of the kit can be enclosed within an individual container and all of the various containers can be within a single package, along with instructions for inteφreting the results ofthe assays performed using the kit.

The diagnostic methods described herein can identify subjects having, or at risk of developing, a disease or disorder associated with misexpressed or aberrant or unwanted SLC5A8 expression or activity. As used herein, the term "unwanted" includes an unwanted phenomenon involved in a biological response such as pain or deregulated cell proliferation.

In one embodiment, a disease or disorder associated with aberrant or unwanted SLC5A8 expression or activity is identified. A test sample is obtained from a subject and SLC5A8 protein or nucleic acid (e.g., mRNA or genomic DNA) is evaluated, wherein the level, e.g., the presence or absence, of SLC5A8 protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant or unwanted SLC5A8 expression or activity.

The prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant or unwanted SLC5A8 expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a pain or solute transport disorder.

In yet another aspect, the invention features a method of evaluating a test compound (see also, "Screening Assays", above). The method includes providing a cell and a test compound; contacting the test compound to the cell; obtaining a subject expression profile for the contacted cell; and comparing the subject expression profile to one or more reference profiles. The profiles include a value representing the level of SLC5A8 expression. In a preferred embodiment, the subject expression profile is compared to a target profile, e.g., a profile for a normal cell or for desired condition of a cell. The test compound is evaluated favorably if the subject expression profile is more similar to the target profile than an expression profile obtained from an uncontacted cell

thods of Assaying Methylation of SLC5A8 Nucleotides In certain aspects, the invention provides assays and methods using the SLC5A8 nucleotide sequences as molecular markers that distinguish between healthy cells and SLC5A8- associated diseased cells (cells of colon cancer, breast cancer, thyroid cancer or stomach cancer). In one aspect, a molecular marker of the invention is a differentially methylated SLC5A8 nucleotide sequence.

Accordingly, in certain embodiments, the invention provides assays for detecting differentially methylated SLC5A8 nucleotide sequences, such as the differential methylation patterns in nucleic acid sequence of SEQ ID NO: 12, 13 or 14. Thus, a differentially methylated SLC5A8 nucleotide sequence, in its methylated state, can be a SLC5A8-associated cancer- specific modification that serves as a target for detection using various methods described herein and the methods that are well within the purview of the skilled artisan in view of the teachings of this application.

In certain aspects, such methods for detecting methylated SLC5A8 nucleotide sequences are based on treatment of SLC5A8 genomic DNA with a chemical compound which converts non-methylated C, but not methylated C (i.e., 5mC), to a different nucleotide base. One such compound is sodium bisulfite, which converts C, but not 5mC, to U. Methods for bisulfite treatment of DNA are known in the art (Herman, et al, 1996, Proc Natl Acad Sci USA, 93:9821-6; Herman and Baylin, 1998, Current Protocols in Human Genetics, N. E. A. Dracopoli, ed., John Wiley & Sons, 2:10.6.1-10.6.10; U.S. Patent No. 5,786,146). To illustrate, when an DNA molecule that contains unmethylated C nucleotides is treated with sodium bisulfite to become a compound-converted DNA, the sequence of that DNA is changed (C->U). Detection ofthe U in the converted nucleotide sequence is indicative of an unmethylated C.

The different nucleotide base (e.g., U) present in compound-converted nucleotide sequences can subsequently be detected in a variety of ways. In a preferred embodiment, the present invention provides a method of detecting U in compound-converted SLC5A8 DNA sequences by using "methylation sensitive PCR" (MSP) (see, e.g., Herman, et al, 1996, Proc. Natl. Acad. Sci. USA, 93:9821-9826; U.S. Patent Nos. 6,265,171; 6,017,704; and 6,200,756). h MSP, one set of primers (i.e., comprising a forward and a reverse primer) amplifies the compound-converted t emplate s equence i f C b ases i n C pG d inucleotides w ithin t he S LC5 A8 DNA are methylated. This set of primers is called "methylation-specific primers." Another set of primers amplifies the compound-converted template sequence if C bases in CpG dinucleotides within the SLC5A8 5' flanking sequence are not methylated. This set of primers is called "unmethylation-specific primers."

In MS-PCR, the reactions use the compound-converted DNA from a sample in a subject. In assays for SLC5A8 methylated DNA, methylation-specific primers are used. In the case where C within CpG dinucleotides of the target sequence of the DNA are methylated, the methylation-specific primers will amplify the compound-converted template sequence in the presence of a polymerase and an MSP product will be produced. If C within CpG dinucleotides ofthe target sequence ofthe DNA are not methylated, the methylation-specific primers will not amplify the compound-converted template sequence in the presence of a polymerase and an MSP product will not be produced

It is often also useful to run a control reaction for the detection of unmethylated SLC5A8 DNA. The reactions uses the compound-converted DNA from a sample in a subject and unmethylation-specific primers are used, hi the case where C within CpG dinucleotides of the target sequence of the DNA are unmethylated, the unmethylation specific primers will amplify the compound-converted template sequence in the presence of a polymerase and an MSP product will be produced. If C within CpG dinucleotides ofthe target sequence ofthe DNA are methylated, the unmethylation-specific primers will not amplify the compound-converted template sequence in the presence of a polymerase and an MSP product will not be produced. Note that a biologic sample will often contain a mixture of both neoplastic cells that give rise to a signal with methylation specific primers, and normal cellular elements that give rise to a signal with unmethylation-specific primers. The unmethyl specific signal is often of use as a control reaction, but does not in this instance imply the absence of cancer (e.g., colon cancer, breast cancer, thyroid cancer, or stomach cancer) as indicated by the positive signal derived from reactions using the methylation specific primers.

Primers for an MSP reaction are derived from the compound-converted SLC5A8 template sequence. Herein, "derived from" means that the sequences of the primers are chosen such that the primers amplify the compound-converted template sequence in an MSP reaction. Each primer comprises a single-stranded DNA fragment which is at least 8 nucleotides in length. Preferably, the primers are less than 50 nucleotides in length, more preferably from 15 to 35 nucleotides in length. Because the compound-converted SLC5A8 template sequence can be either the Watson strand or the Crick strand of the double-stranded DNA that is treated with ^.-^j-^. — ^τ~—ulfite, the sequences ofthe primers is dependent upon whether the Watson or Crick compound-converted template sequence is chosen to be amplified in the MSP. Either the Watson or Crick strand can be chosen to be amplified.

The compound-converted SLC5A8 template sequence, and therefore the product of the MSP reaction, can be between 20 to 3000 nucleotides in length, preferably between 50 to 500 nucleotides in length, more preferably between 80 to 150 nucleotides in length. Preferably, the methylation-specific primers result in an MSP product of a different length than the MSP product produced by the unmethylation-specific primers.

A variety of methods can be used to determine if an MSP product has been produced in a reaction assay. One way to determine if an MSP product has been produced in the reaction is to analyze a portion of the reaction by agarose gel electrophoresis. For example, a horizontal agarose gel of from 0.6 to 2.0% agarose is made and a portion of the MSP reaction mixture is electrophoresed through the agarose gel. After electrophoresis, the agarose gel is stained with ethidium bromide. MSP products are visible when the gel is viewed during illumination with ultraviolet light. By comparison to standardized size markers, it is determined if the MSP product is ofthe correct expected size.

Other methods can be used to determine whether a product is made in an MSP reaction. One such method is called "real-time PCR." Real-time PCR utilizes a thermal cycler (i.e., an instrument that provides the temperature changes necessary for the PCR reaction to occur) that incoφorates a fluorimeter (i.e. an instrument that measures fluorescence). The real-time PCR reaction mixture also contains a reagent whose incoφoration into a product can be quantified and whose quantification is indicative of copy number of that sequence in the template. One such reagent is a fluorescent dye, called SYBR Green I (Molecular Probes, hie; Eugene, Oregon) that preferentially binds double-stranded DNA and whose fluorescence is greatly enhanced by binding of double-stranded DNA. When a PCR reaction is performed in the presence of SYBR Green I, resulting DNA products bind SYBR Green I and fluorescence. The fluorescence is detected and quantified by the fluorimeter. Such technique is particularly useful for quantification of the amount of the product in the PCR reaction. Additionally, the product from the PCR reaction may be quantitated in "real-time PCR" by the use of a variety of probes that h ybridize t o t he p roduct i ncluding T aqMan p robes and m olecular b eacons. Q uantitation may be on an absolute basis, or may be relative to a constitutively methylated DNA standard, or may be relative to an unmethylated DNA standard. In one instance the ratio of methylated nr r-ic Λ o -J -,srived product to unmethylated derived SLC5A8 product maybe constructed. Methods for detecting methylation ofthe SLC5A8 DNA in this invention are not limited to MSP, and may cover any assay for detecting DNA methylation. Another example method for detecting methylation of the SLC5A8 DNA is by using "methylation-sensitive" restriction endonucleases. Such methods comprise treating the genomic DNA isolated from a subject with an methylation-sensitive restriction endonuclease and then using the restriction endonuclease- treated DNA as a template in a PCR reaction. Herein, methylation-sensitive restriction endonucleases recognize and cleave a specific sequence within the DNA if C bases within the recognition sequence are not methylated. If C bases within the recognition sequence of the restriction endonuclease are methylated, the DNA will not be cleaved. Examples of such methylation-sensitive restriction endonucleases include, but are not limited to Hpall, Smal, SacII, Eagl, Mspl, BstUI, and BssHII. In this technique, a recognition sequence for a methylation-sensitive restriction endonuclease is located within the template DNA, at a position between the forward and reverse primers used for the PCR reaction. In the case that a C base within the methylation-sensitive restriction endonuclease recognition sequence is not methylated, the endonuclease will cleave the DNA template and a PCR product will not be formed when the DNA is used as a template in the PCR reaction. In the case that a C base within the methylation-sensitive restriction endonuclease recognition sequence is methylated, the endonuclease will not cleave the DNA template and a PCR product will be formed when the DNA is used as a template in the PCR reaction. Therefore, methylation of C bases can be determined by the absence or presence of a PCR product (Kane, et al, 1997, Cancer Res, 57:808-11). No sodium bisulfite is used in this technique.

Yet another exemplary method for detecting methylation of the SLC5 A8 DNA is called the modified MSP, which method utilizes primers that are designed and chosen such that products of the MSP reaction are susceptible to digestion by restriction endonucleases, depending upon whether the compound-converted template sequence contains CpG dinucleotides or UpG dinucleotides.

Yet other methods for detecting methylation of the SLC5A8 DNA include the MS- SnuPE methods. This method uses compound-converted SLC5A8 DNA as a template in a primer extension reaction wherein the primers used produce a product, dependent upon whether the compound-converted template contains CpG dinucleotides or UpG dinucleotides (see e.g., Gonzalgo, et al, 1997, Nucleic Acids Res., 25:2529-31). Another exemplary method for detecting methylation of the SLC5A8 DNA is called COBRA (i.e., combined bisulfite restriction analysis). This method has been routinely used for DNA methylation detection and is well known in the art (see, e.g., Xiong, et al, 1997, Nucleic

Acids Res, 25:2532-4). i In certain embodiments, the invention provides methods that involve directly sequencing the product resulting from an MSP reaction to determine if the compound-converted SLC5A8 template sequence contains CpG dinucleotides or UpG dinucleotides. Molecular biology techniques such as directly sequencing a PCR product are well known in the art.

XII .SLC5 A8 Oligonucleotides for Methylation Detection

hi yet other aspects, the application provides oligonucleotide primers for amplifying a region within the SLC5A8 nucleic acid sequence of any one of SEQ ID NOs: 5-11. In certain aspects, a pair ofthe oligonucleotide primers (for example, SEQ ID NOs: 5-7) can be used in a detection assay, such as the Hpall assay. In certain aspects, primers used in an MSP reaction can specifically distinguish between methylated and non-methylated SLC5A8 DNA, for example, SEQ ID NOs: 8-11.

The primers of the invention have sufficient length and appropriate sequence so as to provide specific initiation of amplification of SLC5A8 nucleic acids. Primers of the invention are designed to be "substantially" complementary to each strand of the SLC5A8 nucleic acid sequence to be amplified. While exemplary primers are provided in SEQ ID NOs: 5-11, it is understood that any primers that hybridizes with the bisulfite-converted SLC5A8 sequence of SEQ ID NOs: 12-14 are included within the scope of this invention and is useful in the method of the invention for detecting methylated nucleic acid, as described. Similarly, it is understood that any primers that would serve to amplify a methylation sensitive restriction site or sites within the differentially methylated region of SEQ ID NOs: 12-14 are included within the scope of this invention and is useful in the method of the invention for detecting nucleic methylated nucleic acid, as described.

The oligonucleotide primers of the invention may be prepared by using any suitable method, such as conventional phosphotriester and phosphodiester methods or automated embodiments thereof. In one such automated embodiment, diethylphosphoramidites are used as starting materials and may be synthesized as described by Beaucage, et al. (Tetrahedron Letters, 22:1859-1862, 1981). One method for synthesizing oligonucleotides on a modified solid support is described in U.S. Patent No. 4,458,066.

In particular, a pair of primers are selected to amplify the SLC5 A8 methylation target region or a DNA segment thereof. The targeted DNA segment that is amplified by the primers contains a plurality of sites that are recognized by the methylation sensitive restriction enzyme and is located between base pairs 82200 to 83267 of GenBank entry AC063951. In one preferred embodiment, the targeted DNA segment comprises at least four Hpall sites and the primers amplify a region including base pair 82638 through base pair 83080 of GenBank entry AC063951. hi another highly preferred embodiment, the targeted DNA segment comprises at least six Hpall sites and the primers amplify a region including base pair 82430 through base pair 83080 of GenBank entry AC063951.

For example, each primer comprises a single-stranded DNA fragment which is at least 8 nucleotides in length. Preferably, the primers are less than 50 nucleotides in length, more preferably from 15 to 35 nucleotides in length. The sequences of the primers are derived from the sequence of the targeted DNA segment, i.e., the segment that is to be amplified. The sequence of the forward primer is identical to a sequence at the 5' end of the targeted DNA segment. The sequence of the reverse primer is the reverse complement of a sequence at the 3' end of targeted DNA segment.

Xπi. Subjects and Samples

In certain aspects, the invention relates to a subject suspected of having or has a SLC5A8-associated disease, such as colon cancer, breast cancer, thyroid cancer, or stomach cancer. Alternatively, a subject may be undergoing routine screening and may not necessarily be suspected of having such a SLC5A8-associated disease or condition. In a preferred embodiment, the subject is a human subject, and the SLC5A8-associated disease is colon neoplasia.

Assaying for SLC5A8 markers discussed above in a sample from subjects not known to have a cancer (e.g., colon cancer, breast cancer, thyroid cancer, or stomach cancer) can aid in diagnosis of such a cancer in the subject. To illustrate, detecting the methylation status of the SLC5A8 nucleotide sequence by MSP can be used by itself, or in combination with other various assays, to improve the sensitivity and/or specificity for detecting a cancer. Preferably, such a detection is made at an early stage in the development of cancer, so that treatment is more likely to be effective.

In addition to diagnosis, assaying of a SLC5A8 marker in a sample from a subject not lαiown to have a cancer (e.g., colon cancer, breast cancer, thyroid cancer, or stomach cancer) can be prognostic for the subject (e.g., indicating the probable course of the disease). To illustrate, subjects having a predisposition to develop colon neoplasia may possess methylated SLC5A8 nucleotide sequences. Assaying of SLC5A8 markers in a samples from subjects can also be used to select a particular therapy or therapies which are particularly effective against the colon neoplasia in the subject, or to exclude therapies that are not likely to be effective.

Assaying of SLC5A8 markers in samples from subjects that are known to have, or to have had, a cancer associated with silencing of the SLC5A8 gene is also useful. For example, the present methods can be used to identify whether therapy is effective or not for certain subjects. One or more samples are taken from the same subject prior to and following therapy, and assayed for the SLC5A8 markers. A finding that the SLC5A8 marker is present in the sample taken prior to therapy and absent (or at a lower level) after therapy would indicate that the therapy is effective and need not be altered. In those cases where the SLC5A8 marker is present in the sample taken before therapy and in the sample taken after therapy, it may be desirable to alter the therapy to increase the likelihood that the cancer will be eradicated in the subject. Thus, the present method may obviate the need to perform more invasive procedures which are used to determine a patient's response to therapy.

Cancers frequently recur following therapy in patients with advanced cancers. In this and other instances, the assays ofthe invention are useful for monitoring over time the status of an c ancer associated w ith s ilencing o f t he S LC5 A8 gene. For s ubj ects in w hich a c ancer i s progressing, a SLC5A8 marker may be absent from some or all samples when the first sample is taken and then appear in one or more samples when the second sample is taken. For subjects in which cancer is regressing, a SLC5A8 marker may be present in one or a number of samples when the first sample is taken and then be absent in some or all of these samples when the second sample is taken.

Samples for use with the methods described herein may be essentially any biological material of interest. For example, a sample may be a bodily fluid sample from a subject, a tissue sample from a subject, a solid or semi-solid sample from a subject, a primary cell culture or tissue c ulture o f m aterials d erived from a s ubj ect, c ells from a c ell 1 ine, o r m edium o r o ther extracellular material from a cell or tissue culture, or a xenograft (meaning a sample of a cancer from a first subject, e.g., a human, that has been cultured in a second subject, e.g., an immuno- compromised mouse). The term "sample" as used herein is intended to encompass both a biological material obtained directly from a subject (which may be described as the primary sample) as well as any manipulated forms or portions of a primary sample. A sample may also be obtained by contacting a biological material with an exogenous liquid, resulting in the production of a lavage liquid containing some portion of the contacted biological material. Furthermore, the term "sample" is intended to encompass the primary sample after it has been mixed with one or more additive, such as preservatives, chelators, anti-clotting factors, etc.

In certain embodiments, a bodily fluid sample is a blood sample. In this case, the term "sample" is intended to encompass not only the blood as obtained directly from the patient but also fractions of the blood, such as plasma, serum, cell fractions (e.g., platelets, erythrocytes, and lymphocytes), protein preparations, nucleic acid preparations, etc. In certain embodiments, a bodily fluid sample is a urine sample or a colonic effluent sample. In certain embodiments, a bodily fluid sample is a stool sample.

A subject is preferably a human subject, but it is expected that the molecular markers disclosed herein, and p articularly their homologs from other animals, are of similar utility in other animals. In certain embodiments, it may be possible to detect a SLC5A8 marker directly in an organism without obtaining a separate portion of biological material. In such instances, the term "sample" is intended to encompass that portion of biological material that is contacted with a reagent or device involved in the detection process.

In certain embodiments, DNA which is used as the template in an MSP reaction is obtained from a bodily fluid sample. Examples of preferred bodily fluids are blood, serum, plasma, a blood-derived fraction, stool, colonic effluent or urine. Other body fluids can also be used. Because they can be easily obtained from a subject and can be used to screen for multiple diseases, blood or blood-derived fractions are especially useful. For example, it has been shown that DNA alterations in colorectal cancer patients can be detected in the blood of subjects (Hibi, et al, 1998, Cancer Res, 58:1405-7). Blood-derived fractions can comprise blood, serum, plasma, or other fractions. For example, a cellular fraction can be prepared as a "buffy coat" (i.e., leukocyte-enriched blood portion) by centrifuging 5 ml of whole blood for 10 min at 800 ^ti™-^.-^,, rrr, .. i y at room temperature. Red blood cells sediment most rapidly and are present as the bottom-most fraction in the centrifuge tube. The buffy coat is present as a thin creamy white colored layer on top ofthe red blood cells. The plasma portion ofthe blood forms a layer above the buffy coat. Fractions from blood can also be isolated in a variety of other ways. One method is by taking a fraction or fractions from a gradient used in centrifugation to enrich for a specific size or density of cells.

DNA is then isolated from samples from the bodily fluids. Procedures for isolation of DNA from such s amples are well known to those skilled in the art. C ommonly, such DNA isolation procedures comprise lysis of any cells present in the samples using detergents, for example. After cell lysis, proteins are commonly removed from the DNA using various proteases. RNA is removed using RNase. The DNA is then commonly extracted with phenol, precipitated in alcohol and dissolved in an aqueous solution.

XIV. Therapeutic methods for SLC5A8-associated diseases.

Yet another aspect of this application pertains to methods of treating a SLC5A8- associated disease (e.g., a proliferative disease such as cancer) which arises from reduced expression or over-expression of the SLC5A8 gene in cells. In certain cases, such SLC5A8- associated diseases (for example, colon cancer, breast cancer, thyroid cancer, or stomach cancer) can result from a wide variety of pathological cell proliferative conditions, hr certain embodiments, treatment of a SLC5A8-associated disorder includes modulation of the SLC5A8 gene expression or SLC5A8 activity. The term "modulate" envisions the suppression of expression of SLC5A8 when it is over-expressed, or augmentation of SLC5A8 expression when it is under-expressed.

In an embodiment, the present invention provides a therapeutic method by using a SLC5A8 gene construct as a part of a gene therapy protocol, such as to reconstitute the function of a SLC5A8 protein (e.g., SEQ TD NO: 1) in a cell in which the SLC5A8 protein is mis- expressed or non-expressed. T o illustrate, cell types which exhibit pathological or abnormal growth presumably depend at least in part on a function of a SLC5A8 protein. For example, gene therapy constructs encoding the SLC5A8 protein can be utilized in a cancer that is associated with silencing of the SLC5A8 gene, such as colon cancer, breast cancer, thyroid cancer, or stomach cancer.

In certain embodiments, the invention provides therapeutic methods using agents which expression of SLC5A8. Loss of SLC5A8 gene expression in a SLC5A8-associated diseased cells may be due at least in part to methylation of the SLC5A8 nucleotide sequence, methylation suppressive agents such as 5-deoxyazacytidine or 5-azacytidine can be introduced into the diseased cells. Other similar agents will be known to those of skill in the art. In a preferred embodiment, the SLC5A8-associated disease is colon neoplasia associated with increased methylation of SLC5A8 nucleotide sequences.

The present invention also provides gene therapy for the treatment of proliferative or immunologic disorders which are associated with SLC5A8. Such therapy would achieve its therapeutic effect by introduction of the SLC5 A8 polynucleotide encoding full-length SLC5 A8 into diseased cells.

Delivery of the SLC5A8 polynucleotide or the SLC5A8 gene can be achieved using a recombinant expression vector such as a chimeric virus or a colloidal dispersion system. Especially preferred for therapeutic delivery of antisense sequences is the use of targeted liposomes. Various viral vectors which can be utilized for gene therapy as taught herein include adenovirus, heφes virus, vaccinia, or, preferably, an RNA virus such as a retrovirus. Preferably, the retroviral vector is a derivative of a murine or avian retrovirus. Examples of retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). Preferably, when the subject is a human, a vector such as the gibbon ape leukemia virus (GaLV) is utilized. A number of additional retroviral vectors can incoφorate multiple genes. All of these vectors can transfer or incoφorate a gene for a selectable marker so that transduced cells can be identified and generated. By inserting a SLC5A8 sequence of interest into the viral vector, along with another gene which encodes the ligand for a receptor on a specific target cell, for example, the vector is target-specific. Retroviral vectors can be made target-specific by attaching, for example, a sugar, a glycolipid or a protein. Preferred targeting is accomplished by using an antibody to target the retroviral vector. Those skilled in the art will know of, or can readily ascertain without u ndue e xperimentation, s pecifϊc p olynucleotide s equences w hich c an b e i nserted i nto the retroviral genome or attached to a viral envelope to allow target-specific delivery of the retroviral vector containing the SLC5 A8 gene.

The invention also relates to a medicament or pharmaceutical composition comprising a SLC5A8 5' flanking polynucleotide or a SLC5A8 5' flanking polynucleotide operably linked to ^{1C Λ} 8 structural gene, respectively, in a pharmaceutically acceptable excipient or medium wherein the medicament is used for therapy of SLC5A8-associated diseases, such as colon cancer, breast cancer, thyroid cancer, or stomach cancer.

Exemplification

The invention now being generally described, it will be more readily understood by reference to the following examples, which are included merely for puφoses of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.

Abstract:

We identify a new gene, SLC5A8, and show it is a candidate tumor suppressor gene whose silencing by aberrant methylation is a common and early event in human colon neoplasia. Aberrant DNA methylation has been implicated as a component of an epigenetic mechanism that silences genes in human cancers. Using restriction landmark genome scanning, we performed a global search to identify new genes that would be aberrantly methylated at high frequency in human colon cancer. From among 1,231 genomic Notl sites assayed, site 3D41 was identified as methylated in 11 of 12 colon cancers profiled. Site 3D41 mapped to exon 1 of SLC5A8, a novel transcript that we assembled. In normal colon mucosa we found SLC5A8 exon 1 is unmethylated, and SLC5A8 transcript is expressed. In contrast, SLC5A8 exon 1 proved aberrantly methylated in 59% of primary colon cancers and 52% of colon cancer cell lines. SLC5A8 exon 1 methylated cells were uniformly silenced for SLC5A8 expression, but reactivated expression upon treatment with a demethylating drug, 5-azacytidine. Transfection of SLC5A8 suppressed colony growth in each of three SLC5A8 deficient cell lines, but showed no suppressive effect in any of three SLC5A8 proficient cell lines. SLC5A8 exon 1 methylation is an early event, detectable in colon adenomas, and in even earlier microscopic colonic aberrant crypt foci. Structural homology and functional testing demonstrated SLC5A8 is a novel member ofthe family of sodium solute symporters, which are now added as anew class of candidate colon cancer suppressor genes.

Introduction:

Cytosine methylation within CpG dinucleotides is a recognized epigenetic DNA modification, which in normal human tissues is excluded from CpG rich "islands" that mark the oromoters of certain genes (Baylin, et al, 1998, Adv Cancer Res 72:141-96; Jones, et al, 1999, Trends Genet 15: 34-7; Baylin, et al, 2002, Cancer Cell 1: 299-305). Global hypomethylation accompanied by aberrant focal CpG island hypermethylation has emerged as one ofthe signature alterations evidenced by the cancer genome (Baylin, et al, 1998, Adv Cancer Res 72:141-96; Jones, et al, 1999, Trends Genet 15:34-7; Baylin, et al, 2002, Cancer Cell 1:299- 305; Feinberg, et al, 1983, Nature 301:89-92). Moreover, silencing of gene expression as marked by aberrant methylation of CpG island promoter regions has emerged as a novel mechanism for the inactivation of tumor suppressor genes that provides an alternative to either mutation or to allelic loss (Baylin, et al, 1998, Adv Cancer Res 72:141-96; Jones, et al, 1999, Trends Genet 15:34-7; Kane, et al, 1997, Cancer Res 57:808-11; Veigl, et al, 1998, Proc Natl Acad Sci U S A 95:8698-702). Additionally, aberrant methylation of defined genomic sequences can serve as a potentially useful diagnostic marker for detection of human cancers (Grady, et al, 2001, Cancer Res 61:900-2; Usadel, et al, 2002, Cancer Res 62S:371-5).

Restriction landmark genome scanning (RLGS) provides a global analysis of methylation events in a cancer cell by providing a two dimensional display ofthe methylation status of genomic Notl sites (Costello, et al, 2000, Nat Genet 24:132-8). To identify new tumor suppressor genes and /or identify new genes targeted for methylation in human colon cancer, we carried out RLGS analysis of 12 colon cancer cell lines. This analysis lead to the identification of a novel transcript SLC5A8, whose aberrant methylation and transcriptional silencing was found to be a common and early event in human colon cancers, and that was found to encode a novel sodium symporter whose restoration can markedly suppress colony forming ability of colon cells in which endogenous SLC5A8 has been inactivated.

Significance:

This study demonstrates the application of restriction landmark genome scanning to identify a novel high frequency aberrant methylation event in human colon cancer. We extend that observation to identify a novel sodium transporter, SLC5A8, silenced by the methylation event. SLC5A8 methylation is among the most frequent molecular alterations in colon cancer, and finding SLC5A8 is a growth suppressor adds sodium transporters as a new functional class that can act as tumor suppressors. Moreover, detecting SLC5A8 methylation in aberrant crypt foci demonstrates this event as one ofthe earliest molecular changes in colon neoplasia, and adds further molecular support to the model in which at least some aberrant crypt foci are able to progress to more advanced colon adenomas and cancers. Example 1 :

Figure 3 depicts certain aspects ofthe present invention. The numerical coordinates are those of genomic clone AC063951. Lollipops designate CpG sites that are potential acceptors of aberrant methylation. Asterisks designate sites recognized by the Hpall restriction enzyme that cut these sites if unmethylated, but not if methylated. Shown are the positions of PCR primers that amplify regions crossing 6 Hpall sites, or regions crossing 4 Hpall sites. Also shown is the position of PCR primers designed for a methyl-specific PCR (MS-PCR) assays that amplify sodium bisulfite converted DNA specifically derived from templates that are either methylated or unmethylated at CpG dinucleotides interrogated by the PCR primers. Also shown in the gray bar is the 5' end of exon 1 of the SLC5A8 transcript which overlaps with the methylation sites detected in both MS-PCR and Hpall based assays. Lastly indicated is a site corresponding to methylation site 2D41 detected in Restriction Landmark Genome Scanning assay as methylated in colon cancer cell lines, though not in primary tumors.

Colon cancers that are aberrantly methylated can be detected as they are resistant to cutting by the Hpall enzyme. That is methylation in a colon cancer can be assayed by showing PCR amplification of a DNA product using the primers and conditions shown from DNA that has first been digested with the Hpall restriction enzyme. The assay is diagrammed in Figure 4 that provides the sequence of AC063951 between base pairs 82200-83267, and designates every CpG site with a gray lollipop, and shows the Hpall sites in the assay as black lollipops, and also shows the location ofthe PCR primers used in this assay, hi this figure, the base pairs have been renumbered sequentially from 1-1068, with basepair 82200 being renumbered as basepair 1.

Figure 5 tabulates the correspondence of assay for methylation over 4 and 6 Hpall sites with silencing of expression of the SLC5A8 transcript. As noted, assay of methylation over 4 Hpall sites detects 100%> of colon cancer cell lines that silence the SLC5A8 transcript, but also detects some colon cancer cell lines that express SLC5A8. Assay of methylation over 6 Hpall sites has 100% specificity and detects only cell lines that have silenced SLC5A8, with a sensitivity of 68%.

Figure 6 tabulates the results of this assay in actual colon cancer tumors, hi a group of 34 human colon cancers 76% are detected by resistance to cutting at 4 Hpall sites whereas 50%> are detected by resistance to cutting at 6 Hpall sites. Both assays detect methylation in some normal tissues accompanying methylated cancers, suggesting the detection of microscopic colon cancer cells. No methylation is detected in any normal tissue in which the accompanying tumor is unmethylated. Because of its high specificity, the assay which employs methylation over 6 Hpall sites is preferred.

Figure 7 shows the results of assay for methylation at 61 CpG sites enumerated in Figure 4 with site 1 corresponding to basepair 466 in Figure 4 and site 61 corresponding to basepair 1010. The bold arrows correspond to 4 ofthe Hpall sites at respectively basepairs 466, 691, 709 and 716 in Figure 4. Methylation was assayed by sequencing DNA from samples following sodium bisulfite treatment of DNA that converts cytosine to uracil but leaves methyl-cytosine unchanged. Bases that are methylated are coded black, unmethylated bases are coded darker gray, and samples with both methylated and unmethylated bases are coded lighter gray. Samples analyzed included 9 colon cancer cell lines that do not show SLC5A8 transcript expression, 3 colon cancer cell lines that express SLC5A8 transcript, and 6 normal colon tissues. Clearly most colon cancers show substantially more methylation across this region than do normal colon tissues.

To detect the methylation associated with colon cancer a set of methylation specific PCR primers were fashioned. DNA from the assayed tissues was first treated with sodium bisulfite to convert cytosine to uracil, leaving methyl-cytosine unchanged. PCR primers were designed specific for the bisulfite converted sequences arising from methylated or unmethylated templates from the anti-sense strand of the target region (note that after bisulfite conversion the sense and anti-sense strands are no longer complementary to one another).

Figure 8 shows the wild-type sequence of the anti-sense strand of AC063951 between bases 82200-83267. Indicated on this diagram is the position of the MS-PCRl primers (AS- meth) and the UMS-PCRl primers (AS-unmethy). The methyl specific MS-PCRl primers amplify a CpG sites numbered 6, 7, 8 and 15, 16, 17, 18 respectively in Figure 7. The UMS- PCRl primers interrogate CpG sites 7, 8 and 15, 16, 17, 18 respectively.

Figure 9 shows a blow up ofthe region and the sequences ofthe antisense strand that are amplified by the methyl-specific and unmethyl-specific PCR primers.

Figure 10 corresponds to Figure 8, but does not show the wild-type sequence ofthe anti- sense strand, but the bisulfite converted sequence of a uniformly methylated antisense strand. Indicated again are the position of the methylation specific PCR primers for the MS-PCRl Figure 11 also corresponds to Figure 8, but does not shows the wild-type sequence ofthe antisense strand, but the bisulfite converted sequence of a uniformly unmethylated antisense strand. Indicated are the position ofthe unmethylation specific PCR primers for the UMS-PCRl assay.

Figure 12 discloses the bisulfite converted sequence of the unmethylated sense strand of nucleotides 82200-83267 of AC063951, renumbered such that basepair 82200 is designated as nucleotide 1.

Figure 13 similarly discloses the bisulfite converted sequence of a uniformly methylated sense strand of nucleotides 82200-83267. To one skilled in the art these disclosures would permit design of methylation specific PCR primers directed against the bisulfite converted sequences of either the sense or antisense strands of the region 82200-83267 demonstrated herein as enabling the detection of human colon cancers.

Figure 14 shows the tabular results of MS-PCRl assay performed on 31 colon cancer cell lines that do or do not express the SLC5A8 transcript. 70% of cell lines that do not express SLC5A8 score as methylated in the MS-PCRl assay. No methylation is detected in any cell line that expresses SLC5A8 (100% specificity for prediction of SLC5A8 expression).

Figure 15 shows the tabular results of MS-PCRl assay performed on 63 matched sets of primary colon cancer tumor tissue and accompanying normal colon tissue. The assay detects 59%o of all colon cancers. No methylation was detected in any of 26 normal tissues from patients with unmethylated colon cancers. 3 individuals with MS-PCRl positive methylation assays in their cancers also showed positivity in their normal colon tissue. It is likely that this represents detection of microscopic contamination of these tissues by tumor cells.

To further test that assertion, Figure 16 gives the results of testing 12 normal colon tissues from individuals without colon cancer. None ofthe tissues test positive in the MS-PCRl test. We therefore estimate the sensitivity of MS-PCRl for detecting colon cancer at 59%> and the specificity at 100%.

Figure 17 gives the tabular results of the MS-PCRl assay of 28 premalignant colon adenomas, 68% of which are detected. Figure 19 shows RT-PCR detection of the SLC5A8 transcnpt in normal colon and m a minority subset of colon cancer cell lines, but also demonstrates that 23 of 31 colon cancer cell lines do not express SLC5A8.

Figure 20 shows RT-PCR detection of SLC5A8 transcript in colon cancer cell lines that have been treated with the DNA-demethylating agent 5-azacytidine. 5-azacytidine reactivates expression of the SLC5 A8 gene in 6 of 8 colon cancer cell lines, strongly consistent with DNA methylation as the cause of silencing ofthe SLC5A8 transcript.

Figure 21 demonstrates detection of methylation of the SLC5A8 locus by showing resistance ofthe locus to Hpall digestion. T he 4 Hpall assay ( as described in the invention disclosure) is based on PCR amplification of a portion of the SLC5 A8 locus. Lanes labeled U show control amplification of undigested SLC5A8 DNA. Lanes labeled M show amplification of DNA that has first been cut with the restriction enzyme Mspl. Mspl digestion of the DNA eliminates the ability to amplify the locus. Lanes labeled H show amplification of DNA that has first been cut with the restriction enzyme Hpall. Hpall cuts the same sequence as Mspl, but unlike Mspl, Hpall is blocked by DNA methylation. The presence of amplified Hpall cut DNA indicates methylation ofthe DNA in cell lines V5, V6, RKO, V432, HCT116, V5, V6, V489.

Figure 22 demonstrates detection of SLC5A8 DNA methylation in primary colon cancer tumors but not in matched normal tissue from the same patients. Samples labeled T represent colon cancer tumor tissue; whereas samples labeled N represent the matched normal tissue. Detecting a PCR amplified band after Hpall digestion (lanes labeled H) indicates methylation ofthe SLC5A8 locus. Methylation of tumor but not normal tissue is seen in samples 529, 365, and 23-21.

Example 2:

A. Identification ofthe SLC5A8 gene.

Methylation events in genomic DNA from 12 colon cancer cell lines were profiled by restriction landmark genomic scanning. Out of 1,231 unselected CpG islands visualized, spot 3D41 was detected as absent and presumptively methylated in 11 ofthe 12 colon cancer cell lines. A 510 base pair genomic fragment surrounding the 3D41 site was cloned and shown to correspond to genomic sequence on human chromosome 12q22-23. RNA from normal human colon mucosa was used for connection RT-PCR that linked together over 10 EST sequences mapping to this genomic region. New sequence was generated both by sequencing of these RT- PCR amplified products, as well as by sequencing image clones corresponding to these ESTs (Figure 28). This established that the 3D41 site was included within a new transcript encoded by a novel gene (Figure 23B). This gene, located on chromosome 12q22-23 gene, is comprised of 15 exons, with the site from RLGS located in exon 1 (Figure 23A). The newly identified transcript includes an in frame TAA stop codon 5' to the presumptive ATG start codon, which additionally is embedded within a GCCATGG sequence that conforms to the standard for a good Kozak sequence. BLAST alignment ofthe predicted protein product of this novel transcript showed the most closely related proteins to be the human sodium iodide symporter- SLC5A5 (46% homology) and the human sodium-dependent multivitamin transporter- SLC5A6 (43% homology), both of which belong to the solute carrier 5 family (SLC5) of sodium coupled transporters (Figure 29). Moreover, analysis ofthe predicted novel protein by the TMHMM prediction program (http://www.cbs.dtu.dk/seivices/TMHMM-/) identified 13 transmembrane fragments, which is consistent with structural features ofthe sodium iodide symporter. Thus structurally, this new transcript encodes a novel member ofthe SLC5 sodium solute symporter family (SSF) family, and HUGO assigned the encoded protein the name of SLC5A8. A mouse protein of unknown function shows 77% identity to SLC5A8, and is likely the mouse homologs ofthe human protein (Figure 29). RT-PCR confirmed SLC5A8 transcript was expressed by normal colon mucosa, as well as by kidney, lung, esophagus, small bowel, stomach, thyroid, and uterus, with greatest expression seen in kidney.

B. SLC5A8 is frequently silenced and methylated in colon cancer cell lines.

RT-PCR was used to further characterize SLC5A8 expression in normal colon mucosa compared to a collection of 31 colon cancer cell lines. Whereas the SLC5 A8 transcript was well expressed in normal colon, it proved absent in 23 ofthe 31 colon cancer cell lines (Figure 24A). The methylation of SLC5 A8 exon 1 detected by RLGS suggested the hypothesis that aberrant methylation might be the mechanism for silencing of SLC5A8 expression. Consistent with this hypothesis, treatment of SLC5A8 silenced cell lines with the demethylating agent 5-azacytidine reactivated SLC5 A8 expression in 6 of 8 colon cancer cell lines tested (Figure 24B and data not shown). Sequencing ofthe SLC5A8 transcript in the 8 colon cancer cell lines in which it was expressed showed only wild-type sequence with no mutations. Thus methylation, but not mutation, appeared to be the putative mechanism for inactivating SLC5A8 in colon cancer. To identify target sequences for aberrant SLC5A8 methylation in colon cancer, we investigated a dense CpG island (G+C%=70%, CG/GC=0.9) located in SLC5A8 Exon 1, and surrounding the 3D41 site. This region covered 573 base pairs and included 62 CpG dinucleotides (Figure 30A). In contrast, the region immediately 5 ' of exon 1 showed only a 46% G+C content. We used sodium bisulfite treatment of genomic DNA to convert unmethylated cytosines to uracil; while leaving methylated cytosines unchanged (Herman and Baylin, 1998, Current Protocols in Human Genetics, N. E. A. Dracopoli, ed., John Wiley & Sons, 2:10.6.1-10.6.10 ). Sequencing of PCR amplified bisulfite converted SLC5A8 exon 1 genomic DNA was then used to determine the methylation status of each ofthe 62 target cytosines within the CpG island domain. Comparing the findings in nine SLC5A8-silenced cell lines versus those in three SLC5 A8-expressing cell lines and in six samples of SLC5A8 expressing normal colon mucosa defined a 182 bp subregion. In the nine SLC5A8-silenced cell lines this subregion demonstrated uniform methylation of all CpG cytosines; whereas, these cytosines were uniformly unmethylated in the three SLC5A8 expressing cell lines and six normal colon mucosa samples (Figure 30B). Primers for assay of this subregion by methylation specific PCR (MS-PCR) were designed, such that following bisulfite conversion amplification products would selectively be derived from either methylated (M) or unmethylated (U) genomic templates (Herman and Baylin, 1998, Current Protocols in Human Genetics, N. E. A. Dracopoli, ed., John Wiley & Sons, 2:10.6.1-10.6.10). MS-PCR assay of 31 total colon cancer cell lines demonstrated SLC5A8 exon 1 methylation was present in 16 cases (52%), and in each of these methylated cell lines, no SLC5A8 transcript was detectable (Figure 24C). In contrast, in each of the 8 SLC5A8 expressing cell lines MS-PCR assayed exon 1 as unmethylated (Figure 24D). In 7 remaining instances, SLC5 A8 expression was absent, but aberrant methylation was not detected as the reason. Moreover, in the case of two ofthe SLC5A8-methylated cell lines (V425 and V670), DNA from antecedent tumor and matched patient normal tissue was also available. In each of these cases, MS-PCR confirmed that SLC5A8 methylation was present in the primary tumor tissues, but was absent in the matched normal tissues (Figure 24F). Thus the SLC5A8 methylation and silencing detected in colon cancer cell lines reflects somatic aberrations present in primary colon cancer tissues. We note that the finding of gene silencing associated with aberrant methylation in a first exon region corresponding to 5' untranslated sequences has existing precedent at other loci (Attwood et al, 2002, Cell Mol Life Sci 59: 241- 257; Jones, P. A. 1999, Trends Genet 15: 34-37). In previous studies our group has noted that in colon cancers aberrant methylation of hMLHl and of HLTF commonly silences both maternal and paternal alleles in the same tumor Veigl, et al, 1998, Proc Natl Acad Sci U S A 95:8698-702; Moinova, et al, 2002, Proc Natl Acad Sci U S A 99:4562-7). Consistent with this mechanism, testing of microsatellite markers D12S1041 and D12S1727, that flank SLC5A8, showed the presence of two distinguishable parental SLC5A8 chromosomal regions in 10 of 10 colon cancer cell lines that showed the presence of only methylated SLC5A8 exon 1.

C. SLC5A8 methylation is commonly present in primary colon cancers and in colon adenomas.

To further establish the frequency of SLC5 A8 exon 1 methylation in primary colon cancer tumors, we analyzed by MS-PCR an additional 64 pairs of primary colon cancer tumor tissues as well as their accompanying matched normal colon tissues. SLC5A8 methylation was detected in 38 of 64 (59%) primary colon cancers (Figure 24F and Table 2 below). In 35 of 38 cases (92%) in which colon tumors showed SLC5 A8 methylation, this methylation was not detected in the same individuals' normal colon tissues. SLC5A8 exon 1 methylation thus substantially arose in these individuals' cancers as part of and during the neoplastic process. In 3 cases in which SLC5 A8 methylation was detected in both an individuals' cancerous and normal colon tissues, these findings likely indicate either the presence of some cancer cells within the grossly normal resected tissue, or the possibility that the cancer arose from a field of SLC5A8 methylated cells. The rarity of detecting SLC5A8 methylation in normal colon tissues is highlighted by noting that no SLC5A8 methylation was detected in any ofthe 26 normal colon tissues in which the accompanying colon cancer was also unmethylated (Table 2 below), and moreover, that no SLC5A8 methylation was detected in any of 12 additional normal colon tissues from resections done for non-cancer diagnoses.

Table 2. SLC5A8 Methylation in Colon Tumors and Matched Normal Mucosa. Shown is the characterization of 64 pairs of colon cancer tumors and matched normal colon tissues assayed for methylation of SLC5 A8 exon 1 by MS-PCR. Indicated are the numbers (and percentages) of tissue pairs with each ofthe four possible methylation phenotypes.

Among all primary cancers and cell lines analyzed, the finding of SLC5A8 methylation in colon cancer tumors and cell lines was not significantly correlated with either patients' sex (P=0.39 ) or age (P=0.52), with a median age of 69 in persons with SLC5A8-methylated cancers versus 67 in those with SLC5A8 unmethylated cancers. Moreover, the distribution by tumor stage (Dukes' stage B, C, D primary tumor; or metastatic cancer deposit) was not significantly different between SLC5A8-methylated and nonmethylated colon cancers (P=0.77 ) (Table 3 below). SLC5A8 methylated and unmethylated cancers also showed no significant difference with respect to site of origin in the rectum, left colon, or right colon (P= 0.47) (Table 4 below).

Table 3. Distribution of SLC5A8 methylation by tumor stage. Shown are numbers (and %) of colon neoplasms (tumor and cell lines) in each category defined by clinical stage and SLC5A8 methylation status.

Table 4. Distribution of SLC5A8 methylation by tumor site. Shown are numbers (and %) of colon neoplasms (tumor and cell lines) in each category defined by location in the colon and SLC5A8 methylation status.

Tumor site SLC5A8 Methylated SLC5A8 Unmethylated

To determine the timing of onset of SLC5A8 silencing during colon carcinogenesis, we additionally analyzed a group of 29 adenomas for SLC5A8 exon 1 methylation. SLC5A8 methylation was detected in 17 ofthe 29 (59%) adenoma cases. SLC5A8 methylation thus appears to be an early event that is already established in colon neoplasia by the adenoma stage.

D. Quantitative assay of SLC5A8 exon 1 methylation.

To derive a quantitative measure of SLC5A8 methylation, we employed a real time MS- PCR assay whose results were expressed as 1000 times the ratio of methylated SLC5A8 reaction product to a control MYOD1 reaction product (Usadel, et al, 2002, Cancer Res 62:371-5). In this assay, 0 methylation was detected in the Vaco9 SLC5 A8 expressing colon cancer cell line, and a methylation value of 1000 was detected in the SLC5A8 methylated and silenced RKO colon cancer cell line. As shown in Figure 25A, assay for SLC5 A8 exon 1 methylation in 11 normal colon mucosal samples derived from non-cancer resections yielded only barely detectable methylation values (mean value= 24; range= 4 -82) and defined an "unmethylated normal range" of values all < 100. Analysis of 29 normal colon samples derived from colon cancer resections gave similarly low values with a mean value =22 and with a single outlier sample (value =159) falling outside the range defined by the non-cancer derived normal tissues. This observation essentially replicated our previous observation of rare faint methylation events detected in some cancer associated normal tissue. In contrast, analysis of colon cancer samples clearly distinguished two populations of tumors. Twelve cancers were deemed unmethylated, as they showed methylation values falling well within the population normal range (mean value =12; range = 0-58) (Figure 25 A), and hence were indistinguishable from unmethylated normal tissues. In contrast, 17 cancers with methylation values greater than the normal range comprised a distinct "methylated" group of cancers that was characterized by a mean methylation value of 747 and a range = (121- 2549) (Figure 25A). The mean methylated colon cancer thus displayed 75% the level of methylation as was measured in a pure cell line population of methylated RKO cells. The heterogeneity in measured methylation values among the methylated colon cancers may in part derive from differences among the tumors in levels of contaminating and infiltrating non-cancer cells. The methylated and unmethylated cancer populations defined by real time MS-PCR respectively corresponded to the tumors classified as unmethylated and methylated in the previous non-quantitated MS-PCR reaction.

E. Detection of SLC5 A8 methylation in aberrant crypt foci.

The finding of SLC5A8 methylation in colon adenomas prompted us to consider that SLC5A8 methylation might be an early event in human colon neoplasia. The earliest moφhologically identifiable colon neoplasias putatively are aberrant crypt foci (ACF) (Siu et al, 1999, Cancer Res 59: 63-66). These microscopic moφhologically aberrant multicrypt structures are recognizable in unembedded colon under low power magnification. Moreover, a subset of ACF lesions demonstrate both histologic dysplasia and mutations of the APC tumor suppressor gene (Bird, 1987, Cancer Lett 37:147-51; Pretlow, et al, 1991, Cancer Res 51:1564- 7), suggesting that at least some ACF have potential to progress to colon adenomas and cancers. To assess a possible role of SLC5A8 methylation in ACF development, 15 ACF, composed of from 17 to 155 crypts (48+36 crypts, mean ± standard deviation), were dissected from 11 different patients' colons bearing either cancer or adenomas. From these same 11 cases, 24 similarly sized tissue samples were dissected from mucosal regions that appeared normal under low power magnification. Real time MS-PCR analysis of SLC5A8 methylation in the 24 control normal samples gave results similar to those obtained in previous normal mucosal samples, with a mean SLC5A8 methylation value of 12, and with only one of these 24 new samples (methylation value of 117) falling just outside ofthe previously determined normal limit of 100 (Figure 25B). In contrast, analysis of DNA from the ACF revealed two distinct populations, with 8 of 15 ACF falling within the normal range (mean =34, and range =0-113), and with 7 of 15 ACF samples demonstrating SLC5A8 values that fell well within the range of methylated cancers (mean =355, range =287-420) (Figure 25B). In contrast, none of these 15 aberrant crypt foci demonstrated aberrant methylation of hMLHl, which thus likely arises later during colon carcinogenesis. These findings suggest that SLC5A8 methylation is indeed an early aberration that precedes adenoma formation and is detectable in aberrant crypt foci. This finding also further strengthens the model that suggests a subset of aberrant crypt foci are likely to progress to more advanced colonic neoplasms.

F. SLC5A8 methylation as a serologic marker of colon cancer. SLC5A8 methylation was detected in 59% of our primary colon samples. In these same samples we had previously noted a 44% frequency of methylation of HLTF, a SWI/SNF family gene (Moinova et al, 2002, Proc Natl Acad Sci USA 99: 4562-4567), and had also found a 44% frequency of methylation of pi 6 (Figure 31) (Herman et al, 1995, Cancer Res 55: 4525-4530; Gonzalez-Zulueta et al, 1995, Cancer Res 55: 4531-4535). These data suggest SLC5A8 methylation might be a high quality marker of colon cancer presence. In this regard, we and others have shown that aberrantly methylated genomic DNA from specific loci can be detected in the serum of some cancer patients (Grady et al, 2001, Cancer Res 61: 900-902; Hibi et al, 1998, Cancer Res 58: 1405-1407; Jeronimo et al, 2001, J Natl Cancer hist 93: 1747-1752; Usadel et al, 2002, Cancer Res 62: 371-375). Accordingly, we characterized the level of SLC5A8 methylation in ethanol precipitable DNA prepared from the serum of colon cancer patients (Grady et al, 2001, Cancer Res 61 : 900-902). SLC5A8 methylation was totally undetectable with a measured value of 0 in DNA extracted from each of 13 serum samples from individuals with colon cancers in which SLC5A8 assayed as unmethylated (Figure 26). In contrast, SLC5A8 methylation was detectable in serum DNA from 4 of 10 patients in which the underlying colon cancer assayed as SLC5 A8 methylated (Figure 26). A positive signal for MYOD1 verified the presence of input DNA into each of these assays. While serologic assays for methylated DNA as a marker of cancer are clearly in the early stages of investigation, we note that a panel of methylated genes that included SLC5A8, HLTF, pi 6 and hMLHl provided greater sensitivity than any single locus alone for detecting an aberrant methylation event in our set of 64 primary colon cancers (Figure 31).

G. SLC5A8 suppression of colon cancer colony formation.

The high frequency of SLC5A8 methylation observed in colon cancer suggested that inactivation of this gene might confer a selective advantage. To assay for such an advantage, we examined the effect of SLC5A8 transfection in three colon cancer cell lines (V400, RKO and FET) in which the endogenous SLC5A8 gene was methylated and silenced, as compared with three colon cancer cell lines (V457, V9M and V364) in which the endogenous SLC5A8 gene remained unmethylated and expressed. Reconstitution of SLC5A8 expression in SLC5A8- methylated cells suppressed colony-forming ability by at least 75% in each ofthe three lines tested (PO.01) (Figure 27B). hi contrast, transfection of SLC5A8 did not show significant colony suppression in the any ofthe three cell lines that already expressed an endogenous SLC5A8 allele (Figure 27A) (P< 0.01 for the difference in effect of SLC5A8 transfection in lethylated versus unmethylated cell lines). Transient transfection showed that both SLC5A8-methylated and unmethylated cells were able to express comparable levels of exogenous SLC5A8, as determined by western analysis for a V5 epitope tag attached to the SLC5A8 cDNA. These findings suggest that SLC5A8 methylation and silencing confers a specific growth advantage in the subset of colon cancers in which this locus is inactivated.

Consistent with this inteφretation, we found that 4 of 5 ofthe rare SLC5A8 expressing clones that grew out following transfection ofthe SLC5A8 methylated V400 colon cancer cell lines were markedly suppressed in their ability to form xenograft tumors in athymic mice (Figure 32).

H. Discussion.

In this study, we have identified a novel gene, SLC5A8, that we demonstrate is a new candidate colon cancer suppressor gene. We find that SLC5A8 encodes a sodium transporter and is a new member ofthe sodium solute symporter family (SLC5). SLC5A8 is frequently targeted for methylation and silencing in human colon cancer, with aberrant SLC5 A8 exon 1 methylation was detected in 52% of colon cancer cell lines and in 59% of primary colon cancers. All colon cancer cell lines showed that SLC5A8 exon 1 methylation were silenced for SLC5A8 expression, and SLC5A8 expression could be restored by treatment with a demethylating agent 5-azacytidine. We therefore conclude that epigenetic gene silencing, which is reflected by aberrant SLC5A8 methylation represents the principal mechanism for inactivating this gene in colon cancer. Moreover, our finding that exogenous SLC5A8 specifically suppresses colony forming activity in colon cells that have inactivated this allele supports the hypothesis that SLC5A8 inactivation confers a selectable advantage in neoplastic colon epithelial cells. Colon cells that retain SLC5A8 are insensitive to the introduction of an exogenous allele, and presumably bear a mutation elsewhere that renders them tolerant to continued SLC5 A8 expression. Also supporting that SLC5A8 methylation is a pathogenetic event in colon neoplasia is our finding that SLC5A8 methylation is a highly early event that is detectable in 47% of aberrant crypt foci, which are the earliest detectable moφhologic abnormality ofthe colon epithelium.

SLC5A8 methylation may also play an etiologic role in malignancies additional to colon cancer. In earlier studies, we note that SLC5A8 methylation is present in a subset of cancers of the breast and stomach cancers (Table 5 below). Table 5. SLC5A8 methylation in additional cancers. Shows are the results of MS-PCR assay for SLC5A8 exon 1 methylation in primary human tumors. In each case, paired normal tissue assayed as unmethylated.

Both molecular homology and functional data suggest that SLC5A8 functions as a sodium solute symporter. There are 109 currently known members ofthe sodium solute symporter family which functions to co-transport sodium coupled to solutes as diverse as iodine (NIS/SLC5A5), glucose (SGLT1/SLC5A1; SGLT2/SLC5A2), inositol (SMIT/SLC5A3), and water soluble vitamins (SMVT/SLC5A6) (Smanik et al, 1996, Biochem Biophys Res Commun 226: 339-345; Prasad et al, 1998, J Biol Chem 273: 7501-7506; Wright et al, 1994, J Exp Biol 196: 197-212). Elucidating the putative solute cotransported by SLC5A8 may provide future insight both into the mechanism of SLC5A8 growth suppression, as well as leads for potential development of novel agents useful for colon neoplasia prevention and treatment.

Materials And Methods

Sequences. Human SLC5A8 mRNA and gene sequence accession numbers as deposited by our group are AF53621 and AF536217. The SLC5A8 murine homolog is accession number is BCO 17691. Contemporaneously with our Genbank entry, SLC5A8 mRNA sequence was also independently deposited under accession number AY081220 (Rodriguez et al, 2002, J Clin Endocrinol Metab. 87:3500-3).

Restriction Landmark Genomic Scanning (RLGS). RLGS was performed as previously described (Costello et al, 2000, Nat Genet 24: 132-138).

Amplification and Sequencing of SLC5A8. The primers used for RT-PCR assay of a SLC5A8 fragment are 5'-TCCGAGGTCTACCGTTTTG-3', and 5'-GGGCA GGGGC ATAAA n The PCR parameters were 35 cycles of 95°C (45s), 54°C (45s), 72°C (60s), 72°C (lOmin), and 4°C to cool. The full length SLC5A8 ORF was amplified using primers: 5'- TCCGGGATAAGAAGTGCG-3' and 5'-TAGTATCAGAGCAGCTTCACAAAC-3'. GC-rich cDNA polymerase kit (Clonetech) was used and PCR parameters were 35 cycles of 95°C (45s), 62°C (45s), 72°C (90s), 72°C (lOmin), and 4°C to cool. Sequencing primers were: 5'-TTTGT GGTGGTCA TCAGCG-3', 5'-GGGCAGGGGCATAAATAAC-3', 5'-AGGCTGTG GTGATGCAAGGT-3', 5'-TTAATGCCTTAGCAGCAG-3', and 5'-CCTCCACTT CCTGAGAGAAC-3'.

Constructs. To construct the V5 tagged SLC5A8 expression vector, the following PCR primers were used: 5 '-TCCGGGATAAGAAGTGCG-3' and 5'-TCTAGTATCA GAGCAGCTACACAA-3'. The PCR conditions were the same as employed for amplification ofthe full length ORF. PCR products were cloned into pcDNA3.1/N5-His-TOPO vector (Invitrogen).

Serum DΝA purification. Blood was drawn into red/grey vacutainer collection tubes and allowed to clot for 2 hours. It was then spun in a clinical table top centrifuge for 15 min at 3000 φm at room temperature. Serum was collected using a sterile pipette, divided into 1 ml aliquots, and stored at -80°C. Serum DΝA from patients was purified as described previously (Grady et al, 2001, Cancer Res 61:900-902).

Western Analysis. Approximately IO⁷ cells were lysed in cell lysis buffer [50 mM Tris.HCl (pH 7.4)71 mM EGTA/1% Νonidet P-40/0.25% sodium deoxycholate/150 mM ΝaCl]. Equal amounts of protein were subjected to SDS polyacrylamide gel electrophoresis and then transferred to a PVDF nylon membrane (Millipore), which was probed with 1 :200 dilution of mouse anti-V5 monoclonal antibody (Invitrogen). Immune complexes were visualized with ECL+Plus Western blotting detection kit (Amersham) after incubation with horseradish peroxidase-coupled secondary antibody (Santa Cruz).

Sodium Bisulfite Treatment: Flanking PCR and MS-PCR. Sodium bisulfite treatment to convert unmethylated cytosine to thymidine was performed similarly as described (Grady et al, 2001, Cancer Res 61 :900-902). Primers that flank the SLC5A8 exon 1 CpG island are 5'- CGTGAA GGTAAA GATGTT AAAAATG-3' and 5'-ACAACT AAAAAC TCCAAT TCTCATC-3'. PCR were carried out by using a hot start at 95°C (7 min) and following cycling parameters: 35 cycles of 95°C (45s), 56°C (45s), 72°C (45s), 72°C (10 min), and 4°C to cool. Primers to amplify the methylated allele are AS-meth-442-459s: 5'-TCGAAC GTATTT CGAGGC-3' and AS-meth-550as: 5 '-ACAACG AATCGATTTTCCG-3'. PCR parameters are 31 cycles of 95°C (45s), 56°C (45s), 72°C (45s), 72°C (10 min), and 4°C to cool. Primers to amplify the unmethylated allele are AS-unmeth-442s: 5'-TTGAAT GTATTT TGAGGTG-3' and AS-unmeth-542as: 5'-TCAATT TTCCAA AATCCC-3'. PCR parameters are 31 cycles of 95°C (45s), 46°C (45s), 72°C (45s), 1TC (lOmin), and 4°C to cool.

Methylation-Specific Real-time PCR. The same MS-PCR primers as above (As-meth- 442-459s and As-meth-550as), were first used to amplify a bisulfite converted methylated SLC5 A8 exon 1 template. A fluorogenic hybridization probe was designed using sequences specific for the sodium bisulfite converted SLC5A8 methylated template. The sequence was the following: 5'-6FAM-CAACGACGAAT ACAAAAACG ACTACCAAC-BHQ-2-3'. Bisulfite converted sequences from the MYOD1 gene were used as an internal reference as described by (Usadel et al, 2002, Cancer Res 62: 371-375). Primers and probes ioτMYODl were: forward primer: 5'-CCAACTCCA AATCCCCTC TCTAT-3'; reverse primer: 5'-TGATTAATT TA GATTGGGTTT AGAGAAGGA-3'; and probe: 5'-6FAM-TCCCTTCCT ATTCCTAAA TCCAAC CTAAATACCTCC-BH-2-3'. All the above primers and probes were synthesized by Integrated DNA Technologies, Inc. For the gene of interest, SLC5A8, the reaction mix contained 600 nM primer, 200 nM probe, 5.5 mM-Mg²⁺, IX Supermix from Bio-Rad. The total volume was 25 μl. For the MYOD1 gene, the reaction mix contained 400 nM primer, 200 nM probe, 3 mM-Mg²⁺, IX Supermix from Bio-Rad. The total volume was also 25 μl Thermal cycling was initiated with 50°C for 2 min, then 95°C for 10 min, followed by 55 cycles of 95°C for 15 sec and 60°C for 1 min. PCR was performed in separate wells for each probe/primer set. Each plate contained multiple positive controls, negative controls and water blanks. Colon cancer cell line RKO was used for a positive control, and V9M as a negative control. Serial dilutions of RKO DNA were used to create a standard curve. SLC5A8 methylation was determined as the ratio of SLC5A8:MY0D1=2 exp- (CT SLCSAS- CTMYO_DI)-

Aberrant Crypt Foci. Aberrant crypt foci (ACF) (Bird, 1987, Cancer Lett 37: 147-151; Pretlow et al, 1991, Cancer Res 51: 1564-1567; Siu et al, 1999, Cancer Res 59: 63-66) were isolated from grossly normal human colonic mucosa according to the method of Bird et al. (Bird et al, 1997, Cancer Lett 116: 15-19). Strips of human colonic mucosa, stored over liquid nitrogen, were thawed rapidly in 1% paraformaldehyde and fixed flat in 70% ethanol for 30 min at 4°C (Bird et al, 1997, Cancer Lett 116: 15-19). The colonic strips were stained for 2 min in 0.2% methylene blue (Chroma-Gesellschaft Schmid & Co, distributed by Roboz Surgical Co, Washington, DC) in 0.1 M sodium phosphate buffer (pH 7.4), rinsed in 1% paraformaldehyde for 15 min, transferred mucosal side up to a glass slide and viewed at 30X magnification under a dissecting microscope. The ACF were teased from the mucosa with microdissection forceps (FWR #55 Dumont Bio Inox Forceps, 0.05 x 0.02 mm tips), placed in microfuge tubes, and stored over liquid nitrogen. The control for each ACF was a similar number of microscopically normal crypts teased from the same mucosa.

Cell Culture and Clonogenic Assays. Vaco cell lines were cultured as previously described (Veigl et al, 1998, Proc Natl Acad Sci U S A 95: 8698-8702; Markowitz et al, 1995, Science 268: 1336-1338; Willson et al, 1987, Cancer Res 47: 2704-2713). FET and RKO were the kind gift of Dr. M. Brattain (Roswell Cancer Institute, Buffalo, NY). Colony formation assays were performed as described (Moinova et al, 2002, Proc Natl Acad Sci USA 99: 4562- 4567). Briefly, colon cancer cells were plated on a rat tail collagen matrix (Willson et al, 1987, Cancer Res 47: 2704-2713) (which was found necessary for proper membrane localization of SLC5A8 protein). Cells were then transfected with either a SLC5A8 expression vector or a control empty vector, and the number of stable colonies arising after selection in G418 was respectively counted.

5-Azacytidine Treatment. The treatment was performed as described previously (Veigl et al, 1998, Proc Natl Acad Sci U S A 95: 8698-8702). Briefly, cells were treated for 24 h on day 2 and day 5 with 5-azacytidine (Sigma) at 1.5 μg/ml. The medium was changed 24 h after addition ofthe 5-azacytidine (i.e., on day 3 and day 6).

Statistical Methods. Association of SLC5A8 methylation with sex was analyzed by using two-tailed Fishers' exact tests. Association of SLC5A8 methylation status with tumor site or stage was analyzed by using Pearson's χ² statistics. Comparisons of age distributions based on SLC5A8 methylation were done by using Wilcoxon nonparametric tests. Comparisons of colony counts after transfection with different vectors were done by t tests and linear models.

Hap2 site assays. (1) For 4 Hpa2 site assays, the following primers were used: 5'- CCAGCGAAGGCGTAGTAGAT-3' (3D41-Hpa2-190R) and 5'-GGCTCCAGTTCTCA TCTGCT-3' (3D41-Hpa2-633F). The Advantage-GC-genomic DNA polymerase kit was used. Thermal cycling was performed at 95°C for 1 min, 95°C for 45 sec, 63°C for 45, 72°C for 90 sec, then followed by 26 cycles, and finally 72°C for 5 min. (2) For 6 Hpa2 site assays, the following primers were used: 5'-CCAGCGAAGGCGTAGTAGAT-3' (3D41-Hpa2-190R) and 5'- GGCAGTCTAAAAACTCCAGGC-3' (3D41-Hpa2-82430F). The Advantage-GC-genomic DNA polymerase kit was used. Thermal cycling was perforaied at 95°C for 7 mm, y-rι_. ror sec, 64°C for 45, 72°C for 90 sec, then followed by 29 cycles, and finally 72°C for 5 min. In both assays, aberrant methylation of colon cancer cells is indicated by recovery of a PCR product from DNA that has been digested with the restriction enzyme Hpa2.

Incorporation by Reference

All publications and patents mentioned herein are hereby incoφorated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incoφorated by reference. In case of conflict, the present application, including any definitions herein, will control.

Equivalents

While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.

Claims

We claim:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: a) an amino acid sequence at least 95%> identical to SEQ ID NO: 1; and b) an amino acid sequence encoded by a nucleic acid that hybridizes under high stringency conditions to a nucleic acid of any one of SEQ ID NOs: 3 or 4, wherein said polypeptide is a cell surface protein.

2. The isolated polypeptide of claim 1, wherein the polypeptide comprises a transmembrane domain as set forth in any one of SEQ ID NOs: 19-31.

3 An isolated antibody, or fragment thereof, which is specifically immunoreactive with an epitope of an amino acid sequence as set forth in SEQ ID NO: 1.

4. The antibody of claim 3, wherein said antibody is selected from the group consisting of: a polyclonal antibody, a monoclonal antibody, an Fab fragment and a single chain antibody.

5. The antibody of claim 3, wherein said antibody is labeled with a detectable label.

6. An isolated nucleic acid selected from the group consisting of: a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 2, or a complement thereof; b) a nucleic acid molecule that encodes a polypeptide comprising the amino acid sequence at least 95% identical to the amino acid sequence of SEQ ED NO: 7; and c) a nucleic acid molecule that hybridizes under stringent conditions to SEQ DD NO: 2.

7. The nucleic acid of claim 6, further comprising a vector nucleic acid sequence.

8. A host cell which contains the nucleic acid of claim 6.

9. A method for producing the polypeptide of claim 1 , comprising culturing the host cell of claim 5 under conditions in which the nucleic acid molecule is expressed.

10. A method for detecting the presence ofthe polypeptide of claim 1 in a sample, comprising: a) contacting the sample with an antibody which selectively binds to the polypeptide of claim 1; and b) determining whether the antibody binds to the polypeptide in the sample.

11. A kit for detecting a human SCL5 A8 polypeptide comprising: (i) an antibody of claim 3; and (ii) a detectable label for detecting said antibody.

12. A method for detecting the presence ofthe nucleic acid of claim 6 in a sample, comprising: a) contacting the sample with the probe or primer of claim 6; and b) determining whether the probe or primer binds to a nucleic acid in the sample.

13. A kit comprising the probe or primer of claim 6 and instructions for use.

14. A method for identifying a compound which binds to the polypeptide of claim 1, comprising: a) contacting the polypeptide, or a cell expressing the polypeptide of claim 1, with a test compound; and b) determining whether the polypeptide binds to the test compound.

15. A method for modulating the activity of the polypeptide of claim 1 , comprising contacting the polypeptide or a cell expressing the polypeptide of claim 1 with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity ofthe polypeptide.

16. A method of inhibiting aberrant activity of a SLC5 A8-expressing cell, comprising contacting the cell with a compound that modulates the activity or expression ofthe polypeptide of claim 1, in an amount which is effective to reduce or inhibit the aberrant activity ofthe cell.

17. The method of any of claims 14-16, wherein the compound is selected from the group consisting of a peptide, a phosphopeptide, a small organic molecule, an antibody, and a peptidomimetic.

18. The method of any of claims 14-17, wherein the cell is found in the colon, kidney, lung, esophagus, small bowel, stomach, thyroid, uterus, and breast.

19. A method of treating or preventing a disorder characterized by aberrant activity of a SLC5A8-expressing cell, in a subject, comprising administering to the subject an effective amount of a compound that modulates the activity or expression ofthe polypeptide of claim 1, such that the aberrant activity ofthe SLC5A8-expressing cell is reduced or inhibited.

20. A transgenic mouse having germline and somatic cells comprising a chromosomally incoφorated transgene that disrupts the genomic SLC5A8 gene and inhibits expression of said gene, wherein said disruption comprises insertion of a selectable marker sequence resulting in said transgenic mouse exhibiting increased susceptibility to the formation of tumors as compared to the wildtype mouse.

21. The transgenic mouse of claim 20, wherein said mouse is homozygous for said disruption.

22. The transgenic mouse of claim 20, wherein said mouse is heterozygous for said disruption.

23. A transgenic mouse having germline and somatic cells in which at least one allele of a genomic SLC5A8 gene is disrupted by a chromosomally incoφorated transgene, which transgene inhibits the expression of said genomic SLC5A8 gene, wherein (i) said genomic SLC5A8 gene encodes a SLC5A8 protein; and (ii) said disruption comprises insertion of a selectable marker sequence, which replaces all or a portion ofthe genomic SLC5A8 gene or is inserted into the coding sequence of said genomic SLC5A8 gene; and (iii) said transgenic mouse has increased susceptibility to the development of neoplasms.

24. Isolated mammalian cells comprising a diploid genome including a chromosomally incoφorated transgene, which transgene disrupts the genomic SLC5 A8 gene and inhibits expression of said gene.

cells of claim 24, which cells are mouse cells.

26. A method for generating a mouse and mouse embryonic stem cells having a functionally disrupted endogenous SLC5A8 gene, comprising the steps of:

(i) constructing a transgene construct including (a) a recombination region having all or a portion ofthe endogenous SLC5A8 gene, which recombination region directs recombination ofthe transgene with the endogenous SLC5 A8 gene; and (b) a marker sequence which provides a detectable signal for identifying the presence ofthe transgene in a cell;

(ii) transferring the fransgene into embryonic stem cells of a mouse;

(iii) selecting embryonic stem cells having a correctly targeted homologous recombination between the fransgene and the SLC5A8 gene;

(iv) transferring said cells identified in step (iii) into a mouse blastocyst and implanting the resulting chimeric blastocyst into a female mouse; and

(v) selecting offspring harboring an endogenous SLC5A8 gene allele comprising the correctly targeted recombination.

27. A method of evaluating the carcinogenic potential of an agent comprising: (i) contacting the transgenic mouse of claim 20 with a test agent; and (ii) comparing the number of transformed cells in a sample from the treated mouse with the number of transformed cells in a sample from an untreated transgenic mouse or transgenic mouse treated with a confrol agent, wherein the difference in the number of transformed cells in the treated mouse, relative to the number of transformed cells in the absence of treatment or freatment with a control agent, indicates the carcinogenic potential ofthe test compound.

28. A method of evaluating an anti-proliferative activity of a test compound, comprising:

(i) providing a transgenic mouse of claim 20 having germline and somatic cells in which the expression ofthe SLC5A8 gene is inhibited by said chromosomally incoφorated transgene, or a sample of cells derived therefrom;

(ii) contacting the transgenic mouse or the sample of cells with a test agent; and

(iii) determining the number of transformed cells in a specimen from the transgenic mouse or in the sample of cells, wherein a statistically significant decrease in the number of transformed cells, relative to the number of transformed cells in the absence ofthe test agent, indicates the test compound is a potential anti-proliferative agent.

29. A method for detecting differential methylation patterns m a --sU-- --- AS nucleotide sequence, comprising: a) obtaining a sample from a patient; b) assaying said sample for the presence of methylation within a nucleotide sequence as set forth in any one of SEQ ID NOs: 12-13 or fragments thereof; c) obtaining a sample from a healthy subject; d) assaying for the presence of methylation in a nucleotide sequence as set forth in any one of SEQ ID NOs: 12-13 or fragments thereof; and e) comparing the methylation patterns in the sample from the patient to the methylation patterns in the normal sample.

30. A method for detecting a SLC5A8-associated cancer, comprising: a) obtaining a sample from a patient; and b) assaying said sample for the presence of methylation within a nucleotide sequence as set forth in any one of SEQ ID NOs: 12-13 or fragments thereof; wherein methylation of said nucleotide sequence is indicative of a SLC5A8-associated cancer.

31. The method of any one of claims 29 and 30, wherein the sample is a bodily fluid selected from the group consisting of blood, serum, plasma, a blood-derived fraction, stool, urine, and a colonic effluent.

32. The method of claim 31, wherein the bodily fluid is obtained from a subject suspected of having or is known to have a SLC5A8-associated cancer.

33. The method of claim 32, wherein said SLC5A8-associated cancer is selected from the group consisting of: colon cancer, breast cancer, thyroid cancer, and stomach cancer.

34. The method of any one of claims 29 and 30, comprising assaying for the presence of methylation within the SLC5A8 sequence as set forth in SEQ ED NO: 14.

35. The method of any of claims 29-34, wherein the assay is methylation-specific PCR.

36. The method of claim 35, comprising: a) treating DNA from t he sample w ith a c ompound t hat c onverts n on-methylated cytosine bases in the DNA to a different base; b) amplifying a region of the compound converted SLC5A8 nucleotide sequence with a forward primer and a reverse primer; and c) analyzing the methylation patterns of said SLC5A8 nucleotide sequences.

37. The method of claim 35, comprising: a) treating DNA from t he sample w ith a c ompound t hat c onverts n on-methylated cytosine bases in the DNA to a different base; b) amplifying a region of the compound converted SLC5A8 nucleotide sequence with a forward primer and a reverse primer; and c) detecting the presence and/or amount ofthe amplified product.

38. The method of claim 35, wherein the forward primers are selected from SEQ ID NOs: 8 and 10.

39. The method of claim 35, wherein the reverse primers are selected from SEQ ID NOs: 9 and 11.

40. The method of claim 35, wherein the compound used to treat DNA is a bisulfite compound.

41. The method of any of claims 29-34, wherein the assay comprises using a methylation- specific restriction enzyme.

42. The method of claim 41, wherein said methylation-specific restriction enzyme is selected from Hpall, Smal, SacII, Eagl, Mspl, BstUI, and BssHII.

43. The method of claim 41, further comprising a pair of primers selected from SEQ ID NOs: 5-7.

44. A method for detecting a SLC5A8-associated cancer in a subject, comprising detecting SLC5A8 protein or nucleic acid expression in a sample from the subject.

45. The method of claim 44, wherein the sample is a bodily fluid selected from the group consisting of blood, serum, plasma, a blood-derived fraction, stool, urine, and a colonic effluent.

46. The method of claim 45, wherein the bodily fluid is from a subject suspected of having or known to have a SLC5A8-associated cancer.

47. The method of claim 46, wherein the SLC5A8-associated cancer is selected from the group consisting of: colon cancer, breast cancer, thyroid cancer, and stomach cancer.

48. The method of claim 44, wherein the SLC5 A8 protein is detected by immunoassays.

49. A method for identifying an agent which enhances SLC5A8 protein or nucleic acid expression in a diseased cell associated with SLC5A8 gene silencing, comprising: a) contacting the cell with a sufficient amount of the agent under suitable conditions; b) quantitatively determining the amount of SLC5A8 protein or nucleic acid; and c) comparing the amount of SLC5A8 protein or nucleic acid with the amount of

SLC5A8 protein or nucleic acid in the absence ofthe agent, wherein a greater amount of SLC5A8 protein or nucleic acid in the presence ofthe agent than in the absence of the agent indicates that the agent enhances SLC5A8 protein or nucleic acid expression.

50. The method of claim 49, wherein said SLC5A8 gene silencing is due to differential methylation of a SLC5A8 nucleotide sequence.

51. The method of claim 50, wherein differential methylation occurs within a SLC5A8 nucleotide sequence set forth in any one of SEQ ID NOs: 12-13 or fragments thereof.

52. The method of claim 49, wherein the diseased cell is from a subject having colon neoplasia.

53. A method for monitoring over time a SLC5A8-associated cancer comprising: a) detecting the methylation status of a SLC5A8 nucleotide sequence in a sample from the subject for a first time; and b) detecting the methylation status of the SLC5 A8 nucleotide sequence in a sample from the same subject at a later time; wherein absence of methylation in the SLC5A8 nucleotide sequence taken at a later time and the presence of methylation in the SLC5 A8 nucleotide sequence taken at the first time is indicative of cancer regression; wherein presence of methylation in the SLC5A8 nucleotide sequence taken at a later time and the absence of methylation in the SLC5A8 nucleotide sequence taken at the first time is indicative of cancer progression.

54. The method of claim 53, wherein the sample is a bodily fluid selected from the group consisting of blood, serum, plasma, a blood-derived fraction, stool, urine, and a colonic effluent.

55. The method of claim 53, wherein the SLC5A8-associated cancer is selected from the group consisting of: colon cancer, breast cancer, thyroid cancer, and stomach cancer.

56. A method for treating a SLC5A8-associated proliferative disease in a subject, comprising administering to the subject a sufficient amount of a compound, wherein the compound modulates the SLC5A8 protein or nucleic acid expression.

57. The method of claim 56, wherein the disease is associated with methylation of a SLC5A8 nucleic acid sequence, and the compound induces SLC5A8 expression.

58. The method of claim 57, the compound is a demethylation agent selected from 5- azacytidine and 5-deoxy-azacytidine.

59. The method of claim 56, wherein the SLC5 A8-associated proliferative disease is selected from the group consisting of: thyroid nodular hypeφlasia, thyroid adenoma, thyroid cancer, colon neoplasia, breast cancer, and stomach cancer.

60. A method for treating a SLC5A8-associated cancer in a subject, comprising administering to the subject a vector containing a SLC5A8 nucleic acid which is operably linked to a heterologous promoter.

61. The method of claim 60, wherein the SLC5A8 nucleic acid encodes a polypeptide at least 90% identical to SEQ ID NO: 1.

62. The method of claim 60, wherein the cancer is a colon neoplasia.

63. A bisulfite-converted methylated SLC5A8 nucleotide sequence selected from the group consisting of: a) a nucleotide sequence of any one of SEQ ID NOs: 15-18 or a fragment thereof; b) a complement of any one of SEQ ID NOs: 15-18; and c) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence of any one of SEQ TD NOs: 15-18.

64. Ohgonucleotide primers for detecting methylation of a SLC5 A8 nucleotide sequence, selected from SEQ ID NOs: 5-11.

65. A kit for detecting a SLC5A8-associated cancer in a subject, comprising at least two primers of claim 64.

66. The kit of claim 65, further comprising a compound to convert a template DNA.

67. The kit of claim 66, wherein the compound is bisulfite.

68. The kit of claim 67, wherein each primer comprises at least a CpG dinucleotide.

69. A method of converting a nucleic acid sequence at least 95% identical to any one of SEQ TD NOs: 12-13 or fragments thereof, to a bisulfite converted sequence comprising: a) providing a nucleotide acid having a nucleotide sequence, as set forth in any one of SEQ ED NOs: 12-13 or fragments thereof; and b) adding a bisulfite compound, whereby the unmethylated cytosine bases of the CpG islands are converted to a different base.

70. The method of claim 69, wherein the unmethylated cytosine is converted to a uracil.

71. A nucleic acid sequence as prepared by the method of claim 69.

72. An isolated or recombinant methylated SLC5A8 nucleic acid, comprising a nucleotide sequence as set forth in any one of SEQ ED NOs: 12-13 or fragments thereof, wherein the cytosine ofthe CpG island is methylated.

73. An isolated or recombinant SLC5A8 nucleic acid, selected from the group consisting of: a) a nucleotide sequence as set forth in any one of SEQ ED NOs: 12-13 or a fragment thereof; b) a complement of any one of SEQ ID NOs: 12-13; c) a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence of any one of SEQ ID NOs: 12-13; d) a nucleotide sequence that is at least 98%> identical to the nucleotide sequence of any one of SEQ ID NOs: 12-13; and e) a nucleotide sequence comprising at least 50 consecutive base pairs of any one of

SEQ ID NOs: 12-13, wherein the SLC5A8 nucleotide sequence is differentially methylated in a SLC5A8- associated disease cell.

74. A method for detecting colon cancer, comprising: a) obtaining a sample from a patient; and b) assaying said sample for the presence of methylation of nucleotide sequences within at least two genes selected from the group consisting of: SLC5A8, HLTF, pi 6, and hMLHl; wherein methylation of nucleotide sequences within the two genes is indicative of colon cancer.

75. The method of claim 74, wherein the sample is a bodily fluid selected from the group consisting of blood, serum, plasma, a blood-derived fraction, stool, urine, and a colonic effluent.

76. The method of claim 74, wherein the bodily fluid is obtained from a subject suspected of having or is known to have colon cancer.

77. A kit for detecting colon cancer in a subject, comprising primers for detecting methylation of nucleotide sequence within at least two genes selected from the group consisting of: SLC5A8, HLTF, pl6, and hMLHl,

wherein the primers for detecting methylation of SLC5 A8 nucleotide sequence are selected from SEQ ED NOs: 5-11;

wherein the primers for detecting methylation of HLTF nucleotide sequence are selected from 5'-TGGGGTTTCGTGGTTTTTTCGCGC-3', 5'- CCGCGAATCCAATCAAACGTCGACG-3', 5'- ATTTTTGGGGTTTTGTGGTTTTTTTGTGT-3 ', 5 '- ATCACCACAAATCCAATCAAACATCAACA-3', 5'- GCACGACTAAAAAATAAATCGCCGCG-3', 5'- AAACACACAACTAAAAAATAAATCACCACA-3', 5'- TAAAACCTCGTAACTTTCCCGCGCG-3', 5'- GTCGCGAGTTTAGTTAGACGTCGAC-3 ', 5'- TCCTAAAACCTCATAACTTTCCCACACA-3', 5'- AGTTGTTGTGAGTTTAGTTAGATGTTGAT-3'

wherein the primers for detecting methylation of hMLHl nucleotide sequence are selected from 5ΑACGAATTAATAGGAAGAGCGGATAGCG-3', 5'- CGTCCCTCCCTAAAACGACTACTACCC-3', 5'- CGTTTTTTTTTGAAGCGGTTATTGTTTGT-3', and 5'- AACGAACCAATAAAAAAAACAAACAACG-3'

78. The kit of claim 77, further comprising a compound to convert a template DNA.

79. The kit of claim 78, wherein the compound is bisulfite.